

**NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)**

# **Soft Tissue Sarcoma**

Version 2.2014

**NCCN.org**

**Continue**



National  
Comprehensive  
Cancer  
Network®

# NCCN Guidelines® Version 2.2014 Panel Members

## Soft Tissue Sarcoma

[NCCN Guidelines Index](#)  
[Soft Tissue Sarcoma, Table of Contents](#)  
[Discussion](#)

\*Margaret von Mehren, MD †/Chair  
Fox Chase Cancer Center

\*R. Lor Randall, MD ¶/Vice-Chair  
Huntsman Cancer Institute  
at the University of Utah

Robert S. Benjamin, MD †  
The University of Texas  
MD Anderson Cancer Center

Sarah Boles, MD †  
UC San Diego Moores Cancer Center

Marilyn M. Bui, MD, PhD ≠  
Moffitt Cancer Center

Ephraim S. Casper, MD † Ԑ  
Memorial Sloan-Kettering Cancer Center

Ernest U. Conrad, III, MD ¶ τ  
Fred Hutchinson Cancer Research  
Center/Seattle Cancer Care Alliance

\*Thomas F. DeLaney, MD §  
Massachusetts General Hospital  
Cancer Center

Kristen N. Ganjoo, MD †  
Stanford Cancer Institute

\*Suzanne George, MD †  
Dana-Farber/Brigham and Women's  
Cancer Center

Ricardo J. Gonzalez, MD ¶  
Moffitt Cancer Center

Martin J. Heslin, MD ¶  
University of Alabama at Birmingham  
Comprehensive Cancer Center

John M. Kane III, MD ¶  
Roswell Park Cancer Institute

Joel Mayerson, MD ¶ τ  
The Ohio State University  
Comprehensive Cancer Center -  
James Cancer Hospital and  
Solove Research Institute

Sean V. McGarry, MD τ  
UNMC Eppley Cancer Center at  
The Nebraska Medical Center

Christian Meyer, MD, PhD †  
The Sidney Kimmel Comprehensive  
Cancer Center at Johns Hopkins

Richard J. O'Donnell, MD ¶  
UCSF Helen Diller Family  
Comprehensive Cancer Center

Alberto S. Pappo, MD €  
St. Jude Children's Research Hospital/  
University of Tennessee Health Science  
Center

I. Benjamin Paz, MD ¶  
City of Hope  
Comprehensive Cancer Center

John D. Pfeifer, MD, PhD ≠  
Siteman Cancer Center at Barnes-  
Jewish Hospital and Washington  
University School of Medicine

\*Richard F. Riedel, MD †  
Duke Cancer Institute

\*Scott Schuetze, MD, PhD †  
University of Michigan  
Comprehensive Cancer Center

Karen D. Schupak, MD §  
Memorial Sloan-Kettering Cancer Center

Herbert S. Schwartz, MD ¶  
Vanderbilt-Ingram Cancer Center

\*Brian A. Van Tine, MD, PhD †  
Siteman Cancer Center at Barnes-  
Jewish Hospital and Washington  
University School of Medicine

Jeffrey D. Wayne, MD ¶  
Robert H. Lurie Comprehensive Cancer  
Center of Northwestern University

**NCCN**  
Mary Anne Bergman  
Lauren Gallagher, RPh, PhD  
Hema Sundar, PhD

**Continue**

† Medical oncology	€ Pediatric oncology
¶ Surgery/Surgical oncology	ξ Bone marrow transplantation
Ԑ Internal medicine	≠ Pathology
τ Orthopedics/Orthopedic oncology	* Writing Committee Member
§ Radiotherapy/Radiation oncology	

[NCCN Guidelines Panel Disclosures](#)



National  
Comprehensive  
Cancer  
Network®

# NCCN Guidelines Version 2.2014 Sub-Committees

## Soft Tissue Sarcoma

[NCCN Guidelines Index](#)  
[Soft Tissue Sarcoma, Table of Contents](#)  
[Discussion](#)

### Rhabdomyosarcoma

Suzanne George, MD †/Lead  
Dana-Farber/Brigham and Women's  
Cancer Center

Christian Meyer, MD, PhD †  
The Sidney Kimmel Comprehensive  
Cancer Center at Johns Hopkins

Richard F. Riedel, MD †  
Duke Cancer Institute

Karen D. Schupak, MD §  
Memorial Sloan-Kettering Cancer Center

Brian A. Van Tine, MD, PhD †  
Siteman Cancer Center  
at Barnes-Jewish Hospital  
and Washington University  
School of Medicine

Margaret von Mehren, MD †  
Fox Chase Cancer Center

### Systemic Therapy Agents and Regimens

Robert S. Benjamin, MD †  
The University of Texas  
MD Anderson Cancer Center

Ephraim S. Casper, MD † P  
Memorial Sloan-Kettering Cancer Center

Kristen N. Ganjoo, MD †  
Stanford Cancer Institute

Richard F. Riedel, MD †  
Duke Cancer Institute

Margaret von Mehren, MD †  
Fox Chase Cancer Center

### Principles of Surgery

John M. Kane III, MD ¶  
Roswell Park Cancer Institute

Jeffrey D. Wayne, MD ¶  
Robert H. Lurie Comprehensive Cancer  
Center of Northwestern University

### Guidelines for Radiation Therapy

Thomas F. DeLaney, MD §  
Massachusetts General Hospital  
Cancer Center

Karen D. Schupak, MD §  
Memorial Sloan-Kettering Cancer Center

### Principles of Biopsy and Pathology for GISTs

John D. Pfeifer, MD, PhD ≠/Lead  
Siteman Cancer Center at Barnes-Jewish Hospital  
and Washington University School of Medicine

Marilyn M. Bui, MD, PhD ≠  
Moffitt Cancer Center

### Extremity Sarcoma Surgical Outcomes

I. Benjamin Paz, MD ¶  
City of Hope  
Comprehensive Cancer Center

Ricardo Gonzalez, MD ¶  
Moffitt Cancer Center

John M. Kane III, MD ¶  
Roswell Park Cancer Institute

Karen D. Schupak, MD §  
Memorial Sloan-Kettering  
Cancer Center

### Principles Of Ancillary Techniques Useful In The Diagnosis of Sarcomas

John D. Pfeifer, MD, PhD ≠  
Siteman Cancer Center at Barnes-Jewish Hospital  
and Washington University School of Medicine

[NCCN Guidelines Panel Disclosures](#)

**Continue**

† Medical oncology  
¶ Surgery/Surgical oncology  
P Internal medicine  
τ Orthopedics/Orthopedic  
oncology

§ Radiotherapy/Radiation  
oncology  
€ Pediatric oncology  
ξ Bone marrow transplantation  
≠ Pathology

[NCCN Soft Tissue Sarcoma Panel Members](#)  
[NCCN Soft Tissue Sarcoma Sub-Committee Members](#)  
[Summary of the Guidelines Updates](#)

### Soft Tissue Sarcoma

- [Extremity/Superficial Trunk, Head/Neck \(EXTSARC-1\)](#)
- [Retroperitoneal/Intra-Abdominal \(RETSARC-1\)](#)
- [Gastrointestinal Stromal Tumors \(GIST-1\)](#)
  - ▶ [Principles of Biopsy for GIST \(GIST-A\)](#)
  - ▶ [Principles of Pathologic Assessment for GIST \(GIST-B\)](#)
  - ▶ [Principles of Surgery for GIST \(GIST-C\)](#)
  - ▶ [Dosing and Administration of Imatinib \(GIST-D\)](#)
  - ▶ [Dosing and Administration of Sunitinib \(GIST-E\)](#)
  - ▶ [Dosing and Administration of Regorafenib \(GIST-F\)](#)
- [Desmoid Tumors \(Aggressive Fibromatosis\) \(DESM-1\)](#)
- [Rhabdomyosarcoma \(RMS-1\)](#)

[Principles of Pathologic Assessment of Sarcoma Specimens \(SARC-A\)](#)

[Principles of Ancillary Techniques Useful in the Diagnosis of Sarcomas \(SARC-B\)](#)

[Principles of Surgery \(SARC-C\)](#)

[Radiation Therapy Guidelines \(SARC-D\)](#)

[Systemic Therapy Agents and Regimens with Activity in Soft Tissue Sarcoma \(SARC-E\)](#)

[Staging \(ST-1\)](#)

**Bone Sarcomas** - [See the NCCN Guidelines for Bone Cancer](#)

**Uterine Sarcomas** - [See the NCCN Guidelines for Uterine Neoplasms](#)

**Dermatofibrosarcoma Protuberans** - [See the NCCN Guidelines for Dermatofibrosarcoma Protuberans](#)

**Clinical Trials:** NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, [click here:](#)  
[nccn.org/clinical\\_trials/physician.html](http://nccn.org/clinical_trials/physician.html).

**NCCN Categories of Evidence and Consensus:** All recommendations are category 2A unless otherwise specified.

See [NCCN Categories of Evidence and Consensus](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2014.



# NCCN Guidelines Version 2.2014 Updates

## Soft Tissue Sarcoma

The 2.2014 version of the NCCN Guidelines for Soft Tissue Sarcoma represents the addition of the Discussion text ([MS-1](#)).

Updates in version 1.2014 of the NCCN Guidelines for Soft Tissue Sarcoma from version 1.2013 include:

### Extremity/Superficial Trunk, Head/Neck

#### EXTSARC-1

- **Superficial** was added to the title of the page.
- **Workup; Essential**
  - First bullet revised: *Prior to the initiation of therapy*, all patients should be evaluated and managed by a multidisciplinary team with expertise and experience in sarcoma ~~prior to the initiation of therapy.~~ (Also for [RETSARC-1](#), [GIST-1](#), [DESM-1](#), [SARC-E](#))
  - ~~Adequate imaging of a primary tumor is indicated for all lesions with a reasonable chance of being malignant MRI±CT~~, was removed from the guidelines.
    - ◊ Corresponding footnote: ~~CT angiogram may be useful for patients in whom an MRI is not feasible~~ was also removed.
  - ~~Plain radiograph of primary tumor (optional)~~ has been removed.
  - *Patients with personal/family history suggestive of Li-Fraumeni syndrome should be considered for further genetics assessment*, is new to the page. (Also for [RETSARC-1](#))
- **Special Considerations for unique histologies pathway**: Revised as follows, *Ewing's sarcoma family of tumors*.
- **GIST** was added as a unique histology.
- Footnote "a" has been modified as follows: Imaging *studies* should include cross-sectional imaging (MRI±CT) to provide details about the size of tumor and contiguity to nearby visceral structures and neurovascular landmarks. *Other imaging studies such as CT, angiogram, and plain radiograph may be warranted in selected circumstances.*

#### EXTSARC-2

- Under Primary Treatment:
  - ~~Surgery with an intent to obtain negative margins~~ was modified: *Surgery to obtain adequate oncologic margins.*
  - ~~Final margins >1.0 cm or intact fascial plane~~ has been modified: *Oncologically appropriate margins or intact fascial plane.*
  - ~~Final margins ≤1.0 cm (and without an intact fascial plane)~~ has been modified: *Failure to obtain oncologically appropriate margins (and without an intact fascial plane)*
- Footnote "k" and "o" are new to the page.

#### EXTSARC-3

- Under Primary Treatment, modified Surgery to *Surgery to obtain oncologically appropriate margins.* (Also for [EXTSARC-4](#), [RETSARC-2](#))

#### EXTSARC-4

- Third column: Resectable modified to Resectable *with acceptable functional outcomes.*
  - Unresectable modified to Resectable with adverse functional outcomes or Unresectable primary disease.

#### EXTSARC-5

- Modified first branch off Synchronous stage IV to, Single organ and limited tumor bulk that are amenable to ~~complete resection~~ *local therapy.* (Also for [EXTSARC-6](#))
- Under Primary Treatment:
  - First bullet: Metastasectomy was modified to include  $\pm$  *preoperative or postoperative* chemotherapy  $\pm$  RT (similar to [EXTSARC-6](#))
  - Bottom branch, modified options to include *Palliative* options deleting palliative from chemotherapy, RT, and surgery. (Also for [EXTSARC-6](#), [RETSARC-4](#))
- ~~Best~~ was deleted from supportive care. (Also for [EXTSARC-6](#), [RETSARC-4](#))
- Under Follow-up, 2nd bullet was modified, *H&P and imaging of chest and other known sites of metastatic disease.*
- The following footnote has been removed: ~~Thoracotomy and video-assisted thoracic surgery (VATS) should be available and used selectively depending on the clinical presentation of metastatic disease.~~ (Also for [EXTSARC-6](#))
- Modified footnote "cc" to include, *Recommended only for palliative therapy in patients with synchronous stage IV or recurrent disease with disseminated metastases.* (Also for [EXTSARC-6](#))

#### EXTSARC-6

- The options under treatment have been made similar to those listed for single organ involvement on [EXTSARC-5](#). (except for the category 2B)

### Retroperitoneal/Intra-abdominal

#### RETSARC-1

- Fourth bullet modified to "Preresection biopsy not necessarily required, ~~based on degree of suspicion of other malignancies~~ *consider biopsy if there is suspicion of malignancies other than sarcoma*
- Sixth bullet modified to include, *Image-guided (CT or ultrasound) core needle biopsy is preferred over open surgical biopsy.*

#### RETSARC-3

- Footnote "g" has been revised as follows, *Postoperative RT should not be administered routinely.*



# NCCN Guidelines Version 2.2014 Updates

## Soft Tissue Sarcoma

### Retroperitoneal/Intra-abdominal

#### RETSARC-4

- Footnote “k” is new to the page and corresponds to radiation therapy under palliative options.

### Gastrointestinal Stromal Tumors (GIST)

#### GIST-1

- A new footnote was added to the title, *Workup at Primary Presentation*, directing the reader to AJCC Staging, *Staging for GIST*.
  - Fifth bullet under Workup was modified: Endoscopy ± ultrasound as indicated in selected patients as indicated (if not previously done).
  - Sixth bullet is new to the page: Testing for mutations in KIT and PDGFRA is strongly recommended. (Also for GIST-A)
  - Seventh bullet is new to the page: Testing for germline mutations in the succinate dehydrogenase (SDH) genes should be considered for patients with wild-type GIST (lacking KIT or PDGFRA mutations). (Also for GIST-A)
- Footnote “b” was modified: Surgery should induce minimal surgical morbidity; ~~otherwise~~ consider preoperative imatinib *if surgery would induce significant morbidity*. This footnote is now representing the first branch in the second column.
- Top branch, fifth column has a designated footnote “f” See *RETSARC-1*, *if the pathology results indicate sarcomas of GI origin other than GIST*. (Also for GIST-3)

#### GIST-3

- After “Pathology result” the pathway was revised.

#### GIST-4

- Seventh column revised: Surgery if possible, to *Surgery if feasible*.
  - A new footnote has been added: Imatinib can be stopped right before surgery and restarted as soon as the patient is able to tolerate oral medications. If other TKIs, such as sunitinib or regorafenib, are being used, therapy should be stopped at least one week prior to surgery and can be restarted based on clinical judgement or recovery from surgery. (Also for GIST-5, GIST-6, GIST-7, GIST-C)

#### GIST-5

- Imatinib as first-line treatment for unresectable, recurrent, or metastatic disease changed from a category 2A recommendation to a category 1 recommendation.

### Gastrointestinal Stromal Tumors (GIST)

#### GIST-6

- Footnote “m” is new to the page: If life-threatening side effects occur with imatinib not managed by maximum supportive treatment, then consider sunitinib.

#### GIST-7

- Under treatment for progressive disease the branch off “Limited” has been revised as follows:
    - ◊ Continue with the same dose of imatinib and consider the following options for progressing lesions:
      - ◊ Resection, if feasible
      - ◊ Radiofrequency ablation (RFA) or embolization of chemoembolization (category 2B)
      - ◊ Palliative RT (category 2B) for rare patients with bone metastases or
      - ◊ Dose escalation of imatinib as tolerated (Also for the branch below under “performance status”) or Change to sunitinib (category 1) and Reassess therapeutic response with CT
      - ◊ NOTE: Sunitinib changed from a category 2A recommendation to a category 1 recommendation.
  - The recommendation for regorafenib changed from a category 2A to a category 1 recommendation.
  - Footnote “ff” has been modified to include regorafenib: In patients with GIST progressing despite prior imatinib, sunitinib, *and regorafenib* consider *other options listed in SARC-E (based on limited data)* or reintroduction of a previously tolerated and effective TKI for palliation of symptoms. Consider continuation of TKI therapy life-long for palliation of symptoms as part of best supportive care.
- #### GIST-B--Principles of Pathologic Assessment for GIST
- Second bullet, *DOG1* was added as a GIST marker; *DOG1 immunostaining may be useful for cases that cannot be categorized as GIST based on CD117 immunostaining* was added to text.
  - Third bullet, is new to the page: Tumors lacking KIT or PDGFRA mutations should be considered for further evaluations such as staining for SDHB by immunohistochemistry, BRAF mutation analysis and SDH gene mutation analysis.

**Gastrointestinal Stromal Tumors (GIST)---continued**

- Sixth bullet, last sentence modified: However, *they-the type of mutation* cannot be accurately predicted based on the anatomic site of origin or histopathologic features.
- Seventh bullet was modified: In patients with advanced GISTs, approximately 90% of patients ~~respond to~~ *benefit from* imatinib when their tumors have a *KIT* exon 11 mutation; approximately 50% of patients ~~respond-benefit from~~ *benefit from* imatinib when their tumors harbor a *KIT* exon 9 mutation, and the likelihood of response improves with the use of 800 mg imatinib rather than the standard 400 mg dose. Most mutations in the *PDGFRA* gene are associated with a response to imatinib, with the notable exception of D842V. In the absence of *KIT* and *PDGFRA* mutations, ~~advanced GISTs have a 0%-45% likelihood of responding to only a subset of patients with advanced GISTs benefit from~~ *benefit from* imatinib. Metastatic disease with acquired drug resistance is usually the result of secondary, imatinib-resistant mutations in *KIT* or *PDGFRA*. Sunitinib treatment is indicated for patients with imatinib-resistant tumors, or imatinib intolerance. *Regorafenib is indicated for patients with disease progression on imatinib and sunitinib.*

**GIST-D**

- Dosing and Administration of Imatinib
  - This section of the guideline has been modified to reflect the FDA label.

**GIST-F**

- Dosing and Administration of regorafenib is new to the guidelines.

**Desmoid Tumors (Aggressive Fibromatosis)****DESM-1**

- Added *familial adenomatous polyposis (FAP)* to history and physical.

**DESM-2**

- Footnote “d” now corresponds to *Observation* as well as *Treatment*.
- *Monitor for disease progression:* is a new pathway after R0, R1, and R2.
- *Monitor for symptomatic progression* is a new bullet under Follow-up.
- The last column has been modified: *If progression or recurrence, consider resection or systemic therapy.*

**Rhabdomyosarcoma****RMS-1**

- Footnote “c” is new to the page, *Not to be confused with anaplastic variant in children* and corresponds with *Pleomorphic RMS*.
- Footnote “e” is new to the page, *Up to 13% of rhabdomyosarcomas in younger patients may have anaplastic features and should not be confused with the high-grade tumors seen in adults designated as pleomorphic rhabdomyosarcomas* and corresponds with Non-pleomorphic RMS (includes alveolar and embryonal).

**SARC-A**

- Under Principles of Pathologic Assessment of Sarcoma Specimens:
  - Second bullet, *In patients without a definitive diagnosis following initial biopsy due to limited sampling size, repeat image-guided core needle biopsy should be considered to make a diagnosis,* is new to the page.

**SARC-B** (3 of 3)

- Under Principles of Ancillary Techniques Useful in the Diagnosis of Sarcomas, the following is new to the page:

- Tumor: *Epithelioid hemangioendothelioma*
- Aberration: *t(1;13)(p36;q25)*
- Gene(s) involved: *WWTR1-CAMTA1*

**SARC-D** (3 of 4)

- The branch off Preoperative RT was modified as follows: *45-50 GY in 25-28 fractions.*

**SARC-E** (1 of 6)

- *Regorafenib* is now listed under imatinib and sunitinib.
- Tamoxifen plus *sulindac* as an option for systemic therapy for desmoid tumors is new to the page.
- Footnote “c” has been modified: *Alveolar soft part sarcoma (ASPS), well-differentiated liposarcoma/atypical lipomatous tumor, and clear cell sarcomas are generally not sensitive to cytotoxic chemotherapy. (Also for SARC-E (2 of 6)*
- Footnote “h” is new to the page for GIST, *Imatinib, sunitinib and regorafenib are the three FDA agents approved for the treatment of GIST.*

**ST-3**

- American Joint Committee On Cancer (AJCC) Staging System For Gastrointestinal Stromal Tumor is new to the guideline.



# NCCN Guidelines Version 2.2014

## Extremity/Superficial Trunk, Head/Neck

### WORKUP

#### ESSENTIAL:

- Prior to the initiation of therapy, all patients should be evaluated and managed by a multidisciplinary team with expertise and experience in sarcoma
- H&P
- Adequate imaging<sup>a</sup> of primary tumor is indicated for all lesions with a reasonable chance of being malignant
- Carefully planned biopsy (core needle or incisional biopsy after adequate imaging, placed along planned future resection axis with minimal dissection and careful attention to hemostasis)<sup>b</sup>
  - Biopsy should establish grade and histologic subtype<sup>c</sup>
  - Appropriate use of ancillary diagnostic methodologies<sup>d</sup>


#### USEFUL UNDER CERTAIN CIRCUMSTANCES:<sup>e</sup>

- PET scan may be useful in prognostication, grading, and determining response to chemotherapy<sup>f</sup>
- Consider abdominal/pelvic CT for myxoid/round cell liposarcoma, epithelioid sarcoma, angiosarcoma, and leiomyosarcoma
- Consider MRI of total spine for myxoid/round cell liposarcoma
- Consider CNS imaging for alveolar soft part sarcoma (ASPS) and angiosarcoma
- Patients with personal/family history suggestive of Li-Fraumeni syndrome should be considered for further genetics assessment [See NCCN Guidelines for Genetic/Familial High Risk Assessment: Breast and Ovarian](#)

<sup>a</sup>Imaging studies should include cross-sectional imaging (MRI±CT) to provide details about the size of tumor and contiguity to nearby visceral structures and neurovascular landmarks. Other imaging studies such as CT, angiogram, and plain radiograph may be warranted in selected circumstances.

<sup>b</sup>In selected institutions with clinical and pathologic expertise, an FNA may be acceptable.

<sup>c</sup>[See Principles of Pathologic Assessment of Sarcoma Specimens \(SARC-A\).](#)



<sup>d</sup>[See Principles of Ancillary Techniques Useful in the Diagnosis of Sarcomas \(SARC-B\).](#)

<sup>e</sup>Different subtypes have different propensities to spread to various locations. Imaging should be individualized based upon subtypes.

<sup>f</sup>May be useful for lesions that are larger than 3 cm, firm, and deep, not superficial (Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. *Cancer* 2005;103:339-348).

<sup>g</sup>Diagnoses that will impact the overall treatment plan.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 2.2014

## Extremity/Superficial Trunk, Head/Neck

### PRIMARY TREATMENT

### FOLLOW-UP



<sup>h</sup>See American Joint Committee on Cancer (AJCC) Staging, 7th Edition ([ST-1](#)).

<sup>i</sup>See [Principles of Surgery \(SARC-C\)](#).

<sup>j</sup>In selected cases when margin status is uncertain, consultation with a radiation oncologist is recommended. Reresection, if feasible, may be necessary to render margins >1.0 cm.

<sup>k</sup>Resection should be tailored to minimize surgical morbidity for patients with atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDLs). En bloc resection with negative margins is generally sufficient to obtain long-term local control.

<sup>l</sup>See [Radiation Therapy Guidelines \(SARC-D\)](#).

<sup>m</sup>Randomized clinical trial data support the use of radiation therapy as an adjunct to surgery in appropriately selected patients based on an improvement in disease-free survival (although not overall survival). (Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. *J Clin Oncol* 1998;16:197-203).

<sup>n</sup>In situations where the area is easily followed by physical examination, imaging may not be required.

<sup>o</sup>For patients with ALT/WDS, observation is recommended for focally positive margins if re-resection, in the event of recurrence, would not be unduly morbid. RT is reserved for selected patients with recurrent or deeply infiltrative primary lesions with a risk of local recurrence, depending on the tumor location and patient's age.

<sup>p</sup>After 10 y, the likelihood of developing a recurrence is small and follow-up should be individualized.

<sup>q</sup>Consider ultrasound for smaller lesions that are superficial. Ultrasound should be done by an ultrasonographer experienced in musculoskeletal disease. (Choi H, Varma DGK, Fornage BD, Kim EE, et al. Soft-Tissue Sarcoma: MR Imaging vs Sonography for Detection of Local Recurrence After Surgery. *AJR* 1991;157:353-358.)


**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2014

## Extremity/Superficial Trunk, Head/Neck



<sup>i</sup>See [Principles of Surgery \(SARC-C\)](#).

<sup>j</sup>In selected cases when margin status is uncertain, consultation with a radiation oncologist is recommended. Reresection, if feasible, may be necessary to render margins >1.0 cm.

<sup>l</sup>See [Radiation Therapy Guidelines \(SARC-D\)](#).

<sup>n</sup>In situations where the area is easily followed by physical examination, imaging may not be required.

<sup>p</sup>After 10 y, the likelihood of developing a recurrence is small and follow-up should be individualized.

<sup>q</sup>Consider ultrasound for smaller lesions that are superficial. Ultrasound should be done by an ultrasonographer experienced in musculoskeletal disease. (Choi H, Varma DGK, Fornage BD, Kim EE, et al. Soft-Tissue Sarcoma: MR Imaging vs Sonography for Detection of Local Recurrence After Surgery. AJR 1991;157:353-358.)

<sup>r</sup>Patients with stage III tumors with lymph node involvement should undergo regional lymph node dissection at the time of primary tumor resection ± RT.

<sup>s</sup>Treatment options for stage II and III should be made by a multidisciplinary team and involve consideration of the following: performance status, comorbid factors (including age), site of disease, histologic subtype, and institutional experience.

<sup>t</sup>Surgery alone may be an option for small tumors resected with wide margins.

<sup>u</sup>Consider re-imaging to assess primary tumor and to rule out metastatic disease.

<sup>v</sup>See [Systemic Therapy Agents and Regimens with Activity in Soft Tissue Sarcoma \(SARC-E\)](#).

<sup>w</sup>RT may be used in select circumstances such as close or positive margins where re-excision is not feasible or for functional considerations.

<sup>x</sup>Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197-203.

<sup>y</sup>There are limited and conflicting data regarding the potential benefits of adjuvant chemotherapy in stage II or stage III patients.

<sup>z</sup>For residual gross disease or microscopically positive margins.


**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2014

## Extremity/Superficial Trunk, Head/Neck



<sup>i</sup>See Principles of Surgery (SARC-C).

<sup>l</sup>See Radiation Therapy Guidelines (SARC-D).

<sup>n</sup>In situations where the area is easily followed by physical examination, imaging may not be required.

<sup>q</sup>Consider ultrasound for smaller lesions that are superficial. Ultrasound should be done by an ultrasonographer experienced in musculoskeletal disease. (Choi H, Varma DGK, Fornage BD, Kim EE, et al. Soft-Tissue Sarcoma: MR Imaging vs Sonography for Detection of Local Recurrence After Surgery. AJR 1991;157:353-358.)

<sup>s</sup>Treatment options for stage II and III should be made by a multidisciplinary team and involve consideration of the following: performance status, comorbid factors (including age), site of disease, histologic subtype, and institutional experience.

<sup>u</sup>Consider re-imaging to assess primary tumor and to rule out metastatic disease.

<sup>v</sup>See Systemic Therapy Agents and Regimens with Activity in Soft Tissue Sarcoma (SARC-E).

<sup>z</sup>For residual gross disease or microscopically positive margins.

<sup>aa</sup>Should only be done at institutions with experience in regional limb therapy.

<sup>bb</sup>Definitive RT entails delivering the maximal local dose compatible with known normal tissue tolerance, typically in the range of 7000-8000 cGy with sophisticated treatment planning techniques being a necessity in this setting.


**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2014

## Extremity/Superficial Trunk, Head/Neck



<sup>n</sup>In situations where the area is easily followed by physical examination, imaging may not be required.

<sup>p</sup>After 10 y, the likelihood of developing a recurrence is small and follow-up should be individualized.

<sup>q</sup>Consider ultrasound for smaller lesions that are superficial. Ultrasound should be done by an ultrasonographer experienced in musculoskeletal disease. (Choi H, Varma DGK, Fornage BD, Kim EE, et al. Soft-Tissue Sarcoma: MR Imaging vs Sonography for Detection of Local Recurrence After Surgery. AJR 1991;157:353-358.)

<sup>v</sup>See [Systemic Therapy Agents and Regimens with Activity in Soft Tissue Sarcoma \(SARC-E\)](#).

<sup>cc</sup>Palliative RT requires balancing expedient treatment with sufficient dose expected to halt the growth of, or cause tumor regression. Numerous clinical issues regarding rapidity of growth, the status of systemic disease, and the use of chemotherapy must be considered. Recommended only for palliative therapy in patients with synchronous stage IV or recurrent disease with disseminated metastases.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



### RECURRENT DISEASE

Local  
recurrence

Metastatic  
disease

Single organ and  
limited tumor bulk  
that are amenable  
to local therapy

Disseminated  
metastases

Isolated regional  
disease or nodes

### TREATMENT

Follow Workup, then appropriate Primary Treatment<sup>dd</sup> pathway  
([EXTSARC-1](#), [EXTSARC-2](#), [EXTSARC-3](#), [EXTSARC-4](#))

#### Options:

- Metastasectomy ± preoperative or postoperative chemotherapy<sup>v</sup> ± RT (category 2B for chemotherapy and RT)
- Ablation procedures (eg, RFA or cryotherapy)
- Embolization procedures
- SBRT

#### Palliative options:

- Chemotherapy<sup>v</sup>
- RT<sup>cc</sup>
- Surgery
- Observation, if asymptomatic
- Supportive care
- Ablation procedures (eg, RFA or cryotherapy)
- Embolization procedures
- SBRT

#### Options:

- Regional node dissection for nodal involvement ± RT ± chemotherapy<sup>v</sup> (category 2B for chemotherapy)
- Metastasectomy ± preoperative or postoperative chemotherapy<sup>v</sup> ± RT (category 2B for chemotherapy and RT)
- SBRT

<sup>v</sup>See [Systemic Therapy Agents and Regimens with Activity in Soft Tissue Sarcoma \(SARC-E\)](#).

<sup>cc</sup>Palliative RT requires balancing expedient treatment with sufficient dose expected to halt the growth of, or cause tumor regression. Numerous clinical issues regarding rapidity of growth, the status of systemic disease, and the use of chemotherapy must be considered. Recommended only for palliative therapy in patients with synchronous stage IV or recurrent disease with disseminated metastases.

<sup>dd</sup>If local recurrence can be excised, a decision will need to be made on a case-by-case basis whether re-irradiation is possible. Some case series suggest benefit with re-irradiation [Catton C, Davis A, Bell R, et al: Soft tissue sarcoma of the extremity. Limb salvage after failure of combined conservative therapy. Radiother Oncol 41:209, 1996.] while others do not [Torres MA, Ballo MT, Butler CE, et al: Management of locally recurrent soft-tissue sarcoma after prior surgery and radiation therapy. Int J Radiat Oncol Biol Phys 67:1124, 2007], likely reflecting differences in selection of patients for treatment with surgery and radiotherapy or surgery alone. Traditionally, the re-irradiation has been done with postoperative adjuvant brachytherapy but may now be able to be done as a combination of brachytherapy and IMRT to reduce the risks of morbidity with re-irradiation.


**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



### WORKUP

- Prior to the initiation of therapy, all patients should be evaluated and managed by a multidisciplinary team with expertise and experience in sarcoma
- H&P
- Chest/abdominal/pelvic CT with contrast ± MRI
- Preresection biopsy not necessarily required; consider biopsy if there is suspicion of malignancies other than sarcoma
- Biopsy is necessary for patients receiving preoperative RT or chemotherapy
- Image-guided (CT or ultrasound) core needle biopsy is preferred over open surgical biopsy<sup>a</sup>
- Patients with personal/family history suggestive of Li-Fraumeni syndrome should be considered for further genetics assessment [See NCCN Guidelines for Genetic/Familial High Risk Assessment: Breast and Ovarian](#)




<sup>a</sup>[See Principles of Pathologic Assessment of Sarcoma Specimens \(SARC-A\).](#)

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2014

## Retroperitoneal/Intra-Abdominal



<sup>a</sup>See [Principles of Pathologic Assessment of Sarcoma Specimens \(SARC-A\)](#).

<sup>b</sup>Biopsy required if considering preoperative therapy, including endoscopic biopsy for suspected GIST lesions.

<sup>c</sup>See [Principles of Surgery \(SARC-C\)](#).

<sup>d</sup>IORT may be considered provided frozen section pathology can confidently demonstrate a non-GIST/non-desmoid histology.

<sup>e</sup>See [Radiation Therapy Guidelines \(SARC-D\)](#).

<sup>f</sup>See [Systemic Therapy Agents and Regimens with Activity in Soft Tissue Sarcoma \(SARC-E\)](#).


**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2014

## Retroperitoneal/Intra-Abdominal



<sup>c</sup>See Principles of Surgery (SARC-C).

<sup>e</sup>See Radiation Therapy Guidelines (SARC-D).

<sup>g</sup>Postoperative RT should not be administered routinely.

<sup>h</sup>For example, patients with high-grade tumors, an extremely large tumor, critical anatomic surface where recurrence would cause morbidity, or close margins.


<sup>i</sup>If not previously administered, consider preoperative RT and/or chemotherapy.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



**PRIMARY TREATMENT**



<sup>a</sup>See Principles of Pathologic Assessment of Sarcoma Specimens (SARC-A).

<sup>e</sup>See Radiation Therapy Guidelines (SARC-D).

<sup>f</sup>See Systemic Therapy Agents and Regimens with Activity in Soft Tissue Sarcoma (SARC-E).

<sup>j</sup>Balance risks of treatment, likelihood of rendering patient resectable, and performance status of patient with potential clinical benefits. The options listed may be used either alone, sequentially, or in combination.

<sup>k</sup>Palliative RT requires balancing expedient treatment with sufficient dose expected to halt the growth of, or cause tumor regression. Numerous clinical issues regarding rapidity of growth, the status of systemic disease, and the use of chemotherapy must be considered. Recommended only for patients with unresectable or progressive disease.


**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**WORKUP AT PRIMARY PRESENTATION<sup>a</sup>**

- Prior to the initiation of therapy, all patients should be evaluated and managed by a multidisciplinary team with expertise and experience in sarcoma
- For very small gastric GISTs <2 cm ([See GIST-2](#))
- Abdominal/pelvic CT with contrast, and/or MRI
- Consider chest imaging
- Endoscopy ± ultrasound as indicated in selected patients
- Testing for mutations in KIT and PDGFRA is strongly recommended
- Testing for germline mutations in the succinate dehydrogenase (SDH) genes should be considered for patients with wild-type GIST (lacking KIT or PDGFRA mutations)

**RESULTS OF INITIAL DIAGNOSTIC EVALUATION**



<sup>a</sup>See American Joint Committee on Cancer (AJCC) Staging, 7th Edition ([ST-3/GIST](#)).

<sup>b</sup>Surgery should induce minimal surgical morbidity; consider preoperative imatinib if surgery would induce significant morbidity.

<sup>c</sup>Preoperative imatinib may prohibit accurate assessment of recurrence risk. Consider preoperative imatinib only if surgical morbidity could be reduced by downstaging the tumor preoperatively.

<sup>d</sup>[See Principles of Surgery for GIST \(GIST-C\)](#).

<sup>e</sup>Pathology report should include anatomic location, size, and an accurate assessment of the mitotic rate measured in the most proliferative area of the tumor. Mutational analysis may predict response to therapy with tyrosine kinase inhibitors. ([See Principles of Pathologic Assessment For GIST \[GIST-B\]](#)).

<sup>f</sup>[See RETSARC-1](#), if the pathology results indicate sarcomas of GI origin other than GIST.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2014

## Gastrointestinal Stromal Tumors (GIST)

### APPROACH TO PATIENTS WITH VERY SMALL GASTRIC GISTS (<2 CM)<sup>g</sup>

**WORKUP AT  
PRIMARY PRESENTATION**

**RESULTS OF INITIAL  
DIAGNOSTIC EVALUATION**

**INITIAL MANAGEMENT**

**FOLLOW-UP**

- Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)
- Abdominal/pelvic CT with contrast

High-risk EUS features<sup>h</sup>

Complete surgical resection

Consider abdominal/pelvic CT with contrast every 3-6 months for 3-5 years, then annually

No high-risk EUS features

Consider endoscopic surveillance<sup>i</sup> (6- to 12-month intervals)

<sup>g</sup>Adapted with permission from Sepe PS, Brugge WR. A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol. 2009;6:363-371. All recommendations for this algorithm are category 2B.

<sup>h</sup>Possible high-risk EUS features include irregular border, cystic spaces, ulceration, echogenic foci, and heterogeneity.


<sup>i</sup>Endoscopic ultrasonography surveillance should only be considered after a thorough discussion with the patient regarding the risks and benefits.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



### INITIAL DIAGNOSTIC EVALUATION



<sup>c</sup>Preoperative imatinib may prohibit accurate assessment of recurrence risk. Consider preoperative imatinib only if surgical morbidity could be reduced by downstaging the tumor preoperatively.

<sup>d</sup>[See Principles of Surgery for GIST \(GIST-C\).](#)

<sup>e</sup>Pathology report should include anatomic location, size, and an accurate assessment of the mitotic rate measured in the most proliferative area of the tumor. Mutational analysis may predict response to therapy with tyrosine kinase inhibitors. [\(See Principles of Pathologic Assessment for GIST \[GIST-B\]\).](#)

<sup>f</sup>[See RETSARC-1](#), if the pathology results indicate sarcomas of GI origin other than GIST.

<sup>j</sup>[See Principles of Biopsy for GIST \(GIST-A\).](#)

<sup>k</sup>Some patients may rapidly become unresectable; close monitoring is essential.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 2.2014

## Gastrointestinal Stromal Tumors (GIST)

### PRIMARY PRESENTATION

### PRIMARY/PREOPERATIVE TREATMENT

### FOLLOW-UP THERAPY



<sup>d</sup>See Principles of Surgery for GIST (GIST-C).

<sup>k</sup>Some patients may rapidly become unresectable; close monitoring is essential.

<sup>l</sup>Consider baseline PET, if using PET during follow-up. PET is not a substitute for CT.

<sup>m</sup>If life-threatening side effects occur with imatinib not managed by maximum supportive treatment, then consider sunitinib.

<sup>n</sup>Medical therapy is the usual course of treatment. However, patient may proceed to surgery if bleeding or symptomatic.

<sup>o</sup>In patients with advanced GISTs, approximately 90% of patients respond to imatinib when their tumors have a *KIT* exon 11 mutation; approximately 50% of patients respond when their tumors harbor a *KIT* exon 9 mutation, and the likelihood of response improves with the use of 800 mg imatinib rather than the standard 400 mg dose. Most mutations in the *PDGFRA* gene are associated with a response to imatinib, with the notable exception of D842V. In the absence of *KIT* and *PDGFRA* mutations, advanced GISTs have a 0%-45% likelihood of responding to imatinib. Metastatic disease with acquired drug resistance is usually the result of secondary, imatinib-resistant mutations in *KIT* or *PDGFRA*. Sunitinib treatment is indicated for patients with imatinib-resistant tumors, or imatinib intolerance.

<sup>p</sup>See Dosing and Administration of Imatinib (GIST-D).

<sup>q</sup>PET may give indication of imatinib activity after 2-4 wks of therapy when rapid readout of activity is necessary. Diagnostic CT is indicated every 8-12 weeks; routine long-term PET follow-up is rarely indicated.

<sup>r</sup>Rarely, increase in tumor size may not indicate lack of drug efficacy; all clinical and radiographic data should be taken into account, including lesion density on CT.

<sup>s</sup>Progression may be determined by CT or MRI with clinical interpretation; PET scan may be used to clarify if CT or MRI are ambiguous.

<sup>t</sup>Suggest referral to a sarcoma specialty center.

<sup>u</sup>Collaboration between medical oncologist and surgeon is necessary to determine the appropriateness of surgery, following major response or sustained stable disease.

<sup>v</sup>Imatinib can be stopped right before surgery and restarted as soon as the patient is able to tolerate oral medications. If other TKIs, such as sunitinib or regorafenib, are being used, therapy should be stopped at least one week prior to surgery and can be restarted based on clinical judgement or recovery from surgery.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 2.2014

## Gastrointestinal Stromal Tumors (GIST)

### PRIMARY PRESENTATION

### PRIMARY/PREOPERATIVE TREATMENT

### FOLLOW-UP THERAPY



<sup>d</sup>See Principles of Surgery for GIST (GIST-C).

<sup>m</sup>If life-threatening side effects occur with imatinib not managed by maximum supportive treatment, then consider sunitinib.

<sup>o</sup>In patients with advanced GISTs, approximately 90% of patients respond to imatinib when their tumors have a *KIT* exon 11 mutation; approximately 50% of patients respond when their tumors harbor a *KIT* exon 9 mutation, and the likelihood of response improves with the use of 800 mg imatinib rather than the standard 400 mg dose. Most mutations in the *PDGFRA* gene are associated with a response to imatinib, with the notable exception of D842V. In the absence of *KIT* and *PDGFRA* mutations, advanced GISTs have a 0%-45% likelihood of responding to imatinib. Metastatic disease with acquired drug resistance is usually the result of secondary, imatinib-resistant mutations in *KIT* or *PDGFRA*. Sunitinib treatment is indicated for patients with imatinib-resistant tumors, or imatinib intolerance.

<sup>p</sup>See Dosing and Administration of Imatinib (GIST-D).

<sup>r</sup>Rarely, increase in tumor size may not indicate lack of drug efficacy; all clinical and radiographic data should be taken into account, including lesion density on CT.

<sup>s</sup>Progression may be determined by CT or MRI with clinical interpretation; PET scan may be used to clarify if CT or MRI are ambiguous.

<sup>t</sup>Suggest referral to a sarcoma specialty center.

<sup>u</sup>Collaboration between medical oncologist and surgeon is necessary to determine the appropriateness of surgery, following major response or sustained stable disease.

<sup>v</sup>Imatinib can be stopped right before surgery and restarted as soon as the patient is able to tolerate oral medications. If other TKIs, such as sunitinib or regorafenib, are being used, therapy should be stopped at least one week prior to surgery and can be restarted based on clinical judgement or recovery from surgery.

<sup>w</sup>Consider baseline PET, if using PET during follow-up. PET is not a substitute for CT.

<sup>x</sup>Consider PET only if CT results are ambiguous.

<sup>y</sup>In some patients, it may be appropriate to image prior to 3 months.

<sup>z</sup>No definitive data exist to prove whether surgical resection improves clinical outcomes in addition to TKI therapy alone in metastatic GIST. Prospective randomized trials are underway to assess whether or not resection changes outcomes in patients with metastatic GIST responding to TKI therapy.


**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2014

## Gastrointestinal Stromal Tumors (GIST)



<sup>d</sup>See Principles of Surgery for GIST (GIST-C).

<sup>m</sup>If life-threatening side effects occur with imatinib not managed by maximum supportive treatment, then consider sunitinib.

<sup>p</sup>See Dosing and Administration of Imatinib (GIST-D).

<sup>v</sup>Imatinib can be stopped right before surgery and restarted as soon as the patient is able to tolerate oral medications. If other TKIs, such as sunitinib or regorafenib, are being used, therapy should be stopped at least one week prior to surgery and can be restarted based on clinical judgement or recovery from surgery.

<sup>aa</sup>For patients with complete resections following preoperative imatinib, continuation of imatinib should be considered. The duration of postoperative imatinib has not been studied in randomized trials; there are single and multi-institutional trials supporting the benefit for continuation of imatinib for two years following surgery. (See GIST-D for references).

<sup>bb</sup>Postoperative imatinib for at least 36 months should be considered for high-risk tumors. The results of a randomized trial (SSGXVIII/AIO) suggest that postoperative imatinib administered for 36 months improves relapse-free survival (RFS) and overall survival (OS) compared to 12 months for patients with a high estimated risk of recurrence (tumor greater than 5 cm in size with high mitotic rate [ $>5$  mitoses/50 HPF], tumor rupture, or a risk of recurrence of greater than 50% after surgery). The results of the ACOSOG trial Z9001 showed that postoperative imatinib improved RFS in patients with GIST  $\geq 3$  cm in size with the greatest benefit noted in tumors at higher risk of recurrence (intermediate and high risk). This trial did not demonstrate overall survival benefit. (See GIST-D for references).


<sup>cc</sup>Less frequent surveillance may be acceptable for very small tumors ( $<2$  cm).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



**TREATMENT FOR PROGRESSIVE DISEASE**



<sup>d</sup>See Principles of Surgery For GIST (GIST-C).

<sup>p</sup>See Dosing and Administration of Imatinib (GIST-D).

<sup>r</sup>Rarely, increase in tumor size may not indicate lack of drug efficacy; all clinical and radiographic data should be taken into account, including lesion density on CT.

<sup>s</sup>Progression may be determined by CT or MRI with clinical interpretation; PET scan may be used to clarify if CT or MRI are ambiguous.

<sup>t</sup>Suggest referral to a sarcoma specialty center.

<sup>v</sup>Imatinib can be stopped right before surgery and restarted as soon as the patient is able to tolerate oral medications. If other TKIs, such as sunitinib or regorafenib, are being used, therapy should be stopped at least one week prior to surgery and can be restarted based on clinical judgement or recovery from surgery.

<sup>x</sup>Consider PET only if CT results are ambiguous.

<sup>dd</sup>See Dosing and Administration of Sunitinib (GIST-E).

<sup>ee</sup>Clinical experience suggests that discontinuing tyrosine kinase inhibitor (TKI) therapy, even in the setting of progressive disease, may accelerate the pace of disease progression and worsen symptoms.

<sup>ff</sup>In patients with GIST progressing despite prior imatinib, sunitinib, and regorafenib consider other options listed in [SARC-E](#) (based on limited data) or reintroduction of a previously tolerated and effective TKI for palliation of symptoms. Consider continuation of TKI therapy life-long for palliation of symptoms as part of best supportive care.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.**



### PRINCIPLES OF BIOPSY FOR GIST

- GISTs are soft and fragile tumors. EUS-FNA biopsy of primary site is preferred over percutaneous biopsy (due to the risk for hemorrhage and intra-abdominal tumor dissemination).
- Consideration of biopsy should be based upon the suspected tumor type and extent of disease.
- Biopsy is necessary to confirm the diagnosis of primary GIST prior to the initiation of preoperative therapy.
- Percutaneous image-guided biopsy may be appropriate for confirmation of metastatic disease.
- Diagnosis is based on the Principles of Pathologic Assessment ([See SARC-A](#)); referral to centers with expertise in sarcoma diagnosis is recommended for cases with complex or unusual histopathologic features.
- Testing for mutations in KIT and PDGFRA is strongly recommended.
- Testing for germline mutations in the SDH genes should be considered for patients with wild-type GIST (lacking KIT or PDGFRA mutations).
- Risk stratification:
  - ▶ While tumor size and mitotic rate are used to assess the risk of metastasis of GIST, it is notoriously difficult to predict the biologic behavior of GIST based on pathologic features alone; thus, guidelines for risk stratification by tumor site have been developed.
  - ▶ Most gastric GISTs behave in an overall indolent manner and those smaller than 2 cm are almost universally benign; See Table 1: Gastric GISTs: Proposed Guidelines for Assessing the Malignant Potential ([GIST-A 2 of 3](#)).
  - ▶ GIST of the small intestine tends to be more aggressive than its gastric counterpart; See Table 2: Small Intestinal GISTs: Proposed Guidelines for Assessing Malignant Potential ([GIST-A 3 of 3](#)).
  - ▶ GIST of the colon is most commonly seen in the rectum; colonic GIST tends to have an aggressive biological behavior, and tumors with mitotic activity can recur and metastasize despite a small size of <2 cm.
  - ▶ Specific mutations in *KIT* or *PDGFRA* show some correlation with tumor phenotype, but mutations are not strongly correlated with the biologic potential of individual tumors. The accumulated data show that *KIT* mutations are not preferentially present in high-grade tumors, but can also be found in small incidental tumors as well as tumors that have a benign course. Similarly, mutational analysis of *PDGFRA* cannot be used to predict the behavior of individual tumors.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF BIOPSY****Table 1: Gastric GISTs: Proposed Guidelines for Assessing the Malignant Potential<sup>1, 2</sup>**

<b><u>Tumor Size</u></b>	<b><u>Mitotic Rate</u></b>	<b><u>Predicted Biologic Behavior</u></b>
<b>≤2 cm</b>	<b>≤5 mitoses/50 HPFs</b>	<b>Benign, metastasis rate or tumor-related mortality: 0</b>
<b>&gt;2cm ≤10 cm</b>	<b>≤5 mitoses/50 HPFs</b>	<b>Very low malignant potential, metastasis rate or tumor-related mortality: &lt;4%</b>
<b>≤ 5 cm</b>	<b>&gt;5 mitoses/50 HPFs</b>	<b>Low to moderate malignant potential, metastasis rate or tumor-related mortality: 12% to 15%</b>
<b>&gt;10 cm</b>	<b>≤5 mitoses/50 HPFs</b>	
<b>&gt;5 cm</b>	<b>&gt;5 mitoses/50 HPFs</b>	<b>High malignant potential, metastasis rate or tumor-related mortality: 49% to 86%</b>
<b>GISTs: Gastrointestinal stromal tumors; HPFs: High-power fields</b>		

<sup>1</sup>Data from Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. *Sem Diagn Pathol* 2006;23:70-83.<sup>2</sup>Per 50 HPF is a total of 5 mm<sup>2</sup>. For most modern microscopes, 20 HPF 40 x lenses/fields encompasses 5 mm<sup>2</sup>. (Rubin BP, Blanke CD, Demetri G, et al. CAP: Protocol for the examination of specimens from patients with gastrointestinal stromal tumor (GIST) checklist for GIST. June 2012.)Available at: [http://www.cap.org/apps/docs/committees/cancer/cancer\\_protocols/2012/GIST\\_12protocol\\_3021.pdf](http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2012/GIST_12protocol_3021.pdf).**Note: All recommendations are category 2A unless otherwise indicated.****Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.**



# NCCN Guidelines Version 2.2014

## Gastrointestinal Stromal Tumors (GIST)

### PRINCIPLES OF BIOPSY

**Table 2: Small Intestinal GISTs: Proposed Guidelines for Assessing the Malignant Potential<sup>1,2</sup>**

<u>Tumor Size</u>	<u>Mitotic Rate</u>	<u>Predicted Biologic Behavior</u>
≤2 cm	≤5 mitoses/50 HPFs	Benign, metastasis rate or tumor-related mortality: 0
>2 cm ≤5 cm	<5 mitoses/50 HPFs	Low malignant potential, metastasis rate or tumor-related mortality: 2%
>5 cm ≤10 cm	≤5 mitoses/50 HPFs	Moderate malignant potential, metastasis rate or tumor-related mortality: 25%
>10 cm	>5 mitoses/50 HPFs	High malignant potential, metastasis rate or tumor-related mortality: 50%-90%
<b>GISTs: Gastrointestinal stromal tumors; HPFs: High-power fields</b>		

<sup>1</sup>Data from Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. *Sem Diagn Pathol* 2006;23:70-83.

<sup>2</sup>Per 50 HPF is a total of 5 mm<sup>2</sup>. For most modern microscopes, 20 HPF 40 x lenses/fields encompasses 5 mm<sup>2</sup>. (Rubin BP, Blanke CD, Demetri G, et al. CAP: Protocol for the examination of specimens from patients with gastrointestinal stromal tumor (GIST) checklist for GIST. June 2012.)

Available at: [http://www.cap.org/apps/docs/committees/cancer/cancer\\_protocols/2012/GIST\\_12protocol\\_3021.pdf](http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2012/GIST_12protocol_3021.pdf).

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.**



### PRINCIPLES OF PATHOLOGIC ASSESSMENT FOR GIST

- Pathologic assessment should follow the guidelines outlined in [SARC-A](#).
- Morphologic diagnosis based on microscopic examination of histologic sections is the standard for GIST diagnosis. Several ancillary techniques are useful in support of GIST diagnosis, including immunohistochemistry (95% express CD117 and 80% express CD34, DOG1) and molecular genetic testing (for mutations in *KIT* or *PDGFRA*). DOG1 immunostaining may be useful for cases that cannot be categorized as GIST based on CD117 immunostaining. Referral to centers with expertise in sarcoma diagnosis is recommended for cases with complex or unusual histopathologic features.
- Tumors lacking *KIT* or *PDGFRA* mutations should be considered for further evaluations such as staining for SDHB by immunohistochemistry, BRAF mutation analysis and SDH gene mutation analysis.
- Tumor size and mitotic rate are used as guides to predict the malignant potential of GISTs, although it is notoriously difficult to predict the biologic potential of individual cases. The mitotic rate should be measured in the most proliferative area of the tumor, and reported as the number of mitoses per 5 mm<sup>2</sup> of tissue.
- Approximately 80% of GISTs have a mutation in the gene encoding the *KIT* receptor tyrosine kinase; another 5%-10% of GISTs have a mutation in the gene encoding the related *PDGFRA* receptor tyrosine kinase. Since about 10%-15% of GISTs have no detectable *KIT* or *PDGFRA* mutation, the absence of a mutation does not exclude the diagnosis of GIST. The presence and type of *KIT* and *PDGFRA* mutations are not strongly correlated with prognosis.
- The mutations in *KIT* and *PDGFRA* in GIST result in expression of mutant proteins with constitutive tyrosine kinase activity. If tyrosine kinase inhibitors are considered as part of the treatment plan, genetic analysis of the tumor should be considered since the presence of mutations (or absence of mutations) in specific regions of the *KIT* and *PDGFRA* genes are correlated with response (or lack of a response) to specific tyrosine kinase inhibitors. However, the type of mutation cannot be accurately predicted based on the anatomic site of origin or histopathologic features.
- In patients with advanced GISTs, approximately 90% of patients benefit from imatinib when their tumors have a *KIT* exon 11 mutation; approximately 50% of patients benefit from imatinib when their tumors harbor a *KIT* exon 9 mutation, and the likelihood of response improves with the use of 800 mg imatinib rather than the standard 400 mg dose. Most mutations in the *PDGFRA* gene are associated with a response to imatinib, with the notable exception of D842V. In the absence of *KIT* and *PDGFRA* mutations, only a subset of patients with advanced GISTs benefit from imatinib. Metastatic disease with acquired drug resistance is usually the result of secondary, imatinib-resistant mutations in *KIT* or *PDGFRA*. Sunitinib treatment is indicated for patients with imatinib-resistant tumors, or imatinib intolerance. Regorafenib is indicated for patients with disease progression on imatinib and sunitinib.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



### PRINCIPLES OF SURGERY FOR GIST

#### Primary (Resectable) GIST

The surgical procedure performed should aim to resect the tumor with histologically negative margins.

- Given the limited intramural extension, extended anatomic resections (such as total gastrectomy) are rarely indicated. Segmental or wedge resection to obtain negative margins is often appropriate.
- Lymphadenectomy is usually not required given the low incidence of nodal metastases.
- As GIST tends to be very friable, every effort should be made not to violate the pseudocapsule of the tumor.
- Re-resection is generally not indicated for microscopically positive margins on final pathology.

Resection should be accomplished with minimal morbidity and, in general, complex multi-visceral resection should be avoided. If the surgeon feels that a multi-visceral resection may be required, then multidisciplinary consultation is indicated regarding a course of preoperative imatinib. Similarly, rectal GIST should be approached via a sphincter-sparing approach. If abdominoperineal resection (APR) would be necessary to achieve a negative margin resection, then preoperative imatinib should be considered.

A laparoscopic approach may be considered for select GISTs in favorable anatomic locations (greater curvature or anterior wall of the stomach, jejunum, and ileum) by surgeons with appropriate laparoscopic experience.

- All oncologic principles of GIST resection must still be followed, including preservation of the pseudocapsule and avoidance of tumor spillage.
- Resection specimens should be removed from the abdomen in a plastic bag to prevent spillage or seeding of port sites.

#### Unresectable or Metastatic GIST

Imatinib is the primary therapy for metastatic GIST. Surgery may be indicated for:

- Limited disease progression refractory to imatinib.
- Locally advanced or previously unresectable tumors after a favorable response to preoperative imatinib.

Imatinib can be stopped right before surgery and restarted as soon as the patient is able to tolerate oral medications. If other TKIs, such as sunitinib or regorafenib, are being used, therapy should be stopped at least one week prior to surgery and can be restarted based on clinical judgement or recovery from surgery.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



### DOSING AND ADMINISTRATION OF IMATINIB

- The recommended dose of imatinib is:
  - ▶ Preoperative imatinib for GIST that is resectable with negative margins but with risk of significant morbidity:<sup>1-4</sup>
    - ◊ Initiate dosing at 400 mg daily. Patients with documented mutations in KIT exon 9 may benefit from dose escalation up to 800 mg daily (given as 400 mg twice daily), depending upon tolerance.<sup>5-7</sup>
  - ▶ Unresectable and/or metastatic GIST:
    - ◊ Initiate dosing at 400 mg daily. \* Patients with documented mutations in KIT exon 9 may benefit from dose escalation up to 800 mg daily (given as 400 mg twice daily), depending upon tolerance.<sup>5-7</sup>
    - ◊ IF PROGRESSION OF DISEASE IS DOCUMENTED: Imatinib dose increase up to 800 mg daily (given as 400 mg twice daily) may be considered, as clinically tolerated, in patients showing objective signs of disease progression at a lower dose and in the absence of severe adverse drug reactions. \*
  - ▶ Postoperative imatinib:<sup>8,9</sup>
    - ◊ 400 mg daily following complete gross resection of GIST.
- Dose modification (please consult complete prescribing information for detailed instruction on dose modification)
  - ▶ In patients receiving imatinib, selection of an alternate concomitant medication with no or minimal enzyme induction potential is recommended. Strong CYP3A4 inducers should be avoided. Caution is recommended when administering imatinib with strong CYP3A4 inhibitors.
    - ◊ Imatinib dose modification is recommended in patients who must receive concomitant CYP3A4 inducers.
  - ▶ Interrupt imatinib for the following:
    - ◊ Elevations in bilirubin >3x institutional upper limit of normal (IULN) or in liver transaminases >5x IULN
      - Withhold imatinib until bilirubin <1.5x IULN and transaminases <2.5x IULN
    - ◊ Severe nonhematologic adverse reaction (eg, severe hepatotoxicity or severe fluid retention) until resolution of the event. Treatment can be resumed as appropriate depending on the severity of the event.
    - ◊ ANC <1.0 x 10<sup>9</sup>/L and/or platelets <50 x 10<sup>9</sup>/L
      - Withhold imatinib until ANC ≥1.5 x 10<sup>9</sup>/L and platelets ≥75 x 10<sup>9</sup>/L
  - ▶ Reduce the imatinib dose:
    - ◊ By 25% in patients with severe hepatic impairment
    - ◊ By 50% for the starting dose in patients with moderate renal impairment. Future doses can be increased as tolerated.
    - ◊ In adult patients with elevations in bilirubin and liver transaminases that have returned to normal levels, imatinib can be continued at reduced daily doses (ie, 400 mg to 300 mg, 600 mg to 400 mg, or 800 mg to 600 mg).
    - ◊ For recurrence of ANC <1.0 x 10<sup>9</sup>/L and/or platelets <50 x 10<sup>9</sup>/L. Withhold imatinib until ANC ≥1.5 x 10<sup>9</sup>/L and platelets ≥75 x 10<sup>9</sup>/L, then resume at reduced dose of 300 mg.
- Imatinib should be taken with a low-fat meal and a large glass of water.

\* Information from the FDA label. For more detailed information review the full content at: [www.fda.gov](http://www.fda.gov).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



### DOSING AND ADMINISTRATION OF IMATINIB (References)

- <sup>1</sup>Blesius A, Cassier PA, Bertucci F, et al. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. *BMC Cancer* 2011;11:72.
- <sup>2</sup>Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. *J Surg Oncol* 2009;99:42-47.
- <sup>3</sup>Fiore M, Palassini E, Fumagalli E, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). *Eur J Surg Oncol* 2009;35:739-745.
- <sup>4</sup>McAuliffe JC, Hunt KK, Lazar AJF, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. *Ann Surg Oncol* 2009;16:910-919.
- <sup>5</sup>Heinrich MC, Owzar K, Corless CL, et al. Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. *J Clin Oncol* 2008;26:5360-5367.
- <sup>6</sup>Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. *Eur J Cancer* 2006;42:1093-1103. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16624552>.
- <sup>7</sup>Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. *J Clin Oncol* 2010;28:1247-1253. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20124181>.
- <sup>8</sup>Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. *JAMA* 2012;307:1265-1272.
- <sup>9</sup>DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2009;373(9669):1097-1104.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



### DOSING AND ADMINISTRATION OF SUNITINIB

- **The recommended dose of sunitinib is either:**
  - **50 mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off treatment (schedule 4/2).<sup>1</sup>**
  - or
  - **37.5 mg orally once daily without interruption.<sup>2</sup>**
- **Dose modification**
  - **In patients receiving sunitinib, selection of an alternate concomitant medication with no or minimal enzyme induction potential is recommended. Sunitinib dose modification is recommended in patients who must receive concomitant CYP3A4 inhibitors or inducers.**
  - **A dose reduction for sunitinib:**
    - ◊ **For a starting dose of 50 mg (schedule 4/2), decreasing to a minimum of 37.5 mg daily should be considered if sunitinib must be coadministered with a strong CYP3A4 inhibitor.**
    - ◊ **For a starting dose of 37.5 mg orally once daily without interruption, decreasing to a minimum dose of 25 mg daily should be considered if sunitinib must be coadministered with a strong CYP3A4 inhibitor.**
  - **A dose increase for sunitinib:**
    - ◊ **For a starting dose of 50 mg (schedule 4/2), increasing to a maximum of 87.5 mg daily should be considered if sunitinib must be co-administered with a CYP3A4 inducer.**
    - ◊ **For a starting dose of 37.5 mg orally once daily without interruption, increasing to a maximum of 62.5 mg daily should be considered if sunitinib must be co-administered with a CYP3A4 inducer.**
  - **According to the package insert, in vitro studies indicate that sunitinib does not induce or inhibit major cytochrome enzymes.**
- **Sunitinib may be taken with or without food.**

<sup>1</sup>Information from the FDA label. For more detailed information review the full content at: [www.fda.gov](http://www.fda.gov).

<sup>2</sup>George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. *Eur J Cancer* 2009;45:1959 -1968.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.**



### DOSING AND ADMINISTRATION OF REGORAFENIB

- The recommended dose of regorafenib is:
  - ▶ 160 mg orally once daily on a schedule of 3 weeks on treatment followed by 1 week off treatment (schedule 3/1).<sup>1</sup>
- Dose modification (please consult complete prescribing information<sup>1</sup> for detailed instruction on dose modification)
  - ▶ In patients receiving regorafenib, selection of an alternate concomitant medication with no or minimal enzyme induction potential is recommended. Strong CYP3A4 inducers and inhibitors should be avoided.
    - ◊ Regorafenib dose modification is recommended in patients who must receive concomitant CYP3A4 inhibitors or inducers.
  - ▶ Interrupt regorafenib for the following:
    - ◊ NCI CTCAE Grade 2 hand-foot skin reaction (HFSR) (palmar-plantar erythrodysesthesia [PPE]) that is recurrent or does not improve within 7 days despite dose reduction; interrupt therapy for a minimum of 7 days for Grade 3 HFSR
    - ◊ Symptomatic Grade 2 hypertension
    - ◊ Any NCI CTCAE Grade 3 or 4 adverse reaction
  - ▶ Reduce the dose of regorafenib to 120 mg:
    - ◊ For the first occurrence of Grade 2 HFSR of any duration
    - ◊ After recovery of any Grade 3 or 4 adverse reaction
    - ◊ For Grade 3 aspartate aminotransferase (AST)/alanine aminotransferase (ALT) elevation; only resume if the potential benefit outweighs the risk of hepatotoxicity
  - ▶ Reduce the dose of regorafenib to 80 mg:
    - ◊ For re-occurrence of Grade 2 HFSR at the 120 mg dose
    - ◊ After recovery of any Grade 3 or 4 adverse reaction at the 120 mg dose (except hepatotoxicity)
  - ▶ Discontinue regorafenib permanently for the following:
    - ◊ Failure to tolerate 80 mg dose
    - ◊ Any occurrence of AST or ALT more than 20 times in the upper limit of normal (ULN)
    - ◊ Any occurrence of AST or ALT more than 3 times the ULN with concurrent bilirubin more than 2 times the ULN
    - ◊ Re-occurrence of AST or ALT more than 5 times the ULN despite dose reduction to 120 mg
    - ◊ For any Grade 4 adverse reaction; only resume if the potential benefit outweighs the risks
- Regorafenib should be taken with food (for example, a low-fat breakfast with <30% fat).

<sup>1</sup>Information from the FDA label. For more detailed information review the full content at: [www.fda.gov](http://www.fda.gov).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 2.2014

## Desmoid Tumors (Aggressive Fibromatosis)

### WORKUP

- Prior to the initiation of therapy, all patients should be evaluated and managed by a multidisciplinary team with expertise and experience in sarcoma
- H&P including evaluation for Gardner's syndrome<sup>a</sup>/Familial adenomatous polyposis (FAP) ([See NCCN Guidelines for Colorectal Cancer Screening](#))
- Appropriate imaging of primary site with CT or MRI as clinically indicated



<sup>a</sup>Gardner's syndrome is an autosomal dominant disorder characterized by a triad of colonic polyposis, osteoma, and soft tissue tumors. (Traill Z, Tuson J, Woodham C. Adrenal carcinoma in a patient with Gardner's syndrome: imaging findings. AJR 1995;165:1460-1461).

<sup>b</sup>May not be necessary if complete resection is planned.

<sup>c</sup>[See Principles of Pathologic Assessment of Sarcoma Specimens \(SARC-A\)](#).


**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 2.2014

## Desmoid Tumors (Aggressive Fibromatosis)



<sup>d</sup>For tumors that are symptomatic, or impairing or threatening function, patients should be offered therapy with the decision based on the location of the tumor and potential morbidity of the therapeutic option.

<sup>e</sup>For desmoids, microscopic positive margins are acceptable if achieving negative margins would produce excessive morbidity.

<sup>f</sup>RT is not generally recommended for desmoid tumors that are retroperitoneal/intra-abdominal. RT is generally only recommended for desmoid tumors that are in the extremity, superficial trunk, or head and neck.

<sup>g</sup>Dose of definitive RT without surgery: 54-58 Gy in the absence of any prior radiation therapy.

<sup>h</sup>Dose of adjuvant/postoperative RT is 50 Gy. (Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 1998 42:1007-1014.)

<sup>i</sup>[See Systemic Therapy Agents and Regimens with Activity in Soft Tissue Sarcoma \(SARC-E\).](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




# NCCN Guidelines Version 2.2014

## Desmoid Tumors (Aggressive Fibromatosis)

### PRIMARY TREATMENT

### FOLLOW-UP



<sup>f</sup>RT is not generally recommended for desmoid tumors that are retroperitoneal/intra-abdominal. RT is generally only recommended for desmoid tumors that are in the extremity, superficial trunk, or head and neck.

<sup>9</sup>Dose of definitive RT without surgery: 54-58 Gy in the absence of any prior radiation therapy.

<sup>i</sup>[See Systemic Therapy Agents and Regimens with Activity in Soft Tissue Sarcoma \(SARC-E\).](#)

**Note:** All recommendations are category 2A unless otherwise indicated.


**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



**DIAGNOSIS**

**HISTOLOGY**

**TREATMENT**



<sup>a</sup>RMS that is identified within another histology should be treated as the original histology. This pathway refers to patients diagnosed with pure RMS after full slide review.

<sup>b</sup>PET scan may be useful for initial staging because of the possibility of nodal metastases and the appearance of unusual sites of initial metastatic disease in adult patients.

<sup>c</sup>Not to be confused with anaplastic variant in children.

<sup>d</sup>Up to 13% of rhabdomyosarcomas in younger patients may have anaplastic features and should not be confused with the high-grade tumors seen in adults designated as pleomorphic rhabdomyosarcomas.

<sup>e</sup>Pleomorphic RMS is usually excluded from RMS and soft tissue sarcoma randomized clinical trials. Consideration for treatment according to soft tissue sarcoma may be reasonable, including choices for systemic therapy. [See Systemic Therapy Agents and Regimens with Activity in Soft Tissue Sarcoma \(SARC-E\).](#)

<sup>f</sup>Systemic chemotherapy options for RMS may be different than those used with other soft tissue sarcoma histologies. [See Systemic Therapy Agents and Regimens with Activity in Soft Tissue Sarcoma \(SARC-E\).](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



### PRINCIPLES OF PATHOLOGIC ASSESSMENT OF SARCOMA SPECIMENS

- Biopsy should establish malignancy, provide a specific diagnosis where possible, and provide a grade where appropriate or feasible, recognizing that limited biopsy material may underestimate grade.
- In patients without a definitive diagnosis following initial biopsy due to limited sampling size, repeat image-guided core needle biopsy should be considered to make a diagnosis.
- Pathologic assessment of biopsies and resection specimens should be carried out by an experienced sarcoma pathologist.
- Morphologic diagnosis based on microscopic examination of histologic sections remains the gold standard for sarcoma diagnosis. However, since several ancillary techniques are useful in support of morphologic diagnosis (including immunohistochemistry, classical cytogenetics, and molecular genetic testing), sarcoma diagnosis should be carried out by pathologists who have access to these ancillary methods.<sup>1</sup>
- The pathologic assessment should include evaluation of the following features, all of which should be specifically addressed in the pathology report:
  - ▶ Organ, site, and operative procedure
  - ▶ Primary diagnosis (using standardized nomenclature, such as the World Health Organization Classification of Soft Tissue Tumors<sup>2</sup>)
  - ▶ Depth of tumor
    - ◊ Superficial (tumor does not involve the superficial fascia)
    - ◊ Deep
  - ▶ Size of tumor
  - ▶ Histologic grade (at the least, specify low or high grade if applicable); ideally, grade using the French Federation of Cancer Centers Sarcoma Group (FNCLCC) or National Cancer Institute (NCI) system
  - ▶ Necrosis
    - ◊ Present or absent
    - ◊ Microscopic or macroscopic
    - ◊ Approximate extent (percentage)
  - ▶ Status of margins of excision
    - ◊ Uninvolved
    - ◊ Involved (state which margins)
    - ◊ Close (state which margins and measured distance)
  - ▶ Status of lymph nodes
    - ◊ Site
    - ◊ Number examined
    - ◊ Number positive
  - ▶ Results of ancillary studies<sup>1</sup>
    - ◊ Type of testing (electron microscopy, immunohistochemistry, molecular genetic analysis)
    - ◊ Where performed
  - ▶ Additional tumor features of potential clinical value
    - ◊ Mitotic rate
    - ◊ Presence or absence of vascular invasion
    - ◊ Character of tumor margin (well circumscribed or infiltrative)
    - ◊ Inflammatory infiltrate (type and extent)
  - ▶ TNM Stage ([See ST-1](#))

<sup>1</sup> [See Principles of Ancillary Techniques Useful in the Diagnosis of Sarcomas \(SARC-B\).](#)

<sup>2</sup> Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone, Fourth Edition. IARC, Lyon, 2013.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF ANCILLARY TECHNIQUES USEFUL IN THE DIAGNOSIS OF SARCOMAS**

Morphologic diagnosis based on microscopic examination of histologic sections remains the gold standard for sarcoma diagnosis. However, several ancillary techniques are useful in support of morphologic diagnosis, including immunohistochemistry, classical cytogenetics, electron microscopy, and molecular genetic testing. Molecular genetic testing has emerged as a particularly powerful ancillary testing approach since many sarcoma types harbor characteristic genetic aberrations, including single base pair substitutions, deletions and amplifications, and translocations. Most molecular testing utilizes fluorescence in situ hybridization (FISH) approaches or polymerase chain reaction (PCR)-based methods.<sup>1</sup> Recurrent genetic aberrations in sarcoma<sup>2</sup> are listed below:

TUMOR	ABERRATION	GENE(S) INVOLVED
<b><u>Malignant Round Cell Tumors</u></b>		
Ewing's sarcoma / peripheral neuroectodermal tumor	t(11;22)(q24;q12) t(21;22)(q22;q12) t(2;22)(q33;q12) t(7;22)(p22;q12) t(17;22)(q12;q12) inv(22)(q12q;12) t(16;21)(p11;q22)	<i>EWS1-FLI1</i> <i>EWS1-ERG</i> <i>EWSR1-FEV</i> <i>EWSR1-ETV1</i> <i>EWSR1-E1AF</i> <i>EWSR1-ZSG</i> <i>FUS-ERG</i>
Desmoplastic small round cell tumor	t(11;22)(p13;q12)	<i>EWSR1-WT1</i>
Embryonal RMS	Complex alterations	Unknown
Alveolar RMS	t(2;13)(q35;q14) t(1;13)(p36;q14) t(X;2)(q13;q35)	<i>PAX3-FOXO1</i> <i>PAX7-FOXO1</i> <i>PAX3-AFX</i>

<sup>1</sup>Molecular genetic analysis involves highly complex test methods. None of the methods are absolutely sensitive or provide results that are absolutely specific; test results must always be interpreted in the context of the clinical and pathologic features of the case. Testing should therefore be carried out by a pathologist with expertise in sarcoma diagnosis and molecular diagnostic techniques.

<sup>2</sup>This table is not exhaustive for either sarcomas with characteristic genetic changes or the genes involved. Consultation with a pathologist who has expertise in sarcoma diagnosis and molecular diagnostic techniques should be obtained prior to testing.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF ANCILLARY TECHNIQUES USEFUL IN THE DIAGNOSIS OF SARCOMAS**

<b>TUMOR</b>	<b>ABERRATION</b>	<b>GENE(S) INVOLVED</b>
<b><u>Lipomatous Tumors</u></b>		
<b>Myxoid/round cell liposarcoma</b>	<b>t(12;16)(q13;p11) t(12;22)(q13;q12)</b>	<b><i>FUS-DD1T3</i> <i>EWSR1-DD1T3</i></b>
<b>Atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDLPS)</b>	<b>Supernumerary ring chromosomes; giant marker chromosomes</b>	<b>Amplification of region 12q14-15, including <i>MDM2</i>, <i>CDK4</i>, <i>HMGA2</i>, <i>SAS</i>, <i>GL1</i></b>
<b>Dedifferentiated liposarcoma</b>	<b>Same as for ALT/WDLPS</b>	<b>Same as for ALT/WDLPS</b>
<b>Pleomorphic liposarcoma</b>	<b>Complex alterations</b>	<b>Unknown</b>
<b><u>Other Sarcomas</u></b>		
<b>Alveolar soft part sarcoma</b>	<b>der(17)t(X;17)(p11;q25)</b>	<b><i>ASPL-TFE3</i></b>
<b>Angiomatoid fibrous histiocytoma</b>	<b>t(12;22)(q13;q12) t(2;22)(q33;q12) t(12;16)(q13;p11)</b>	<b><i>EWSR1-ATF1</i> <i>EWSR1-CREB1</i> <i>FUS-ATF1</i></b>
<b>Clear cell sarcoma</b>	<b>t(12;22)(q13;q12) t(2;22)(q33;q12)</b>	<b><i>EWSR1-ATF1</i> <i>EWSR1-CREB1</i></b>
<b>Congenital/infantile – fibrosarcoma</b>	<b>t(12;15)(p13;q25)</b>	<b><i>ETV6-NTRK3</i></b>
<b>Dermatofibrosarcoma protuberans</b>	<b>t(17;22)(q21;q13) and derivative ring chromosomes</b>	<b><i>COLIA1-PDGFB</i></b>
<b>Desmoid fibromatosis</b>	<b>Trisomy 8 or 20; loss of 5q21</b>	<b><i>CTNNB1</i> or <i>APC</i> mutations</b>
<b>Epithelioid sarcoma</b>	<b>Inactivation of <i>INI1</i></b>	<b><i>INI1</i></b>
<b>Extrarenal rhabdoid tumor</b>	<b>Inactivation of <i>INI1</i></b>	<b><i>INI1</i></b>

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



**PRINCIPLES OF ANCILLARY TECHNIQUES USEFUL IN THE DIAGNOSIS OF SARCOMAS**

TUMOR	ABERRATION	GENE(S) INVOLVED
<b>Other Sarcomas--(continued)</b>		
Extraskeletal myxoid chondrosarcoma	t(9;22)(q22;q12) t(9;17)(q22;q11) t(9;15)(q22;q21) t(3;9)(q11;q22)	<i>EWSR1-NR4A3</i> <i>TAF2N-NR4A3</i> <i>TCF12-NR4A3</i> <i>TFG-NR4A3</i>
Sporadic and familial GIST Carney-Stratakis syndrome (gastric GIST and paraganglioma)	Activating kinase mutations Krebs cycle mutation	<i>KIT</i> or <i>PDGFRA</i> <i>germline SDH</i> subunit mutations
Inflammatory myofibroblastic tumor (IMT)	t(1;2)(q22;p23) t(2;19)(p23;p13) t(2;17)(p23;q23) t(2;2)(p23;q13) t(2;11)(p23;p15) inv(2)(p23;q35)	<i>TPM3-ALK</i> <i>TPM4-ALK</i> <i>CLTC-ALK</i> <i>RANBP2-ALK</i> <i>CARS-ALK</i> <i>ATIC-ALK</i>
Leiomyosarcoma	Complex alterations	Unknown
Low-grade fibromyxoid sarcoma	t(7;16)(q33;p11) t(11;16)(p11;p11)	<i>FUS-CREB3L2</i> <i>FUS-CREB3L1</i>
Malignant peripheral nerve sheath tumor	Complex alterations	Unknown
Synovial sarcoma	t(X;18)(p11;q11) t(X;18)(p11;q11) t(X;18)(p11;q11)	<i>SS18-SSX1</i> <i>SS18-SSX2</i> <i>SS18-SSX4</i>
Tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT/PVNS)	t(1;2)(p13;q35)	<i>CSF1</i>
Epithelioid hemangioendothelioma	t(1;13)(p36;q25)	<i>WWTR1-CAMTA1</i>

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



### PRINCIPLES OF SURGERY

#### Biopsy

- A pretreatment biopsy to diagnose and grade a sarcoma is highly preferred. Biopsy should be carried out by an experienced surgeon (or radiologist) and may be accomplished by open incisional or needle technique. Core needle biopsy is preferred; however, an open incisional biopsy may be considered by an experienced surgeon. Endoscopic or needle biopsy may be indicated for deep, thoracic, abdominal, or pelvic sarcomas.

#### Surgery

- The surgical procedure necessary to resect the tumor with appropriately negative margins should be used. Close margins may be necessary to preserve uninvolved critical neurovascular structures, bones, joints, etc.
- Ideally, the biopsy site should be excised en bloc with the definitive surgical specimen. Dissection should be through grossly normal tissue planes uncontaminated by tumor. If the tumor is close to or displaces major vessels or nerves, these need not be resected if the adventitia or perineurium is removed and the underlying neurovascular structures are not involved with gross tumor.
- Radical excision/entire anatomic compartment resection is not routinely necessary. Surgical clips should be placed to mark the periphery of the surgical field and other relevant structures to help guide potential future radiation therapy. If closed suction drainage is used, the drains should exit the skin close to the edge of the surgical incision (in case re-resection or radiation is indicated).

#### Resection Margins

- Surgical margins should be documented by both the surgeon and the pathologist in evaluating a resected specimen. If surgical resection margins are positive on final pathology (other than bone, nerve, or major blood vessels), surgical re-resection to obtain negative margins should strongly be considered if it will not have a significant impact upon functionality.
- Consideration for adjuvant radiation therapy should be given for a close soft tissue margin or a microscopically positive margin on bone, major blood vessels, or a major nerve.
- In selected cases when margin status is uncertain, consultation with a radiation oncologist is recommended.
  - R0 resection - No residual microscopic disease
  - R1 resection - Microscopic residual disease
  - R2 resection - Gross residual disease

#### Limb Salvage Surgery

- For extremity sarcomas, the goal of surgery should be functional limb preservation, if possible, within the realm of an appropriate oncologic resection.

#### Amputation


- Prior to considering amputation, patients should be evaluated by a surgeon with expertise in the treatment of soft tissue sarcomas.
- Consideration for amputation to treat an extremity sarcoma should be made for patient preference or if gross total resection of the tumor is expected to render the limb nonfunctional.
- Evaluate postoperative rehabilitation (PT, OT) for patients with extremity sarcoma. Continue rehabilitation until maximal function is achieved.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



**RADIATION THERAPY GUIDELINES FOR SOFT TISSUE SARCOMA OF EXTREMITY/TRUNK/HEAD-NECK<sup>1,2</sup>**



<sup>1</sup> If an R1 or R2 resection is anticipated, clips to high-risk areas for recurrence is encouraged. When external beam RT is used, sophisticated treatment planning with IMRT, tomotherapy, and/or protons can be used to improve the therapeutic ratio.

• Musat E, et al. Comparison of intensity-modulated postoperative radiotherapy with conventional postoperative radiotherapy for retroperitoneal sarcoma. *Cancer Radiother* 2004;8:255-261;

• Alektiar KM, et al. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. *J Clin Oncol* 2008;26:3440-3444;

• Chung CS, et al. A comparison of 3D conformal proton therapy, intensity modulated proton therapy, and intensity modulated photon therapy for retroperitoneal sarcomas. *Int J Radiat Oncol Biol Phys* 2006;66(3S):116;

• Kraybill WG, Harris J, Spiro IJ, et al. Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall: Radiation Therapy Oncology Group Trial 9514. *J Clin Oncol*. 2006;24:619-625.

<sup>2</sup> Haas RL, DeLaney TF, O'Sullivan B, et al: Radiotherapy for Management of Extremity Soft Tissue Sarcomas: Why, When, and Where? *Int J Radiat Oncol Biol Phys*, 2012; 84:572-580.

<sup>3</sup> [See Principles of Surgery \(SARC-C\).](#)

<sup>4</sup> Total doses should always be determined by normal tissue tolerance. There are data to suggest that some patients with positive margins following preoperative RT such as those with low-grade, well-differentiated liposarcoma and a focally, "planned" positive margin on an anatomically fixed critical structure may do well without a boost. (Al Yami, et al, *Int J Radiat Oncol Biol Phys* 2010;77:1191-1197.)

<sup>5</sup> RT does not substitute for definitive surgery with negative margins; re-resection may be necessary.


<sup>6</sup> [See Resection Margins \(SARC-C\).](#)

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.**



**RADIATION THERAPY GUIDELINES FOR SOFT TISSUE SARCOMA OF EXTREMITY/TRUNK/HEAD-NECK<sup>1,2</sup>**




<sup>1</sup>If an R1 or R2 resection is anticipated, clips to high-risk areas for recurrence is encouraged. When external beam RT is used, sophisticated treatment planning with IMRT, tomotherapy, and/or protons can be used to improve the therapeutic ratio:  
 • Musat E, et al. Comparison of intensity-modulated postoperative radiotherapy with conventional postoperative radiotherapy for retroperitoneal sarcoma. *Cancer Radiother* 2004;8: 255-261;  
 • Alektiar KM, et al. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. *J Clin Oncol* 2008;26:3440-3444;  
 • Chung CS, et al. A comparison of 3D conformal proton therapy, intensity modulated proton therapy, and intensity modulated photon therapy for retroperitoneal sarcomas. *Int J Radiat Oncol Biol Phys* 2006;66(3S):116;  
 • Kraybill WG, Harris J, Spiro IJ, et al. Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall: Radiation Therapy Oncology Group Trial 9514. *J Clin Oncol.* 2006;24:619-625.

<sup>2</sup>Haas RL, DeLaney TF, O'Sullivan B, et al: Radiotherapy for Management of Extremity Soft Tissue Sarcomas: Why, When, and Where? *Int J Radiat Oncol Biol Phys*, 2012; 84:572-580.  
<sup>3</sup>[See Principles of Surgery \(SARC-C\).](#)  
<sup>4</sup>Total doses should always be determined by normal tissue tolerance. There are data to suggest that some patients with positive margins following preoperative RT such as those with low-grade, well-differentiated liposarcoma and a focally, "planned" positive margin on an anatomically fixed critical structure may do well without a boost. (Al Yami, et al, *Int J Radiat Oncol Biol Phys* 2010;77:1191-1197.)  
<sup>5</sup>RT does not substitute for definitive surgery with negative margins; re-resection may be necessary.  
<sup>6</sup>[See Resection Margins \(SARC-C\).](#)  
<sup>7</sup>For intra-abdominal or retroperitoneal tumors, external beam RT may be decreased to 45 Gy. A boost may not be possible if potential radiation morbidity is high.  
<sup>8</sup>Data are still limited on the use of HDR brachytherapy for sarcomas. Until more data are available, HDR fraction sizes are recommended to be limited to 3-4 Gy. (Nag et al, *Int J Radiat Onco Biol Phys* 2001;49:1033-1043, 2001).

**Note: All recommendations are category 2A unless otherwise indicated.**  
**Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.**



**RADIATION THERAPY GUIDELINES FOR RETROPERITONEAL/INTRA-ABDOMINAL SARCOMA<sup>1</sup>**



<sup>1</sup>If an R1 or R2 resection is anticipated, clips to high-risk areas for recurrence is encouraged. When external beam RT is used, sophisticated treatment planning with IMRT, tomotherapy, and/or protons can be used to improve the therapeutic ratio:

- Musat E, et al. Comparison of intensity-modulated postoperative radiotherapy with conventional postoperative radiotherapy for retroperitoneal sarcoma. *Cancer Radiother* 2004;8: 255-261;
- Alektiar KM, et al. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. *J Clin Oncol* 2008;26:3440-3444;
- Chung CS, et al. A comparison of 3D conformal proton therapy, intensity modulated proton therapy, and intensity modulated photon therapy for retroperitoneal sarcomas. *Int J Radiat Oncol Biol Phys* 2006;66(3S):116;
- Kraybill WG, Harris J, Spiro IJ, et al. Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall: Radiation Therapy Oncology Group Trial 9514. *J Clin Oncol*. 2006;24:619-625.

<sup>3</sup>[See Principles of Surgery \(SARC-C\).](#)

<sup>4</sup>Total doses should always be determined by normal tissue tolerance. There are data to suggest that some patients with positive margins following preoperative RT such as those with low-grade, well-differentiated liposarcoma and a focally, “planned” positive margin on an anatomically fixed critical structure may do well without a boost. (Al Yami, et al, *Int J Radiat Oncol Biol Phys* 2010;77:1191-1197.)

<sup>5</sup>RT does not substitute for definitive surgery with negative margins; re-resection may be necessary.

<sup>6</sup>[See Resection Margins \(SARC-C\).](#)


<sup>9</sup>Tzeng CW, Fiveash JB, Popple, et al. Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma. *Cancer* 2006;107:371-379.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



**RADIATION THERAPY GUIDELINES FOR RETROPERITONEAL/INTRA-ABDOMINAL SARCOMA<sup>10</sup>**



<sup>3</sup>See [Principles of Surgery \(SARC-C\)](#).

<sup>4</sup>Total doses should always be determined by normal tissue tolerance. There are data to suggest that some patients with positive margins following preoperative RT such as those with low-grade, well-differentiated liposarcoma and a focally, “planned” positive margin on an anatomically fixed critical structure may do well without a boost. (Al Yami, et al, *Int J Radiat Oncol Biol Phys* 2010;77:1191-1197.)

<sup>5</sup>RT does not substitute for definitive surgery with negative margins; re-resection may be necessary.

<sup>6</sup>See [Resection Margins \(SARC-C\)](#).

<sup>7</sup>For intra-abdominal or retroperitoneal tumors, external beam RT may be decreased to 45 Gy. A boost may not be possible if potential radiation morbidity is high.

<sup>10</sup>If an R1 or R2 resection is anticipated, clips to high-risk areas for recurrence are encouraged. When external beam RT is used, sophisticated treatment planning with IMRT, tomotherapy, and/or protons can be used to improve the therapeutic ratio:

- Musat E, et al. Comparison of intensity-modulated postoperative radiotherapy with conventional postoperative radiotherapy for retroperitoneal sarcoma. *Cancer Radiother* 2004;8: 255-261;
- Alektiar KM, et al. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. *J Clin Oncol* 2008;26:3440-3444;
- Chung CS, et al. A comparison of 3D conformal proton therapy, intensity modulated proton therapy, and intensity modulated photon therapy for retroperitoneal sarcomas. *Int J Radiat Oncol Biol Phys* 2006;66(3S):116;
- Kraybill WG, Harris J, Spiro IJ, et al. Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall: Radiation Therapy Oncology Group Trial 9514. *J Clin Oncol* 2006;24:619-625).
- Yoon SS, Chen YL, Kirsch DG, Maduekwe UN, Rosenberg AE, Nielsen GP, Sahani DV, Choy E, Harmon DC, and DeLaney TF. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas. *Ann Surg Oncol* 2010;17:1515-1529.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



**SYSTEMIC THERAPY AGENTS AND REGIMENS WITH ACTIVITY IN SOFT TISSUE SARCOMA SUBTYPES (NON-SPECIFIC)<sup>a,b,c</sup>**

<p><b>Soft Tissue Sarcoma Subtypes with Non-Specific Histologies<sup>d,e</sup></b></p> <p><b>Combination regimens</b></p> <ul style="list-style-type: none"> <li>• AD (doxorubicin, dacarbazine)<sup>1-4</sup></li> <li>• AIM (doxorubicin, ifosfamide, mesna)<sup>3-6</sup></li> <li>• MAID (mesna, doxorubicin, ifosfamide, dacarbazine)<sup>3,4,7,8</sup></li> <li>• Ifosfamide, epirubicin, mesna<sup>9</sup></li> <li>• Gemcitabine and docetaxel<sup>10,11</sup></li> <li>• Gemcitabine and vinorelbine<sup>12</sup></li> <li>• Gemcitabine and dacarbazine<sup>13</sup></li> </ul> <p><b>Single agents</b></p> <ul style="list-style-type: none"> <li>• Doxorubicin<sup>3,4,14</sup></li> <li>• Ifosfamide<sup>9,15</sup></li> <li>• Epirubicin<sup>16</sup></li> <li>• Gemcitabine</li> <li>• Dacarbazine</li> <li>• Liposomal doxorubicin<sup>17</sup></li> <li>• Temozolomide<sup>f,18</sup></li> <li>• Vinorelbine<sup>19</sup></li> <li>• Pazopanib<sup>f,g,20</sup></li> </ul>		<p><b>GIST<sup>h</sup></b></p> <ul style="list-style-type: none"> <li>• Imatinib<sup>21,22</sup></li> <li>• Sunitinib<sup>23</sup></li> <li>• Regorafenib<sup>24</sup></li> </ul> <p><b>Disease progression after imatinib, sunitinib, and regorafenib</b></p> <ul style="list-style-type: none"> <li>• Sorafenib<sup>25-27</sup></li> <li>• Nilotinib<sup>28,29</sup></li> <li>• Dasatinib<sup>30</sup> (for patients with D842V mutation)</li> </ul>	<p><b>Desmoid Tumors (Aggressive fibromatosis)</b></p> <ul style="list-style-type: none"> <li>• Sulindac<sup>31</sup> or other non-steroidal anti-inflammatory drugs (NSAIDs) including celecoxib</li> <li>• Tamoxifen ± Sulindac<sup>32,33</sup></li> <li>• Toremifene<sup>34</sup></li> <li>• Methotrexate and vinblastine<sup>35</sup></li> <li>• Low-dose interferon<sup>36</sup></li> <li>• Doxorubicin-based regimens<sup>37-39</sup></li> <li>• Imatinib<sup>40,41</sup></li> <li>• Sorafenib<sup>42</sup></li> <li>• Methotrexate and vinorelbine<sup>43</sup></li> <li>• Liposomal doxorubicin<sup>44</sup></li> </ul>
<p><b>Non-Pleomorphic Rhabdomyosarcoma</b></p> <p><b>Combination regimens</b></p> <ul style="list-style-type: none"> <li>• Vincristine, dactinomycin, cyclophosphamide<sup>45</sup></li> <li>• Vincristine, doxorubicin, cyclophosphamide<sup>46</sup></li> <li>• Vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide<sup>47</sup></li> <li>• Vincristine, doxorubicin, ifosfamide<sup>48</sup></li> <li>• Cyclophosphamide and topotecan<sup>49,50</sup></li> <li>• Ifosfamide and doxorubicin<sup>51</sup></li> <li>• Ifosfamide and etoposide<sup>52</sup></li> <li>• Irinotecan and vincristine<sup>53,54</sup></li> <li>• Vincristine and dactinomycin<sup>55</sup></li> <li>• Carboplatin and etoposide<sup>56</sup></li> <li>• Vinorelbine and low-dose cyclophosphamide<sup>57</sup></li> <li>• Vincristine, irinotecan, temozolomide<sup>58</sup></li> </ul> <p><b>Single agents</b></p> <ul style="list-style-type: none"> <li>• Doxorubicin<sup>59</sup></li> <li>• Irinotecan<sup>53,60</sup></li> <li>• Topotecan<sup>61</sup></li> <li>• Vinorelbine<sup>62</sup></li> <li>• High-dose methotrexate<sup>i,63</sup></li> </ul>			

<sup>a</sup>Prior to the initiation of therapy, all patients should be evaluated and managed by a multidisciplinary team with expertise and experience in sarcoma.

<sup>b</sup>For uterine sarcomas, see the [NCCN Guidelines for Uterine Neoplasms](#).

<sup>c</sup>Alveolar soft part sarcoma (ASPS), well-differentiated liposarcoma/atypical lipomatous tumor, and clear cell sarcomas are generally not sensitive to cytotoxic chemotherapy.

<sup>d</sup>Anthracycline-based regimens are preferred in the neoadjuvant and adjuvant setting.

<sup>e</sup>Regimens appropriate for pleomorphic rhabdomyosarcoma.

<sup>f</sup>Recommended only for palliative therapy.

<sup>g</sup>Pazopanib should not be used for lipogenic sarcomas.

<sup>h</sup>Imatinib, sunitinib, and regorafenib are the three FDA agents approved for the treatment of GIST.

<sup>i</sup>High-dose methotrexate may be useful for select patients with CNS or leptomeningeal involvement when RT is not feasible.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continue](#)



**SYSTEMIC THERAPY AGENTS AND REGIMENS WITH ACTIVITY IN SOFT TISSUE SARCOMA<sup>a,c</sup>**

<p><b><u>Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor (PVNS/TGCT)</u></b></p> <ul style="list-style-type: none"> <li>• Imatinib<sup>64</sup></li> </ul>	
<p><b><u>Angiosarcoma</u></b></p> <ul style="list-style-type: none"> <li>• Paclitaxel<sup>65,66</sup></li> <li>• Docetaxel</li> <li>• Vinorelbine</li> <li>• Sorafenib<sup>67</sup></li> <li>• Sunitinib<sup>68</sup></li> <li>• Bevacizumab<sup>69</sup></li> <li>• All other systemic therapy options as per Soft Tissue Sarcoma Subtypes with Non-Specific Histologies (<a href="#">SARC-E 1 of 6</a>)</li> </ul>	<p><b><u>Solitary Fibrous Tumor/Hemangiopericytoma</u></b></p> <ul style="list-style-type: none"> <li>• Bevacizumab and temozolomide<sup>70</sup></li> <li>• Sunitinib<sup>71,72</sup></li> </ul>
<p><b><u>Alveolar Soft Part Sarcoma (ASPS)</u></b></p> <ul style="list-style-type: none"> <li>• Sunitinib<sup>73,74</sup> (category 2B)</li> </ul>	<p><b><u>PEComa, Recurrent Angiomyolipoma, Lymphangioliomyomatosis</u></b></p> <ul style="list-style-type: none"> <li>• Sirolimus<sup>75-78</sup></li> <li>• Everolimus<sup>79</sup></li> </ul>
<p><b><u>Inflammatory Myofibroblastic Tumor (IMT) with anaplastic lymphoma kinase (ALK) Translocation</u></b></p> <ul style="list-style-type: none"> <li>• Crizotinib<sup>80</sup></li> </ul>	

<sup>a</sup>Prior to the initiation of therapy, all patients should be evaluated and managed by a multidisciplinary team with expertise and experience in sarcoma.

<sup>c</sup>Alveolar soft part sarcoma, well-differentiated liposarcoma/atypical lipomatous tumor, and clear cell sarcomas are generally not sensitive to cytotoxic chemotherapy.

[References on next page](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**SYSTEMIC THERAPY AGENTS AND REGIMENS WITH ACTIVITY IN SOFT TISSUE SARCOMA (References)**

- <sup>1</sup>Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwest Oncology Group Study. *J Natl Cancer Inst.* 1991;83:926-932.
- <sup>2</sup>Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. *J Clin Oncol* 1993;11:1276-1285.
- <sup>3</sup>Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. *Lancet* 1997;350:1647-1654.
- <sup>4</sup>Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. *Cancer* 2008;113:573-581.
- <sup>5</sup>Grobmyer SR, Maki RG, Demetri GD, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. *Ann Oncol* 2004;15:1667-1672.
- <sup>6</sup>Edmonson J, Ryan L, Blum R, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. *J Clin Oncol* 1993;11:1269-1275.
- <sup>7</sup>Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. *J Clin Oncol* 1989;7:1208-1216.
- <sup>8</sup>Kraybill WG, Harris J, Spiro IJ, et al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. *Cancer* 2010;116:4613-4621.
- <sup>9</sup>Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant Chemotherapy for Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial. *J Clin Oncol* 2001;19:1238-1247.
- <sup>10</sup>Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. *J Clin Oncol* 2002;20:2824-2831.
- <sup>11</sup>Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. *J Clin Oncol* 2007; 25:2755-2763.
- <sup>12</sup>Dileo P, Morgan JA, Zahrieh D, et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. *Cancer* 2007;109:1863-1869.
- <sup>13</sup>Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. *J Clin Oncol* 2011;29:2528-2533.
- <sup>14</sup>Mack LA, Crowe PJ, Yang JL, et al. Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcoma. *Ann Surg Oncol* 2005;12:646-653.
- <sup>15</sup>Antman KH, Elias A. Dana-Farber Cancer Institute studies in advanced sarcoma. *Semin Oncol* 1990;1(Suppl 2):7-15.
- <sup>16</sup>Petrioli R, Coratti A, Correale P, et al. Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma. *Am J Clin Oncol* 2002;25:468-473.
- <sup>17</sup>Judson I, Radford J, Harris M, et al. Randomized phase II trial of pegylated liposomal doxorubicin versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer* 2001; 37:870-877.
- <sup>18</sup>Talbot SM, Keohan ML, Hesdorffer M, et al. A Phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. *Cancer* 2003; 98:1942-1946.
- <sup>19</sup>Kuttesch JF Jr, Krailo MD, Madden T, et al. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study. *Pediatr Blood Cancer* 2009; 53:590-593.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**SYSTEMIC THERAPY AGENTS AND REGIMENS WITH ACTIVITY IN SOFT TISSUE SARCOMA----References**

- <sup>20</sup>van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2012;379:1879-1886.
- <sup>21</sup>Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med* 2002;347:472-480.
- <sup>22</sup>Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial. *Lancet* 2004;364(9440):1127-1134.
- <sup>23</sup>Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet* 2006;368:1329-1338.
- <sup>24</sup>Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013;381:295-302.
- <sup>25</sup>Montemurro M, Gelderblom H, Bitz U, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. *Eur J Cancer* 2013;49:1027-1031.
- <sup>26</sup>Kindler HL, Campbell NP, Wroblewski K, et al. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. *J Clin Oncol* 2011;29:Abstract 10009.
- <sup>27</sup>Park SH, Ryu MH, Ryoo BY, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. *Invest New Drugs* 2012;30:2377-2383.
- <sup>28</sup>Montemurro M, Schoffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. *Eur J Cancer* 2009;45:2293-2297.
- <sup>29</sup>Sawaki A, Nishida T, Doi T, et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. *Cancer* 2011;117:4633-4641.
- <sup>30</sup>Trent JC, Wathen K, von Mehren M, et al. A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). *J Clin Oncol* 2011;29:Abstract 10006.
- <sup>31</sup>Tsukada K, Church JM, Jagelman DJ et al. Noncytotoxic therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. *Dis Colon Rectum* 1992; 35: 29–33.
- <sup>32</sup>Chao AS, Lai CH, Hsueh S, et al. Successful treatment of recurrent pelvic desmoid tumor with tamoxifen: case report. *Hum Reprod* 2000;15:311-313.
- <sup>33</sup>Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. *Cancer* 2004;100:612-620.
- <sup>34</sup>Benson JR MK, Baum M. Management of desmoid tumours including a case report of toremifene. *Ann Oncol* 1994;5:173-177.
- <sup>35</sup>Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. *Cancer* 2001;92(5):1259-1264.
- <sup>36</sup>Leithner A, Schnack B, Katterschafka T, et al. Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin. *J Surg Oncol* 2000;73:21-25.
- <sup>37</sup>Seiter K, Kemeny N. Successful treatment of a desmoid tumor with doxorubicin. *Cancer* 1993;71:2242-2244.
- <sup>38</sup>Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. *Cancer* 1993;72:3244-3247.
- <sup>39</sup>de Camargo VP, Keohan ML, D'Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). *Cancer* 2010;116:2258-2265.
- <sup>40</sup>Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. *Clin Cancer Res* 2010;16:4884-4891.
- <sup>41</sup>Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. *Ann Oncol* 2011;22:452-457.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.**

**SYSTEMIC THERAPY AGENTS AND REGIMENS WITH ACTIVITY IN SOFT TISSUE SARCOMA----References**

- <sup>42</sup>Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of Sorafenib against desmoid tumor/deep fibromatosis. *Clin Cancer Res* 2011;17:4082-4090.
- <sup>43</sup>Weiss AJ, Horowitz S, Lackman RD. Therapy of desmoid tumors and fibromatosis using vinorelbine. *Am J Clin Oncol* 1999;22:193-195.
- <sup>44</sup>Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. *Eur J Cancer* 2009;45:2930-2934.
- <sup>45</sup>Arndt CAS, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. *J Clin Oncol* 2009;27:5182-5188.
- <sup>46</sup>Little DJ, Ballo MT, Zagars GK, et al. Adult rhabdomyosarcoma: outcome following multimodality treatment. *Cancer* 2002;95:377-388.
- <sup>47</sup>Arndt CAS, Hawkins DS, Meyer WH, et al. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group. *Pediatr Blood Cancer* 2008;50:33-36.
- <sup>48</sup>Ogilvie CM, Crawford EA, Slotcavage RL, et al. Treatment of adult rhabdomyosarcoma. *Am J Clin Oncol* 2010;33:128-131.
- <sup>49</sup>Saylors RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. *J Clin Oncol* 2001;19:3463-3469.
- <sup>50</sup>Walterhouse DO, Lyden ER, Breitfeld PP, et al. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. *J Clin Oncol* 2004;22:1398-1403.
- <sup>51</sup>Sandler E, Lyden E, Ruymann F, et al. Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. *Med Pediatr Oncol* 2001;37:442-448.
- <sup>52</sup>Breitfeld PP, Lyden E, Raney RB, et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. *J Pediatr Hematol Oncol* 2001;23:225-233.
- <sup>53</sup>Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. *J Clin Oncol* 2007;25:362-369.
- <sup>54</sup>Mascarenhas L, Lyden ER, Breitfeld PP, et al. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group. *J Clin Oncol* 2010;28:4658-4663. Erratum in *J Clin Oncol* 2011;4629(4610):1394.
- <sup>55</sup>Raney RB, Walterhouse DO, Meza JL, et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *J Clin Oncol* 2011;29:1312-1318.
- <sup>56</sup>Klingebl T, Pertl U, Hess CF, et al. Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial. *Med Pediatr Oncol* 1998;30:269-275.
- <sup>57</sup>Casanova M, Ferrari A, Bisogno G, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. *Cancer* 2004;101:1664-1671.
- <sup>58</sup>McNall-Knapp,RY, Williams,CN, Reeves,EN, et al. Extended Phase I Evaluation of Vincristine, Irinotecan, Temozolomide, and Antibiotic in Children with Refractory Solid Tumors. *Pediatr Blood Cancer* 2010; 54:909-915.
- <sup>59</sup>Bergeron C, Thiesse P, Rey A, et al: Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: An up-front window study in newly diagnosed children with high-risk metastatic disease. *Eur J Cancer* 2008; 44:427-431.
- <sup>60</sup>Vassal G, Couanet D, Stockdale E, et al. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. *J Clin Oncol* 2007;25:356-361.
- <sup>61</sup>Pappo AS, Lyden E, Breneman J, et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. *J Clin Oncol* 2001;19:213-219.
- <sup>62</sup>Ferrari A, Spreafico F, Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. *Cancer* 2002;94:3263-3268.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.**



### SYSTEMIC THERAPY AGENTS AND REGIMENS WITH ACTIVITY IN SOFT TISSUE SARCOMA----References

- <sup>63</sup>Pappo AS, Bowman LC, Furman WL, et al. A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma. *J Pediatr Hematol Oncol* 1997;19:438-442.
- <sup>64</sup>Cassier PA, Gelderblom H, Stacchiotti S, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. *Cancer* 2012;118:1649-1655.
- <sup>65</sup>Penel N, Bui BN, Bay J-O, et al. Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study. *J Clin Oncol* 2008;26:5269-5274.
- <sup>66</sup>Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. *Eur J Cancer* 2008;44:2433-2436.
- <sup>67</sup>Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. *J Clin Oncol* 2009;27:3133-3140.
- <sup>68</sup>George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. *J Clin Oncol* 2009;27:3154-3160.
- <sup>69</sup>Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangi endotheliomas. *Ann Oncol* 2013;24:257-263.
- <sup>70</sup>Park MS, Patel SR, Ludwig JA, et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. *Cancer* 2011;117:4939-4947.
- <sup>71</sup>Stacchiotti S, Negri T, Libertini M, et al. Sunitinib malate in solitary fibrous tumor (SFT). *Ann Oncol* 2012;23:3171-3179.
- <sup>72</sup>George S, Merriam P, Maki RG, et al. Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas. *J Clin Oncol* 2009;27:3154-3160.
- <sup>73</sup>Stacchiotti S, Negri T, Zaffaroni N, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. *Ann Oncol* 2011;22:1682-1690.
- <sup>74</sup>Stacchiotti S, Tamborini E, Marrari A, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. *Clin Cancer Res* 2009;15:1096-1104.
- <sup>75</sup>Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangiomyomatosis. *N Engl J Med* 2008;358:140-151.
- <sup>76</sup>Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangiomyomatosis: a phase 2 trial. *Clin Cancer Res* 2011;17:4071-4081.
- <sup>77</sup>Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors. *J Clin Oncol* 2010;28:835-840.
- <sup>78</sup>McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangiomyomatosis. *N Engl J Med* 2011;364:1595-1606.
- <sup>79</sup>Gennatas C, Michalaki V, Kairi PV, et al. Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor. *World J Surg Oncol* 2012;10:181.
- <sup>80</sup>Butrynski JE, D'Adamo DR, Hornick JL, et al. NEJM Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor. *N Engl J Med* 2010; 363:1727-1733.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



**Table 1**  
**American Joint Committee On Cancer (AJCC) Staging System**  
**For Soft Tissue Sarcoma**  
**(7th ed, 2010)**

**Primary Tumor (T)**

- TX** Primary tumor cannot be assessed
- T0** No evidence of primary tumor
- T1** Tumor 5 cm or less in greatest dimension\*
  - T1a** Superficial tumor
  - T1b** Deep tumor\*
- T2** Tumor more than 5 cm in greatest dimension\*
  - T2a** Superficial tumor
  - T2b** Deep tumor

\*Superficial tumor is located exclusively above the superficial fascia without invasion of the fascia; deep tumor is located either exclusively beneath the superficial fascia, superficial to the fascia with invasion of or through the fascia, or both superficial yet beneath the fascia.

**Regional Lymph Nodes (N)**

- NX** Regional lymph nodes cannot be assessed
- N0** No regional lymph node metastasis
- N1†** Regional lymph node metastasis

†Presence of positive nodes (N1) in M0 tumors is considered Stage III.

**Distant Metastases (M)**

- M0** No distant metastasis
- M1** Distant metastasis

**Histologic Grade**

- GX** Grade cannot be assessed
- G1** Grade 1
- G2** Grade 2
- G3** Grade 3

**Anatomic Stage/Prognostic Groups**

<b>Stage IA</b>	T1a	N0	M0	G1, GX
	T1b	N0	M0	G1, GX
<b>Stage IB</b>	T2a	N0	M0	G1, GX
	T2b	N0	M0	G1, GX
<b>Stage IIA</b>	T1a	N0	M0	G2, G3
	T1b	N0	M0	G2, G3
<b>Stage IIB</b>	T2a	N0	M0	G2
	T2b	N0	M0	G2
<b>Stage III</b>	T2a,T2b	N0	M0	G3
	Any T	N1	M0	Any G
<b>Stage IV</b>	Any T	Any N	M1	Any G

[Continued...](#)

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science +Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit [www.springer.com](http://www.springer.com).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.



**Table 1 - Continued**

**Histopathologic Type**

Tumors included in the soft tissue category are listed below as per the 2002 World Health Organization classification of tumors:

**Adipocytic Tumors**

- Dedifferentiated liposarcoma\*
- Myxoid/round cell liposarcoma
- Pleomorphic liposarcoma

**Fibroblastic/Myofibroblastic Tumors**

- Fibrosarcoma\*\*
- Myxofibrosarcoma, low grade
- Low-grade fibromyxoid sarcoma
- Sclerosing epithelioid fibrosarcoma

**So-called Fibrohistiocytic Tumors**

- Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma (MFH) (including pleomorphic, giant cell, myxoid/high-grade myxofibrosarcoma and inflammatory forms)

**Smooth Muscle Tumors**

- Leiomyosarcoma

**Skeletal Muscle Tumors**

- Rhabdomyosarcoma (embryonal, alveolar, and pleomorphic forms)

**Vascular Tumors**

- Epithelioid hemangioendothelioma
- Angiosarcoma, deep\*\*\*

**Tumors of Peripheral Nerves**

- Malignant peripheral nerve sheath tumor

**Chondro-osseous Tumors**

- Extraskeletal chondrosarcoma (mesenchymal and other variants)
- Extraskeletal osteosarcoma

**Tumors of Uncertain Differentiation**

- Synovial sarcoma
- Epithelioid sarcoma
- Alveolar soft-part sarcoma
- Clear cell sarcoma of soft tissue
- Extraskeletal myxoid chondrosarcoma
- Primitive neuroectodermal tumor (PNET)/extraskeletal Ewing tumor
- Desmoplastic small round cell tumor
- Extrarenal rhabdoid tumor
- Undifferentiated sarcoma; sarcoma, not otherwise specified (NOS)

Notes: \*It is recognized that dedifferentiated liposarcoma primarily arises in the context of deep atypical lipomatous tumor/well-differentiated liposarcoma, a sarcoma of intermediate malignancy due to lack of metastatic capacity.

\*\*The category of fibrosarcoma can be considered to be inclusive of fibrosarcomatous differentiation in dermatofibrosarcoma protuberans.  
\*\*\*Cutaneous angiosarcoma may be difficult to stage using the AJCC system.

The following histologic types are *not* included: inflammatory myofibroblastic tumor, fibromatosis (desmoid tumor), mesothelioma, sarcomas arising in tissues apart from soft tissue (eg, parenchymal organs).

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit [www.springer.com](http://www.springer.com).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.



# NCCN Guidelines Version 2.2014 Staging Soft Tissue Sarcoma

## American Joint Committee On Cancer (AJCC) Staging System

### For Gastrointestinal Stromal Tumor

(7th ed, 2010)

#### Primary Tumor (T)

<b>TX</b>	Primary tumor cannot be assessed
<b>T0</b>	No evidence for primary tumor
<b>T1</b>	Tumor 2 cm or less
<b>T2</b>	Tumor more than 2 cm but not more than 5 cm
<b>T3</b>	Tumor more than 5 cm but not more than 10 cm
<b>T4</b>	Tumor more than 10 cm in greatest dimension

#### Regional Lymph Nodes (N)

<b>N0</b>	No regional lymph node metastasis*
<b>N1</b>	Regional lymph node metastasis

\* If regional node status is unknown, use N0, not NX.

#### Distant Metastasis (M)

<b>M0</b>	No distant metastasis
<b>M1</b>	Distant metastasis

#### Histologic Grade (G)

<b>GX</b>	Grade cannot be assessed
<b>G1</b>	Low grade; mitotic rate ≤5/50 HPF
<b>G2</b>	High grade; mitotic rate >5/50 HPF

#### Anatomic Stage/Prognostic Groups

*Gastric GIST\**

Group	T	N	M	Mitotic rate
<b>Stage IA</b>	T1 or T2	N0	M0	Low
<b>Stage IB</b>	T3	N0	M0	Low

#### Anatomic Stage/Prognostic Groups (Continued)

<b>Stage II</b>	T1	N0	M0	High
	T2	N0	M0	High
	T4	N0	M0	Low
<b>Stage IIIA</b>	T3	N0	M0	High
<b>Stage IIIB</b>	T4	N0	M0	High
<b>Stage IV</b>	Any T	N1	M0	Any rate
	Any T	Any N	M1	Any rate

*Small Intestinal GIST\*\**

Group	T	N	M	Mitotic rate
<b>Stage IA</b>	T1 or T2	N0	M0	Low
<b>Stage II</b>	T3	N0	M0	Low
<b>Stage IIIA</b>	T1	N0	M0	High
	T4	N0	M0	Low
	T2	N0	M0	High
<b>Stage IIIB</b>	T3	N0	M0	High
	T4	N0	M0	High
	Any T	N1	M0	Any rate
<b>Stage IV</b>	Any T	Any N	M1	Any rate

\*Note: Also to be used for omentum.

\*\*Note: Also to be used for esophagus, colorectal, mesentery, and peritoneum.

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit [www.springer.com](http://www.springer.com).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.



### Discussion

#### NCCN Categories of Evidence and Consensus

**Category 1:** Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2A:** Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2B:** Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

**Category 3:** Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

**All recommendations are category 2A unless otherwise noted.**

#### Table of Contents

<b>Overview</b> .....	<b>MS-2</b>
<b>Genetic Cancer Syndromes with Predisposition to STS</b> .....	<b>MS-2</b>
<b>Pathology of Soft Tissue Sarcomas</b> .....	<b>MS-4</b>
Biopsy.....	MS-4
Principles of Pathologic Assessment.....	MS-4
Molecular Diagnosis of Soft Tissue Sarcomas.....	MS-4
<b>Staging</b> .....	<b>MS-5</b>
<b>Surgery</b> .....	<b>MS-6</b>
<b>Radiation Therapy</b> .....	<b>MS-6</b>
<b>Chemotherapy/Chemoradiation</b> .....	<b>MS-7</b>
Resectable Disease.....	MS-7
Advanced, Unresectable, or Metastatic Disease .....	MS-9
<b>Targeted Therapy</b> .....	<b>MS-10</b>
<b>Soft Tissue Sarcomas of the Extremities, Superficial Trunk, or</b>	
<b>Head and Neck</b> .....	<b>MS-10</b>
Surgery.....	MS-10

Radiation Therapy.....	MS-11
Evaluation and Workup .....	MS-13
Stage I .....	MS-14
Stage II-III .....	MS-15
Unresectable Disease .....	MS-16
Stage IV (Synchronous Metastatic Disease).....	MS-17
Surveillance .....	MS-18
Recurrent Disease .....	MS-19

#### **Retroperitoneal/Intra-abdominal Soft Tissue Sarcomas.....MS-19**

Surgery .....	MS-19
Radiation Therapy.....	MS-19
Evaluation and Workup .....	MS-21
Resectable Disease .....	MS-21
Unresectable or Stage IV Disease .....	MS-22
Surveillance .....	MS-23
Recurrent Disease .....	MS-23

#### **Gastrointestinal Stromal Tumors.....MS-23**

Principles of Biopsy and Pathologic Assessment.....	MS-23
Prognostic Factors .....	MS-24
Principles of Surgery .....	MS-25
Targeted Therapy.....	MS-26
Initial Evaluation and Workup.....	MS-32
Imaging of GISTs .....	MS-32
Response Assessment.....	MS-33
Resectable Disease .....	MS-33
Unresectable, Metastatic, or Recurrent Disease .....	MS-35
Progressive Disease .....	MS-35
Continuation of TKI Therapy .....	MS-36
Surveillance .....	MS-36

#### **Desmoid Tumors (Aggressive Fibromatoses).....MS-36**

Evaluation and Workup .....	MS-37
Resectable Tumors .....	MS-37
Unresectable Tumors.....	MS-38
Surveillance .....	MS-40

#### **Rhabdomyosarcoma.....MS-40**

#### **References.....MS-43**



## Overview

Sarcomas constitute a heterogeneous group of rare solid tumors of mesenchymal cell origin with distinct clinical and pathologic features; they are usually divided into two broad categories:

- Sarcomas of soft tissues (including fat, muscle, nerve and nerve sheath, blood vessels, and other connective tissues); and
- Sarcomas of bone.

Sarcomas collectively account for approximately 1% of all adult malignancies and 15% of pediatric malignancies. In 2014, an estimated 12,020 people will be diagnosed with soft tissue sarcoma (STS) in the United States, with approximately 4,740 deaths.<sup>1</sup> The true incidence of STS is underestimated, especially because a large proportion of patients with gastrointestinal stromal tumors (GISTs) may not have been included in tumor registry databases before 2001. In the United States, the incidence of GISTs is expected to be at least 5000 new cases per year.<sup>2,3</sup> Prior radiation therapy (RT) to the affected area is a risk factor for the development of STS.<sup>4-6</sup> More than 50 different histologic subtypes of STS have been identified. The most common subtypes of STS are undifferentiated pleomorphic sarcoma, GISTs, liposarcoma, leiomyosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumors.<sup>7</sup> The anatomic site of the primary disease represents an important variable that influences treatment and outcome. Extremities (43%), the trunk (10%), visceral (19%), retroperitoneum (15%), or head and neck (9%) are the most common primary sites.<sup>8</sup> STS most commonly metastasizes to the lungs; tumors arising in the abdominal cavity more commonly metastasize to the liver and peritoneum. Rhabdomyosarcoma (RMS) is the most common STS of children and adolescents and is less common in adults.

The NCCN Guidelines for STS address the management of STS in adult patients from the perspective of the following disease subtypes:

- STS of extremity, superficial/trunk, or head and neck
- Retroperitoneal or intra-abdominal STS
- GISTs
- Desmoid tumors (aggressive fibromatoses)
- RMS

Prior to initiation of treatment, all patients should be evaluated and managed by a multidisciplinary team with extensive expertise and experience in the treatment of STS.<sup>9</sup>

## Genetic Cancer Syndromes with Predisposition to STS

Genetic cancer syndromes caused by germline mutations in a number of different genes are also associated with an inherited predisposition for the development of STS.<sup>5,10-14</sup>

Li-Fraumeni syndrome (resulting from germline mutations in the *TP53* tumor suppressor gene) is characterized by an increased risk of developing multiple primary malignancies, predominantly STS, osteosarcomas, breast cancer, leukemia, brain tumors, and adrenocortical carcinoma before 45 years of age.<sup>10,15-17</sup> The incidence of STS ranges from 12% to 21% in individuals with *TP53* germline mutations.<sup>18-20</sup> In general, STS associated with Li-Fraumeni syndrome is diagnosed at significantly younger ages than sporadic STS. The mean age at diagnosis, however, varies with the histologic subtype. In an analysis of 475 tumors in 91 families with *TP53* germline mutations, Kleihues and colleagues reported RMS, fibrosarcomas, and undifferentiated pleomorphic sarcomas as the most frequent histologic subtypes identified in 55%, 13%, and 10% of patients, respectively.<sup>18</sup> The mean age at diagnosis for RMS was younger than 6 years, and the

mean age at diagnosis for undifferentiated pleomorphic sarcomas was older than 50 years.

Familial adenomatous polyposis (FAP) is an inherited autosomal-dominant colorectal cancer syndrome resulting from the germline mutations in the adenomatous polyposis coli [*APC*] gene on chromosome 5q21.<sup>11,13</sup> FAP is characterized by adenomatous colorectal polyps that progress to colorectal cancer at 35 to 40 years of age. Gardner's syndrome is considered a variant of FAP with extracolonic manifestations such as osteomas, skin cysts, congenital hypertrophy of the retinal pigmented epithelium, and desmoid tumors (aggressive fibromatosis).<sup>21</sup> Desmoid tumors have been reported to occur in 7.5% to 16% of patients with FAP, and the relative risk of developing desmoid tumors is much higher in patients with FAP than the general population.<sup>22-25</sup> In an International Dutch Cohort study involving 2260 patients with FAP, positive family history for desmoid tumors, abdominal surgery, and the *APC* mutation site were identified as significant risk factors for the development of desmoid tumors.<sup>25</sup> The median age at diagnosis was 31 years, with the majority of desmoid tumors arising in the intra-abdominal and abdominal wall locations (53% and 24%, respectively).

Carney-Stratakis syndrome is an autosomal-dominant familial syndrome characterized by a predisposition to GISTs and paragangliomas.<sup>26</sup> Germline loss-of-function mutations within the succinate dehydrogenase (*SDH*) gene subunits (*SDHB*, *SDHC*, and *SDHD*) have been identified in individuals with GISTs associated with Carney-Stratakis syndrome.<sup>27</sup> In an analysis of 11 patients from 9 families presenting with the GIST and paragangliomas associated with Carney-Stratakis syndrome, Pasini and colleagues identified germline mutations in *SDHB*, *SDHC*, or *SDHD* genes in 8 patients (from 7 untreated families) with GISTs.<sup>27</sup> The tumors also lacked activating *KIT*

or platelet-derived growth factor receptor alpha (*PDGFRA*) mutations associated with sporadic GISTs. GISTs associated with Carney-Stratakis syndrome are also reported to be negative for SDHB protein expression by immunohistochemistry (IHC), in contrast to GIST with *KIT* or *PDGFRA* mutations or sporadic GIST.<sup>28,29</sup>

Hereditary retinoblastoma caused by a germline mutation in the retinoblastoma tumor suppressor gene (*RB1*) is also associated with an increased risk for the development of STS.<sup>12,30</sup> Leiomyosarcoma is the most frequent STS subtype (with 78% of leiomyosarcomas diagnosed 30 or more years after the diagnosis of retinoblastoma). Although patients with RT for retinoblastoma are at significantly increased risk of developing STS, the risks of developing STS are also increased in non-irradiated patients as well, indicating a genetic predisposition to STS that is independent of RT in patients with hereditary retinoblastoma.<sup>12</sup>

### NCCN Recommendations for Genetic Testing and Counseling for Patients with Germline Mutations

- Patients (and their families) with a personal and/or family history suggestive of Li-Fraumeni syndrome should be considered for further genetics assessment as outlined in the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian.
- *SDH* gene mutational analysis for the identification of germline mutations in the *SDH* gene subunits should be considered for patients with GIST lacking *KIT* or *PDGFRA* mutations. Loss of SDHB protein expression by IHC is a useful screen to identify patients who would be appropriate for germline mutation testing, but it is not diagnostic of a germline mutation.

- Evaluation for family history of FAP or Gardner's syndrome is recommended for patients diagnosed with desmoid tumors (aggressive fibromatoses).

## Pathology of Soft Tissue Sarcomas

### Biopsy

A pretreatment biopsy is highly preferred for the diagnosis and grading of STS, and should be performed by an experienced surgeon or radiologist. Biopsy should establish the malignancy, provide a specific diagnosis where possible and a grade where appropriate or feasible, recognizing that limited biopsy material may underestimate grade. Biopsy may be accomplished by open incisional or core needle technique. Core needle biopsy is preferred; however, an open incisional biopsy may be considered by an experienced surgeon. In patients without a definitive diagnosis following initial biopsy due to limited sampling size, repeat image-guided core needle biopsy should be considered to make a diagnosis. Although fine-needle aspiration (FNA) is a convenient technique, it can be difficult to make an accurate primary diagnosis with FNA alone due to small specimen size and is thus discouraged.<sup>31</sup> FNA may be acceptable in selected institutions with clinical and pathologic expertise. Endoscopic or needle biopsy may be indicated for deep thoracic, abdominal, or pelvic STS.

### Principles of Pathologic Assessment

Pathologists with expertise in STS should review the pathologic assessment of biopsies and resected specimens, especially for initial histopathologic classification. Margins must be thoroughly evaluated in these specimens. Morphologic assessment based on microscopic examination of histologic sections remains the gold standard of sarcoma diagnosis. The differential diagnosis of a soft tissue mass includes malignant lesions (such as primary or metastatic carcinoma,

melanoma, or lymphoma), desmoids, and benign lesions (such as lipomas, lymphangiomas, leiomyomas, and neuromas). However, since the identification of the histopathologic type of a sarcoma is often difficult, several ancillary techniques have been used as an adjunct to morphologic diagnosis. These techniques include conventional cytogenetics, IHC, electron microscopy, and molecular genetic testing. The pathologists should have access to optimal cytogenetic and molecular diagnostic techniques. The results of appropriate ancillary studies used as an adjunct to morphologic diagnosis should be included in the pathology report.

The pathology report should include specific details about the primary diagnosis (using standardized nomenclature according to the WHO Classification of STS tumor); the organ and site of sarcoma; depth, size, and histologic grade of the tumor; presence or absence of necrosis; status of excision margins and lymph nodes; tumor, node, and metastasis (TNM) stage; and additional features such as mitotic rate, presence or absence of vascular invasion, and the type and extent of inflammatory infiltration.

### Molecular Diagnosis of Soft Tissue Sarcomas

Molecular genetic testing has emerged as a particularly useful ancillary technique since many subtypes of STS are associated with characteristic genetic aberrations including single base-pair substitutions, deletions, amplifications, and translocations. STS can be divided into two major genetic groups: (i) sarcomas with specific genetic alterations (eg, chromosomal translocations or point mutations) and usually simple karyotypes; and (ii) sarcomas with non-specific genetic alterations and complex unbalanced karyotypes.<sup>32</sup>

STS with recurrent chromosomal translocations can be classified into subtypes depending on the presence of fusion gene transcripts (eg,



*EWSR1-ATF1* in clear cell sarcoma, *TLS-CHOP* [also known as *FUS-DDIT3*] in myxoid or round cell liposarcoma, *SS18-SSX* [*SS18-SSX1* or *SS18-SSX2*] in synovial sarcoma, and *PAX-FOXO1* [*PAX3-FOXO1* or *PAX7-FOXO1*] in alveolar RMS). The fusion genes resulting from chromosomal translocations can provide useful diagnostic and prognostic information. See *Principles of Ancillary Techniques Useful in the Diagnosis of Sarcomas* in the guidelines for a list of recurrent genetic aberrations associated with other subtypes.

Conventional cytogenetic analysis, fluorescence in situ hybridization and polymerase chain reaction (PCR) are the most common techniques used in the molecular diagnosis of STS.<sup>33</sup> In a prospective study, Hill and colleagues concluded that PCR-based molecular analysis is more sensitive than conventional cytogenetics and is a useful adjunct for the diagnosis of alveolar RMS, synovial sarcoma, and myxoid liposarcoma that have variation in fusion gene partners.<sup>34</sup>

The molecular heterogeneity of fusion gene transcripts has been suggested to predict prognosis in certain sarcoma subtypes. In patients with alveolar RMS presenting with metastatic disease, *PAX7-FOXO1* was associated with a favorable prognosis compared to *PAX3-FOXO1*.<sup>35</sup> In patients with synovial sarcoma, the prognostic impact of *SS18-SSX1* or *SS18-SSX2* is less clear with two large studies showing conflicting results.<sup>36,37</sup> In myxoid liposarcoma, the variability of fusion gene transcript has no effect on clinical outcome.<sup>38</sup>

While molecular genetic testing looks promising, it involves highly complex techniques and the methods are not absolutely sensitive or they do not provide specific results. Molecular testing should be performed by a pathologist with expertise in the use of molecular diagnostic techniques for the diagnosis of STS. In addition, technical limitations associated with molecular testing suggest that molecular

evaluation should be considered only as an ancillary technique. Molecular test results should therefore only be interpreted in the context of the clinical and pathologic features of a sarcoma.<sup>33</sup>

## Staging

The AJCC staging system for STS has historically used a four-grade system, but within the staging groups this effectively functioned as a 2-tiered system (G1/G2 [low] and G3/G4 [high]). The two most widely employed systems, the French Federation of Cancer Centers Sarcoma Group (FNCLCC) or the National Cancer Institute (NCI) system, are three-tiered grading systems. The NCI system is based on the evaluation of tumor histology, location, and amount of tumor necrosis. The FNCLCC system is based on tumor differentiation, mitosis count, and tumor necrosis. In a comparative study of these two systems in 410 adult patients with STS, the FNCLCC system showed a slightly increased ability to predict distant metastasis development and tumor mortality.<sup>39</sup> Riad and colleagues examined the impact of lymph node involvement on survival in patients with extremity sarcoma.<sup>40</sup> Lymph node metastases developed in 3.7% (39 out of 1066) patients who had surgery. The outcome of patients with isolated lymph node metastases was significantly better than with synchronous systemic and lymph node involvement (the estimated 4-year survival rates were 71% and 21%, respectively).<sup>40</sup> The outcome for patients with isolated lymph node involvement, treated with lymph node dissection, was also similar to that of patients with AJCC stage III extremity sarcomas.<sup>40,41</sup> The revised 2010 AJCC staging system incorporates a 3-tiered grading system, and lymph node disease has been reclassified as stage III rather than stage IV disease.<sup>42</sup> However, many clinicians prefer the 2-tiered system, which is also used in the algorithm.

### Surgery

Surgical resection (with appropriately negative margins) is the standard primary treatment for most patients with STS, although close margins may be necessary to preserve uninvolved critical neurovascular structures. RT and/or chemotherapy (in the case of chemosensitive histologies) are often used prior to surgery in many centers to downstage large high-grade tumors to enable effective surgical resection, because the risk of failure in the surgical bed can be high. Postoperative RT should be considered following resections with close soft tissue margins (less than 1 cm) or a microscopically positive margin on bone, major blood vessels, or a nerve. In selected cases when margin status is uncertain, consultation with a radiation oncologist is recommended.

The biopsy site should be excised en bloc with the definitive surgical specimen. Dissection should be through grossly normal tissue planes uncontaminated by tumor. If the tumor is close to or displaces major vessels or nerves, these need not be resected if the adventitia or perineurium is removed and the underlying neurovascular structures are not involved with gross tumor. Radical excision or entire anatomic compartment resection is not routinely necessary. If resections with microscopically positive or grossly positive margins are anticipated, surgical clips should be left in place to identify high-risk areas for recurrence, particularly for retroperitoneal or intra-abdominal sarcomas to help guide future RT. If closed suction drainage is used, the drains should exit the skin close to the edge of the surgical incision (in case re-resection or RT is indicated).

Both the surgeon and the pathologist should document surgical margins, while evaluating a resected specimen. If surgical margins are positive on final pathology, re-resection to obtain negative margins

should strongly be considered if it will not have a significant impact upon functionality.<sup>43</sup> In an analysis of 666 consecutive patients with localized STS treated with an apparent macroscopic total tumor resection, 295 patients underwent re-resection of their tumor bed (residual tumor was found in 46% of patients, including macroscopic tumor in 28% of patients).<sup>43</sup> Reresection remained a significant predictor of local control. The local control rates at 5, 10, and 15 years were 85%, 85%, and 82%, respectively, for patients who underwent re-resection. The corresponding local control rates were 78%, 73%, and 73%, respectively ( $P = .03$ ), for patients who did not undergo re-resection.

### Radiation Therapy

RT can be administered either as primary, preoperative, or postoperative treatment. Total RT doses are always determined based on the tissue tolerance. Newer RT techniques such as brachytherapy, intraoperative RT (IORT), and intensity-modulated RT (IMRT) have led to the improvement of treatment outcomes in patients with STS. Brachytherapy involves the direct application of radioactive seeds into the tumor bed through catheters placed during surgery. Options include low-dose rate (LDR) brachytherapy, fractionated high-dose rate (HDR) brachytherapy, or intraoperative HDR brachytherapy. LDR and HDR brachytherapy are associated with similar rates of local control.<sup>44</sup> It has been suggested that HDR brachytherapy may be associated with lower incidences of severe toxicity; however, this has not been proven in randomized clinical trials.<sup>44</sup> The main advantage of IMRT is its ability to more closely contour the high-dose radiation volume thereby minimizing the volume of high-dose radiation to the surrounding normal tissues.<sup>45</sup> IORT is the delivery of radiation during surgery and it can be performed using different techniques such as electron beam RT or brachytherapy.<sup>46</sup>



Preoperative RT may reduce seeding during the surgical manipulation of the tumor. The tumor may or may not regress with preoperative RT, but the pseudocapsule may thicken and become acellular, easing resection and decreasing the risk of recurrence.<sup>47-49</sup> Most institutions include the entire operative bed within the RT field. The main disadvantage of preoperative RT, however, is its effect on wound healing.<sup>50,51</sup> After preoperative RT, a 3- to 6-week interval is necessary before resection to allow acute reactions to subside and decrease the risk of wound complications. Involvement of a plastic surgeon in the team may be necessary to reduce wound complications when preoperative RT is contemplated.

Postoperative RT is associated with higher rates of long-term treatment-related side effects. In one retrospective analysis, although there was no evidence for differences in disease outcome associated with the use of either preoperative or postoperative RT, there was a slight increase in late treatment-related side effects with postoperative RT, mainly due to the higher doses used.<sup>52</sup> Positive surgical margins are associated with higher rates of local recurrence.<sup>53</sup> Postoperative RT has been shown to improve local control in patients with positive surgical margins.<sup>54</sup> Of those with positive margins, RT doses >64 Gy, microscopically positive margins, superficial location, and extremity site are associated with improved local control. Postoperative RT boost of 16 Gy has been used in patients with positive surgical margins after the wound has healed. However, the results of a recent retrospective analysis showed that postoperative RT boost did not provide any advantage in preventing local recurrence in some patients with positive surgical margins (such as those with low-grade, well-differentiated liposarcoma and a focally, “planned” positive margin on an anatomically fixed critical structure).<sup>55</sup>

The advantage of adding postoperative RT boost has not yet been evaluated in a randomized clinical trial. Intervals beyond 8 weeks between resection and postoperative RT are not recommended, because of the development of late fibrosis and the proliferation of malignant cells. The risk of local recurrence versus the toxicity of postoperative RT should be assessed before making a decision regarding the use of postoperative RT.

## **Chemotherapy/Chemoradiation**

### **Resectable Disease**

#### ***Preoperative Therapy***

Preoperative chemotherapy<sup>56-59</sup> or chemoradiation<sup>60-67</sup> has been evaluated in single and multicenter studies in patients with high-grade tumors.

Studies that have evaluated preoperative chemotherapy followed by surgery have reported inconsistent findings. The results of the only randomized study that compared surgery alone vs. preoperative chemotherapy followed by surgery in 134 evaluable patients with high-risk tumors (tumors ≥8 cm of any grade, grade II/III tumors <8 cm, grade II/III locally recurrent tumors, or tumors with inadequate surgery) did not show a major survival benefit for patients receiving chemotherapy.<sup>57</sup> At a median follow-up of 7.3 years, the estimated 5-year disease-free survival (DFS) rate was 52% for the no chemotherapy arm and 56% for the chemotherapy arm ( $P = .3548$ ). The corresponding 5-year overall survival (OS) rate for both arms was 64% and 65%, respectively ( $P = .2204$ ). A cohort analysis of 674 patients with stage III STS of extremity treated at a single institution revealed that clinical benefits associated with preoperative or postoperative doxorubicin-based chemotherapy were not sustained beyond one year.<sup>58</sup> In another retrospective study, the benefit of

preoperative chemotherapy was only seen in patients with high-grade extremity tumors larger than 10 cm but not in patients with tumors 5 to 10 cm.<sup>59</sup>

In a single-institution study involving 48 patients with high-grade extremity STS (8 cm or larger), the outcome of patients treated with preoperative chemoradiation with the MAID (mesna, doxorubicin, ifosfamide, and dacarbazine) regimen followed by surgery and postoperative chemotherapy with the same regimen were superior to that of historical controls.<sup>62</sup> The 5-year actuarial local control, freedom from distant metastasis, DFS, and OS rates were 92% and 86% ( $P = .1155$ ), 75% and 44% ( $P = .0016$ ), 70% and 42% ( $P = .0002$ ), and 87% and 58% ( $P = .0003$ ) for the MAID and control groups, respectively.<sup>62</sup> The same protocol was later evaluated in the RTOG 9514 study of 66 patients with large (8 cm or larger), high-grade (stage II or III; grade 2 or 3 in a three-tier grading system), primary, or locally recurrent STS of the extremities or trunk.<sup>64,65</sup> The 5-year rates of locoregional failure (including amputation) and distant metastasis were 22% and 28%, respectively, with a median follow-up of 7.7 years. The estimated 5-year DFS, distant DFS, and OS rates were 56%, 64%, and 71%, respectively.<sup>65</sup> Long-term follow-up data of these studies confirmed that preoperative chemoradiation followed by resection and postoperative chemotherapy with a doxorubicin-based regimen improves local control and OS and DFS rates in patients with high-grade STS of extremity and body wall; however, preoperative chemoradiation was associated with significant short-term toxicities.<sup>65,66</sup>

### **Postoperative Therapy**

Available evidence from meta-analyses<sup>68-72</sup> and randomized clinical trials<sup>73-77</sup> suggest that postoperative chemotherapy improves relapse-free survival (RFS) in patients with STS of extremities. However, data regarding OS advantage are conflicting.

The Sarcoma Meta-Analysis Collaboration (SMAC) performed a meta-analysis of 14 randomized studies (1,568 patients), which compared postoperative chemotherapy to follow-up and in some cases RT after surgery with a variety of sarcomas.<sup>69</sup> The result of the meta-analysis showed that doxorubicin-based chemotherapy prolongs local and distant recurrence and overall RFS in adults with localized, resectable STS of the extremity and is associated with decreased recurrence rates. The OS advantage was not significant, although there was a trend in favor of postoperative chemotherapy.

An updated meta-analysis also confirmed the marginal efficacy of postoperative chemotherapy in terms of local, distant, and overall recurrence as well as OS (which is contrary to that reported in the SMAC meta-analysis) in patients with localized STS.<sup>71</sup> A recent large, cohort-based analysis with a median follow-up of 9 years indicated that postoperative chemotherapy may be associated with significantly improved 5-year metastasis-free survival (58% vs. 49%,  $P = .01$ ) and 5-year OS (58% vs. 45%,  $P = .0002$ ) in patients with FNCLCC grade 3 STS, whereas it was not significantly different in those with FNCLCC grade 2 STS (5-year metastasis-free survival: 76% vs. 73%,  $P = .27$ ; 5-year OS: 75% vs. 65%,  $P = .15$ ).<sup>72</sup>

In the Italian randomized cooperative study, which randomized patients with high-grade or recurrent extremity sarcoma to receive postoperative chemotherapy with epirubicin and ifosfamide or observation alone, after a median follow-up of 59 months, median DFS (48 vs. 16 months) and median OS (75 months vs. 46 months) were significantly better in the treatment group; the absolute benefit for OS from chemotherapy was 13% at 2 years and increased to 19% at 4 years for patients receiving chemotherapy.<sup>74</sup> After a median follow-up of 90 months, the estimated 5-year OS rate was 66% and 46%, respectively ( $P = .04$ ), for the

treatment group and the control group; however, the difference was not statistically different in the intent-to-treat analysis.<sup>78</sup>

In another phase III randomized study (EORTC-62931), 351 patients with macroscopically resected grade II-III tumors with no metastases were randomized to observation or postoperative chemotherapy with ifosfamide and doxorubicin with lenograstim.<sup>76</sup> A planned interim analysis of this study showed that there is no survival advantage for postoperative chemotherapy in patients with resected high-grade STS. The estimated 5-year RFS was 52% in both arms and the corresponding OS rates were 64% and 69%, respectively, for patients assigned to postoperative chemotherapy and observation. Further analysis of this study is needed to make a detailed assessment of the role of postoperative chemotherapy in resected STS. These findings are consistent with the results reported in an earlier EORTC study by Bramwell and colleagues.<sup>73</sup> In this study, postoperative chemotherapy with CYVADIC (cyclophosphamide, vincristine, doxorubicin, and dacarbazine) was associated with higher RFS rates (56% vs. 43% for the control group;  $P = .007$ ) and significantly lower local recurrence rates (17% vs. 31% for the control group;  $P = .004$ ). However, there were no differences in distant metastases (32% and 36%, respectively, for CYVADIC and the control group;  $P = .42$ ) and OS rates (63% and 56%, respectively, for CYVADIC and the control group;  $P = .64$ ). Long-term follow-up results of another prospective randomized study also showed that postoperative chemotherapy with IFADIC (ifosfamide, dacarbazine, and doxorubicin given every 14 days with growth factor support) did not result in significant benefit in terms of RFS (39% for IFADIC and 44% for the control group;  $P = .87$ ) as well as OS ( $P = .99$ ) for patients with grade 2 or 3 STS.<sup>77</sup>

### Advanced, Unresectable, or Metastatic Disease

Chemotherapy with single agents (dacarbazine, doxorubicin, epirubicin, or ifosfamide) or anthracycline-based combination regimens (doxorubicin or epirubicin with ifosfamide and/or dacarbazine) have been widely used for patients with advanced, unresectable, or metastatic disease.<sup>79-90</sup> Other chemotherapeutic agents such as gemcitabine, docetaxel, vinorelbine, pegylated liposomal doxorubicin, and temozolomide have also been evaluated in clinical trials.

Gemcitabine in combination with docetaxel, vinorelbine, or dacarbazine has been shown to be active in patients with unresectable or metastatic STS of various histologic subtypes.<sup>91-94</sup> In a randomized phase II study, the combination of gemcitabine and docetaxel was associated with superior PFS (6.2 months and 3.0 months, respectively) and OS (17.9 months and 11.5 months, respectively) compared to gemcitabine alone in patients with metastatic STS.<sup>92</sup> In another phase II study, the combination of gemcitabine and vinorelbine was also associated with clinically meaningful rates of disease control in patients with advanced STS.<sup>93</sup> Clinical benefit (complete response [CR], partial response [PR], or stable disease at 4 months or more) was seen in 25% of patients. In a more recent randomized study, the combination of gemcitabine and dacarbazine resulted in superior progression-free survival (PFS; 4.2 months vs. 2 months;  $P = .005$ ), OS (16.8 months vs. 8.2 months;  $P = .014$ ), and objective response rate (49% vs. 25%;  $P = .009$ ) than dacarbazine alone in patients with previously treated advanced STS.<sup>94</sup>

Temozolomide,<sup>95-97</sup> pegylated liposomal doxorubicin,<sup>98</sup> and vinorelbine<sup>99,100</sup> have also shown activity as single agents in patients with advanced, metastatic, relapsed, or refractory disease. In a phase II study by the Spanish Group of Research on Sarcomas, temozolomide resulted in an overall response rate of 15.5% with a median OS of 8

months in patients with advanced pretreated STS.<sup>97</sup> The PFS rates at 3 months and 6 months were 39.5% and 26%, respectively. In a prospective randomized phase II study, pegylated liposomal doxorubicin had equivalent activity and improved toxicity profile compared to doxorubicin; response rates were 9% and 10% for doxorubicin and pegylated liposomal doxorubicin, respectively, in patients with advanced or metastatic STS.<sup>98</sup> In a retrospective study of pretreated patients with metastatic STS, vinorelbine induced overall response in 6% of patients and 26% had stable disease.<sup>99</sup>

Trabectedin is a novel DNA-binding agent that has shown objective responses in phase II studies of patients with advanced STS.<sup>101-105</sup> An interventional, open-label, multicenter safety study is being conducted to facilitate access to trabectedin for eligible previously treated patients with STS (excluding leiomyosarcoma and liposarcoma), who cannot be expected to benefit from currently available therapeutic options but who may benefit from treatment with trabectedin.

### Targeted Therapy

More recently, a number of targeted therapies have shown promising results in patients with certain histologic types of advanced or metastatic STS.

Pazopanib, a multitargeted tyrosine kinase inhibitor (TKI) has demonstrated single-agent activity in patients with advanced STS subtypes except liposarcomas.<sup>106</sup> In a phase III study (EORTC 62072), 369 patients with metastatic non-lipogenic STS who had failed at least one anthracycline-based chemotherapy regimen were randomized to either pazopanib or placebo.<sup>107</sup> Pazopanib significantly prolonged median PFS (4.6 months vs. 1.6 months for placebo;  $P < .0001$ ) and there was also a trend toward improved OS (12.5 months and 11 months, respectively;  $P = .25$ ), although it was not statistically

significant. The guidelines have included pazopanib as an option for palliative therapy for patients with progressive, unresectable, or metastatic non-lipogenic STS.

Imatinib<sup>108</sup> and sunitinib<sup>109,110</sup> have also shown efficacy in patients with advanced and/or metastatic STS other than GIST. Crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, was active in inflammatory myofibroblastic tumor with ALK translocation.<sup>111</sup> mTOR inhibitors such as sirolimus and everolimus have also shown promising results in patients with metastatic perivascular epithelioid cell tumors (PEComas) and in patients with recurrent lymphangiomyomatosis or angiomyolipomas.<sup>112-116</sup>

Bevacizumab either alone or in combination with temozolomide was well tolerated and effective in patients with metastatic or locally advanced or recurrent epithelioid hemangiopericytoma and malignant solitary fibrous tumor.<sup>117,118</sup>

### Soft Tissue Sarcomas of the Extremities, Superficial Trunk, or Head and Neck

#### Surgery

Positive surgical margin is a strong predictor of local recurrence for patients with extremity STS.<sup>119-124</sup> Microscopically positive margins are associated with a higher rate of local recurrence and a lower rate of DFS in patients with extremity sarcomas.<sup>119,120,122</sup> In a large cohort study (1668 patients) that examined the clinical significance of the main predictors of local recurrence in patients with STS of extremity and trunk, the 10-year cumulative possibility of local recurrence was significantly higher for patients with positive surgical margins (23.9 vs. 9.2 for those with negative margins;  $P < .001$ ).<sup>123</sup> In a recent retrospective study that evaluated 278 patients with STS of the extremities treated between 2000 and 2006, the risk of patients with a

positive margin were 3.76 times more likely to develop local recurrence than those with negative margins (38% risk of local recurrence after 6 years if the margins are positive compared to 12% if the margins are negative).<sup>124</sup>

Amputation was once considered as the standard treatment to achieve local control in patients with extremity sarcomas.<sup>125</sup> In recent years, technical advances in reconstructive surgical procedures, implementation of multimodality therapy, and improved selection of patients for adjuvant therapy have minimized the functional deficits in patients who might otherwise require amputation.

In 1982, a randomized control study of 43 patients showed that limb-sparing surgery with RT was an effective treatment in patients with high-grade STS of the extremities, with a local recurrence rate of 15% and no difference in OS and DFS as compared to amputation.<sup>126</sup> In another series of 77 patients treated with limb-sparing surgery without RT, the local recurrence rate was only 7% and resection margin status was a significant predictor of local recurrence.<sup>127</sup> The local recurrence rate was 13% when the resection margin was 1 cm or less as compared to 0% when the resection margin was 1 cm or more. In a retrospective study of 115 patients with a STS of hand or foot, radical amputation as an initial treatment did not decrease the probability of regional metastasis and also did not improve the disease-specific survival.<sup>128</sup> These results suggest that limb-sparing surgery with or without postoperative RT is an effective treatment option for extremity STS and amputation should be reserved only for cases where resection or reresection with adequate margins cannot be performed without sacrificing the functional outcome. The guidelines recommend that the goal of surgery for patients with STS of extremities should be functional limb preservation, if possible, within the realm of an appropriate oncologic resection. Limb-sparing surgery is recommended for most

patients with STS of extremities to achieve local tumor control with minimal morbidity.

Amputation may improve local control in patients who might not be candidates for limb salvage surgery and it should be considered with patient preference, or if the gross total resection of the tumor is expected to render the limb nonfunctional.<sup>129-132</sup>

Prior to considering amputation, the patient should be evaluated by a surgeon with expertise in the treatment of STS. Evaluation for postoperative rehabilitation is recommended for all patients with extremity sarcoma. If indicated, rehabilitation should be continued until maximum function is achieved.

### Radiation Therapy

Data from randomized studies<sup>53,133,134</sup> and retrospective analyses<sup>50,135-137</sup> support the use of preoperative or postoperative external beam RT (EBRT) in appropriately selected patients. Brachytherapy (alone or in combination with EBRT)<sup>135,138,139</sup> and IMRT<sup>140,141</sup> have also been evaluated as an adjunct to surgery.

In a phase III randomized study conducted by the Canadian Sarcoma group, local control and PFS rates were similar in patients receiving either preoperative or postoperative RT in patients with localized primary or recurrent disease.<sup>134,142</sup> However, preoperative RT was associated with a greater incidence of acute wound complications (35% vs. 17% for postoperative RT), especially in lower extremity tumors (43% vs. 5% for upper extremity tumors), and late-treatment-related side effects were more common in patients receiving postoperative RT, which is believed to be related to the higher RT dose (66 Gy vs. 50 Gy for preoperative RT) and the larger treatment volume.<sup>134,143</sup> In a more recent phase II study, O'Sullivan and colleagues reported that



preoperative IMRT resulted in lower wound complication rate in patients with high-grade lesions (30.5% vs. 43% reported in earlier study using conventional EBRT).<sup>144</sup>

The efficacy of postoperative EBRT following limb-sparing surgery was demonstrated in a prospective randomized study (91 patients with high-grade lesions and 51 patients with low-grade lesions).<sup>133</sup> Postoperative RT significantly reduced the 10-year local recurrence rate among patients with high-grade lesions (no local recurrences in patients who underwent surgery plus RT vs. 22% in those who underwent surgery alone;  $P = .0028$ ). Among patients with low-grade lesions, the corresponding recurrence rates were 5% and 32%, respectively.<sup>133</sup> The probability of reduction in the local recurrence rate in patients receiving EBRT was not significant in patients with low-grade lesions, suggesting postoperative RT after limb-sparing surgery may not be necessary for this group of patients. In a report from the Memorial Sloan-Kettering Cancer Center (MSKCC) that reviewed the long-term outcomes of 200 patients treated with limb-sparing surgery, pathologically negative re-resection without RT was associated with a 5-year overall local recurrence rate of 9%, at a median follow-up of 82 months.<sup>145</sup> Old age and/or stage III disease were associated with a higher rate of local recurrence. Therefore, treatment decisions regarding the use of postoperative RT should be individualized and not be solely based on the findings of margin negative re-resection.

In a prospective randomized study, 164 patients with completely resected STS of the extremity or superficial trunk were randomized intraoperatively to receive either brachytherapy or no brachytherapy.<sup>138</sup> With a median follow-up time of 76 months, the 5-year local control rates were 82% and 69% in the brachytherapy and no brachytherapy groups, respectively. Patients with high-grade lesions who received

brachytherapy had higher local control rates compared to those who received no brachytherapy (89% and 66%, respectively). However, brachytherapy had no impact on local control in patients with low-grade lesions. The 5-year freedom-from-distant-recurrence rates were 83% and 76%, respectively, in the two groups. In a retrospective analysis of 202 adult patients with primary high-grade STS of the extremity, brachytherapy following limb-sparing surgery resulted in lower rates of wound complications, favorable 5-year local control, and distant RFS and OS rates (84%, 63%, and 70%, respectively).<sup>139</sup>

In a retrospective analysis of 41 patients with STS of extremity treated with limb-sparing surgery, postoperative IMRT resulted in a 5-year local control rate of 94% in patients with negative as well as positive or close margins, in selected patients with high-risk features.<sup>140</sup> The risk of complications such as edema and joint stiffness were also favorable when compared with conventional RT. In a nonrandomized comparison of IMRT and brachytherapy in patients with high-grade, primary, nonmetastatic STS of extremity, local control was significantly better with IMRT than brachytherapy (5-year local control rates were 92% and 81%, respectively;  $P = .04$ ) despite higher rates of adverse features for IMRT.<sup>141</sup>

Recent reports from a retrospective study suggest that IORT provides excellent local control to STS of the extremity.<sup>146,147</sup> Call and colleagues recently reported long-term outcome of patients with STS of upper extremity treated with EBRT, surgery, and IORT. The 10-year local control and OS rates were 88% and 58%, respectively.<sup>147</sup> The 10-year local control rates were 89% and 86%, respectively, following margin-negative (R0) and margin-positive (R1 and R2) resections.

Although the use of IMRT and IORT has resulted in excellent clinical outcomes, their efficacy needs to be confirmed in larger cohorts of patients with longer follow-up.

### **Guidelines for Radiation Therapy**

When EBRT is used, sophisticated treatment planning with IMRT, tomotherapy, and/ or proton therapy can be used to improve therapeutic effect. RT is not a substitute for definitive surgical resection with negative margins, and re-resection to negative margins is preferable. If the patient has not previously received RT, one could attempt to control microscopic residual disease with postoperative RT if re-resection is not feasible. The usual dose of preoperative RT is 50 Gy. Postoperative RT is recommended for all patients with positive margins.<sup>148</sup> If wide margins are obtained, postoperative RT may not be necessary.

For patients treated with preoperative RT followed by surgery, the guidelines recommend consideration of postoperative RT boost for patients with positive margins. The recommended EBRT doses are 16 to 18 Gy for microscopic residual disease, and 20 to 26 Gy for macroscopic residual disease. Brachytherapy boosts should be delivered several days after surgery, through catheters placed at operation, with doses of 16 to 26 Gy for LDR brachytherapy and 14 to 24 Gy for HDR brachytherapy, based on the margin status. Alternatively, IORT (10 to 12.5 Gy for microscopic residual disease and 15 Gy for gross residual disease) can be delivered immediately after resection to the area at risk, avoiding the uninvolved organs.<sup>146</sup>

For patients who have not received preoperative RT, the postoperative choices include EBRT (50 Gy irrespective of surgical margins), IORT (10 to 16 Gy followed by 50 Gy EBRT), or brachytherapy. The guidelines recommend 45 Gy LDR brachytherapy or HDR equivalent

for patients with negative margins. LDR brachytherapy (16 to 20 Gy) or HDR equivalent is recommended for patients with positive margins followed by EBRT. EBRT following IORT or brachytherapy is delivered to the target volume to a total dose of 50 Gy, after surgical healing is complete (3 to 8 weeks).

For patients treated with postoperative EBRT, the guidelines recommend an additional EBRT boost to the original tumor bed based on the margin status (10 to 16 Gy for negative surgical margin; 16 to 18 Gy for microscopic residual disease; and 20 to 26 Gy for grossly positive margins). However, many institutions are no longer giving a boost after preoperative RT to patients who have widely negative margins, based on local control rates approaching 95% with preoperative RT at 50 Gy and negative margins. The panel also emphasizes that RT does not substitute for suboptimal surgical resection and re-resection is preferred for patients with positive surgical margins.

### **Evaluation and Workup**

The differential diagnosis of STS of the extremities includes ruling out desmoid tumors (aggressive fibromatosis), as well as the other malignant and benign lesions. An essential element of the workup is a history and physical (H&P) examination, adequate imaging of the primary tumor and distant metastases, and a carefully planned biopsy (core needle or incisional biopsy). Adequate and high-quality imaging studies are crucial to good clinical management of patients, because the presence of metastatic disease may change the management of the primary lesion and the overall approach to the patient's disease management. The propensities to spread to various locations vary between the subtypes of sarcoma. Therefore, imaging should be

individualized based on the subtype of sarcoma. Laboratory tests have a limited role.

Imaging studies should include cross sectional imaging (MRI with or without CT) to provide details about tumor size and contiguity to nearby visceral structures and neurovascular landmarks. MRI is preferred for extremity sarcomas, whereas CT is preferred for retroperitoneal sarcomas.<sup>149-151</sup> Other imaging studies such as CT angiogram and plain radiograph may be warranted in selected circumstances. Given the risk for hematogenous spread from a high-grade sarcoma to the lungs, imaging of the chest is essential for accurate staging. Abdominal/pelvic CT should be considered for angiosarcoma, leiomyosarcoma, myxoid round cell liposarcoma or epithelioid sarcoma as well as STS without definitive pathology prior to final resection. MRI of the total spine should be considered for myxoid round cell liposarcomas due to the higher risk of metastasis to the spine compared to other STS.<sup>152-154</sup> Alveolar soft part sarcoma has a relatively increased propensity to metastasize to the brain, especially in patients with stage IV disease in the presence of pulmonary metastases.<sup>155</sup> Central nervous system imaging should be considered for patients with alveolar soft part sarcoma and angiosarcoma.

PET scans may be useful in prognostication, grading, and determining histopathologic response to chemotherapy for firm and deep (not superficial) lesions larger than 3 cm in patients with high-grade extremity STS.<sup>156-161</sup> The maximum standardized uptake (SUVmax) value of F18-deoxyglucose has been shown to correlate with tumor grade and prognostication.<sup>162,163</sup> In a retrospective study, tumor SUVmax determined by PET was an independent predictor of survival and disease progression.<sup>156</sup> Schuetze and colleagues reported that the pretreatment SUVmax and change in SUVmax after preoperative chemotherapy independently identified patients with a high risk of

recurrence.<sup>157</sup> Patients with a change in the SUVmax of 40% or more in response to chemotherapy were at a significantly lower risk of recurrence and death after complete resection and postoperative RT; the projected 5-year RFS rate for this group of patients was 80% compared to 40% for those with a less than 40% reduction in SUVmax.<sup>157</sup> PET was useful in the early assessment of response to preoperative chemotherapy and was also significantly more accurate than the RECIST criteria in the assessment of histopathologic response to preoperative chemotherapy.<sup>160,159</sup> In a prospective study of 50 patients with resectable, high-grade STS, a 35% reduction in the SUV after first cycle of chemotherapy was a sensitive predictor of histopathologic response.<sup>160</sup> The value of combined PET/CT in predicting DFS in patients receiving preoperative chemotherapy for STS is being evaluated in an ongoing large prospective study.

Based on the initial workup, the patients are assigned to one of the following categories:

- Stage I
- Stage II-III
- Unresectable disease
- Stage IV (Synchronous Metastatic Disease)
- Recurrent disease

### Stage I

Surgery (with intent to obtain negative margins) is the primary treatment for T1a-2b, N0, M0 tumors and is considered definitive if margins are greater than 1 cm or the fascial plane is intact.<sup>164,165</sup> If the surgical margins are 1.0 cm or less and without an intact fascial plane, re-resection may be necessary.<sup>145</sup>

Data from prospective studies support the use of RT as an adjunct to surgery in appropriately selected patients based on an improvement in DFS although not OS.<sup>120,122,138</sup> Postoperative RT is recommended for patients with final surgical margins of 1.0 cm or less and without an intact fascial plane (category 2B for T1a-1b tumors and category 1 for T2a-2b tumors). RT may not be necessary in patients with small low-grade lesions (5 cm or less), because these tumors are less frequently associated with local recurrence.<sup>133</sup> Therefore, observation is included as an option for patients with T1a-1b tumors with final surgical margins of 1.0 cm or less and with an intact fascial plane.

En bloc resection with negative margins is generally sufficient to obtain long-term local control in patients with atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDLS).<sup>166,167</sup> In one report that reviewed 91 patients with ALT/WDLS of the extremity and trunk, positive surgical margins were associated with reduced local RFS, suggesting that function-preserving re-resection when possible or adjuvant RT could be considered for selected patients with positive surgical margins.<sup>168</sup> RT may also be an appropriate treatment option for selected patients with recurrent disease or deeply infiltrative primary lesions with a risk of local recurrence, depending on the tumor location and patient's age.<sup>169</sup>

### Stage II-III

Treatment options should be decided by a multidisciplinary team with extensive experience in the treatment of patients with STS, based on the patient's age, performance status, comorbidities, location, and histologic subtype of the tumor.

Preoperative chemoradiation has been shown to improve OS, DFS, and local control rates in patients with high-grade STS of extremity and trunk, although acute reactions must be considered.<sup>65,66</sup> The results of

the only randomized study showed that preoperative chemotherapy is not associated with a major survival benefit for patients with high-grade tumors.<sup>57</sup>

The results of a recent phase III randomized study (EORTC 62961) showed that regional hyperthermia (RHT) increases the benefit of preoperative chemotherapy in patients with localized high-risk STS.<sup>170</sup> In this study, 341 patients were randomized to receive either preoperative chemotherapy with etoposide, ifosfamide, and doxorubicin (EIA) alone, or combined with RHT (EIA plus RHT). After a median follow-up of 34 months, among 149 patients with STS of the extremity, the 2-year DFS and local PFS rates were 70% and 92%, respectively, for patients treated with EIA plus RHT. The corresponding survival rates were 57% and 80% for those treated with EIA alone. However, these results need to be confirmed in large cohort studies and the use of RHT with preoperative chemotherapy is not recommended in the guidelines.

Available evidence, although underpowered, suggests that anthracycline-based postoperative chemotherapy (now most commonly given as doxorubicin and ifosfamide or epirubicin and ifosfamide) would improve DFS in selected patients with good performance status who are at high risk of recurrence.<sup>73-77</sup> Postoperative EBRT has been shown to improve local control in patients with high-grade lesions.<sup>133,135</sup>

Large stage II or III high-grade extremity resectable tumors (greater than 8–10 cm) that are at high risk for local recurrences and metastases should be considered for preoperative and postoperative therapy. However, there are data supporting that surgery alone is an adequate treatment option in selected patients with high-grade lesions. Long-term results of a prospective study demonstrated that selected patients with high-grade T1 lesions can be treated by surgery alone (R0

resection) with acceptable local control and excellent long-term survival.<sup>171</sup> In the surgery alone arm, the cumulative incidence rates of local recurrence at 5 and 10 years were 7.9% and 10.6%, respectively, in patients who underwent R0 resection and the 5- and 10-year sarcoma-specific death rates were 3.2%. In an analysis of 242 patients with localized STS of the trunk and extremity treated with limb-sparing surgery, the 10-year local control rate was 87% to 93% for patients with resection margins of less than 1 cm compared with 100% for those with resection margins of 1 cm or more ( $P = .04$ ).<sup>127</sup> Recently, Al-Refaie and colleagues also reported that the addition of RT to did not result in any significant difference in OS or sarcoma-specific survival in patients with early-stage STS of the extremity.<sup>172</sup>

Surgery followed by RT is recommended for patients with stage IIA tumors that are resectable with acceptable functional outcomes.<sup>133</sup> Since preoperative RT has been shown to decrease the risk of recurrence following surgery (albeit with wound complications),<sup>134,142</sup> the panel has included preoperative RT followed by surgery as one of the treatment options. Surgery alone may be an option for patients with small tumors that can be resected with wider surgical margins.

Surgery followed by RT with or without postoperative chemotherapy is the primary treatment for patients with stage IIB or III tumors that are resectable with acceptable functional outcomes. Since there are only limited and conflicting data regarding the potential benefits of postoperative chemotherapy for stage II or III patients, postoperative chemotherapy is included as a category 2B recommendation.<sup>73-77</sup> Preoperative RT, chemotherapy (category 2B), or chemoradiation (category 2B) are also included as options for this group of patients.

Radical lymphadenectomy may provide long-term survival benefit for patients with isolated lymph node involvement. In a study that

examined the natural history of lymph node metastasis in patients with STS, the median survival was 4.3 months for patients not treated with radical lymphadenectomy compared to 16.3 months in patients who underwent radical lymphadenectomy.<sup>173</sup> The 5-year survival rate for the latter group of patients was 46%. The guidelines recommend regional lymph node dissection at the time of primary surgery for patients with stage III tumors with lymph node involvement.

Patients with stage II or III tumors that are resectable with adverse functional outcomes should be managed as described below for unresectable disease.

### Unresectable Disease

Patients with unresectable tumors can be treated primarily with RT, chemoradiation, or chemotherapy. Tumors that become resectable with acceptable functional outcomes following primary treatment can be treated with surgery followed by RT with or without postoperative chemotherapy. Since there are only limited and conflicting data regarding the potential benefits of postoperative chemotherapy, it is included as a category 2B recommendation. For patients whose tumors remain resectable with adverse functional outcomes or unresectable following primary treatment, a subsequent distinction is made between asymptomatic and symptomatic patients. Observation is an option for asymptomatic patients. For symptomatic patients, the treatment options include chemotherapy, palliative surgery, amputation, or best supportive care.

Definitive RT (70–80 Gy) can be considered for selected patients with unresectable tumors following primary treatment. In a single-institution study (112 patients, 43% extremity STS) tumor size and the dose of RT influenced local control and survival in patients with unresectable STS.<sup>174</sup> The local control rate was 51% for tumors less than 5 cm and

9% for tumors greater than 10 cm. Patients who received 63 Gy or more had better 5-year local control, DFS, and OS rates (60%, 36% and 52%, respectively) compared to patients who received less than 63 Gy (22%, 10%, and 14%, respectively). Local control for patients receiving more than 63 Gy was 72% for lesions 5 cm or less, 42% for lesions 5 to 10 cm, and 25% for lesions more than 10 cm.

Regional limb therapy (isolated limb perfusion [ILP] and isolated limb infusion [ILI]) has been evaluated as a limb-sparing treatment for unresectable intermediate or high-grade extremity STS. ILP requires the use of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) along with chemotherapy, which is not approved in the United States. ILI is a less invasive alternative to ILP for patients with unresectable STS of the extremities and can be used without TNF- $\alpha$ . Preliminary data from clinical trials suggest that ILP with melphalan or doxorubicin in combination with TNF- $\alpha$ <sup>175-177</sup> or ILI with doxorubicin or melphalan and dactinomycin<sup>178-181</sup> may be effective in the treatment of patients with unresectable STS of extremity. Further prospective clinical trials are needed to better define the role for ILP or ILI in the management of patients with unresectable STS of the extremity. The guidelines have included regional limb therapy as a primary treatment option for patients with unresectable tumors treated at institutions with experience in regional limb therapy.

### Stage IV (Synchronous Metastatic Disease)

Patients who present with metastatic disease have a poor prognosis with no disease-free interval.<sup>182,183</sup> In a retrospective study of 48 patients with synchronous metastases, there was no improvement in OS for patients treated with metastasectomy compared to those with unresectable disease.<sup>182</sup> In a more recent retrospective study involving 112 patients with metastatic disease at presentation, resection of metastatic disease, less than 4 pulmonary metastases, and the

presence of lymph node metastases vs. pulmonary metastases were identified as statistically significant variables for improved OS; the 5-year survival rate was 59% and 8%, respectively, for patients presenting lymph node metastases and pulmonary metastases.<sup>183</sup>

Since there are no data to support the optimal management of patients presenting with metastatic disease, the guidelines are intentionally nonspecific about the treatment options for this group of patients. Referral to a medical oncologist with extensive experience in the treatment of STS is recommended. Treatment options should be based on many factors including performance status, patient preferences, specific clinical problems from the metastases, and treatment availability. In addition, clinical trial is the preferred treatment option for patients with metastatic disease.

### Limited Metastases

Patients with limited metastasis confined to a single organ and limited tumor bulk that are amenable to local therapy should receive primary tumor management as described for stage II or III tumors. Another option is to consider metastasectomy with or without chemotherapy with or without RT. The guidelines do not specify rules governing metastasectomy, which remains controversial. Several variables including tumor resectability, number of metastases, and performance status influence the decision to use metastasectomy. In addition, patients can also receive stereotactic body RT (SBRT) or chemotherapy as an alternate method for control of metastatic lesions.

### Disseminated Metastases

For patients presenting with disseminated disease, a subsequent distinction is made between asymptomatic and symptomatic patients. Observation with a “watchful waiting” strategy is a reasonable management option for asymptomatic patients, especially if patients

have only a minimal burden of metastases (eg, sub-centimeter pulmonary nodules). Symptomatic patients can be treated with palliative RT, surgery, or chemotherapy. Palliative RT involves expedient treatment with sufficient dose to halt tumor growth or cause tumor regression. The outcome of this approach depends on the rapidity of growth and the status of systemic disease. In addition, the guidelines have included ablation procedures (eg, radiofrequency ablation [RFA] or cryotherapy) or SBRT as options for symptomatic patients.

### Surveillance

Surveillance is deemed important to detect recurrences that might still be potentially curable. However, very limited data are available in the literature on effective surveillance strategies.<sup>184-186</sup> Because patient risk never returns to zero, long-term follow-up is indicated, including consideration of MRI or CT scan.<sup>187</sup> There has never been a study to prove that the use of more sensitive CT scans in routine surveillance would improve clinical outcomes. According to the report from MD Anderson Cancer Center, routine use of chest CT adds little clinical benefit, when risk of pulmonary metastases is low.<sup>188</sup> However, in certain subsets of patients in whom chest radiographs are difficult to interpret because of anatomic considerations (eg, scarring, emphysema), chest CT may be indicated.

Ultrasound has been used for the detection of early local recurrences and for the detection of micronodules less than 0.5 cm in diameter.<sup>189-191</sup> In a retrospective analysis that evaluated the value of MRI and ultrasound for the detection of local recurrence after surgery in 21 patients with STS of extremities, the sensitivity of ultrasound was slightly higher than that of MRI (100% vs. 83%) and the specificity was slightly lower than that of MRI (79% vs. 93%).<sup>189</sup> However, the

differences were not statistically significant, suggesting that both MRI and ultrasound were equally useful in the detection of local recurrences after surgery. In a subsequent report, Arya and colleagues also reported that ultrasound is associated with high sensitivity and specificity (92% and 94%, respectively) in the detection of early local recurrences in patients with STS.<sup>190</sup> These results confirm that ultrasound can be useful for the detection of local recurrences. However, as reported by Choi and colleagues, ultrasound may be more difficult to interpret than MRI during the early postoperative period.<sup>189</sup> Therefore, MRI should be used if ultrasound results are inconclusive.

The guidelines outline a prudent follow-up schedule that avoids excessive testing. Higher grade and larger tumors have a higher risk of dissemination; therefore, the surveillance recommendations for patients with these tumors are somewhat more intensive, particularly for the first 3 years after resection. Periodic imaging (MRI, CT, or ultrasound) of the primary site should be done based on the estimated risk of locoregional recurrence. The guidelines recommend that ultrasound can be considered for the detection of local recurrences in patients with smaller lesions that are superficial and should be performed by an ultrasonographer with experience in musculoskeletal disease.<sup>189,190</sup> However, in situations where the area is easily followed by physical examination, imaging may not be required. After 10 years, the likelihood of developing a recurrence is small and follow-up should be individualized. Stage I tumors are routinely followed with H&P every 3 to 6 months for 2 to 3 years and then annually. Chest imaging should also be considered every 6 to 12 months. For stage II to IV disease, H&P and imaging of the chest and other known sites of metastatic disease should be done every 3 to 6 months for 2 to 3 years, then every 6 months for the next 2 years, and then annually.

**Recurrent Disease**

The management of recurrent disease encompasses a heterogeneous group of patients and clinical scenarios. In retrospective studies, isolated local recurrence at sites other than the head and neck and deep trunk, resectability of recurrent and metastatic disease, disease-free interval, and number of metastases were identified as important predictive factors for long-term survival.<sup>192-194</sup>

For a patient with a local recurrence, treatment decisions should be made using the same algorithm as for patients with a new primary lesion.<sup>195</sup> In patients with local recurrence, some case series suggest that combined conservative surgery and re-irradiation provide superior local control compared to local re-excision alone.<sup>196</sup> However, others have reported that conservative surgery alone results in local control in a minority of patients who have failed locally after previous excision and EBRT,<sup>197</sup> likely reflecting differences in patient selection for surgery and RT or surgery alone. Therefore, the guidelines recommend that if local recurrence can be excised, a decision regarding the use of re-irradiation will need to be made on a case-by-case basis.

Traditionally, the re-irradiation has been done with postoperative brachytherapy, but now brachytherapy may be used in combination with IMRT to reduce the risks of morbidity with re-irradiation.

For patients with metastatic recurrences the guidelines distinguish between limited metastases confined to a single organ, disseminated metastases, and isolated regional disease with nodal involvement. The treatment options for patients with limited metastases confined to a single organ or disseminated metastases are similar to that described for stage IV disease at presentation. In patients with isolated regional disease or nodal involvement, options include regional node dissection with or without RT or chemotherapy (category 2B for chemotherapy),

metastasectomy, or SBRT. Limited data are available on the use of chemotherapy in patients undergoing metastasectomy. Results from a recent retrospective analyses suggest that chemotherapy has minimal impact on the survival of patients with metastatic extremity STS undergoing pulmonary metastasectomy.<sup>198</sup> The guidelines have included the use of chemotherapy and RT (before or after metastasectomy) with a category 2B recommendation.

**Retroperitoneal/Intra-abdominal Soft Tissue Sarcomas**  
**Surgery**

Surgical resection of a localized tumor with grossly negative margins remains the standard, potentially curative treatment for patients with retroperitoneal/intra-abdominal STS. Postoperative margin status is the most important factor contributing to long-term DFS.<sup>199-202</sup> In the largest single-institution series involving 500 patients, the median survival was 103 months for those who underwent complete resection with grossly negative margins in contrast to 18 months for those who underwent incomplete resection.<sup>202</sup>

Two recent retrospective analyses reported improved local control in patients with primary retroperitoneal sarcoma operated with more aggressive approaches such as complete compartmental resection and a more liberal visceral en bloc resection performed in high-volume centers.<sup>203,204</sup> While the results are encouraging, this technique needs to be investigated in prospective clinical trials.

**Radiation Therapy**

RT can be administered either as preoperative or postoperative treatment for patients with resectable disease and as a primary treatment for those with unresectable disease. The panel emphasizes that RT is not a substitute for definitive surgical resection with



oncologically appropriate margins and re-resection may be necessary. If re-resection is not feasible, postoperative RT may be considered in highly selected patients, who have not received preoperative RT, to attempt to control microscopic residual disease, although this approach has not been validated in randomized trials.

Newer RT techniques such as IMRT and 3D conformal RT using protons or photons may allow tumor target coverage and acceptable clinical outcomes within normal tissue dose constraints to adjacent organs at risk.<sup>137,205-207</sup> When EBRT is used, sophisticated treatment planning with IMRT, tomotherapy, and/ or proton therapy can be used to improve therapeutic effect. However, the safety and efficacy of adjuvant RT techniques is yet to be evaluated in multicenter randomized controlled studies.

#### ***Preoperative RT***

Preoperative RT is often preferred, because it reduces the risk of tumor seeding at the time of surgery and may render tumors more amenable to resection.<sup>208</sup> Long-term results of two prospective studies showed favorable 5-year local RFS (60%), DFS (46%), and OS rates (61%) following R0 or R1 resection after preoperative RT in patients with intermediate or high-grade retroperitoneal STS.<sup>209</sup> The usual dose of preoperative RT is 50 Gy. In a single-institution study, Tzeng and colleagues demonstrated that preoperative RT with selective dose escalation (45 Gy in 25 fractions to the entire tumor plus margin and a boost dose of 57.5 Gy to the posterior retroperitoneal tumor margin determined by the surgeon and the radiation oncologist to be at highest risk) was tolerable and allowed for the use of higher RT doses to the high-risk clinical target volume (high-risk CTV) judged to be at greatest risk for local tumor recurrence.<sup>210</sup> In this study, which included 16 patients with biopsy-proven retroperitoneal STS, 14 patients (88%) had undergone macroscopic resection. With a median follow-up of 28

months, there were only 2 local recurrences, with the actuarial 2-year local control rate of 80%. Since this approach is used in many NCCN Member Institutions, the guidelines have included this dosing schedule (45 to 50 Gy to the entire CTV with dose-painted simultaneous integrated boost to total dose of 57.5 Gy) as another option for preoperative RT. The panel recommends that higher-risk retroperitoneal margins should be jointly defined by the surgeon and the radiation oncologist.

#### ***Postoperative RT***

Postoperative RT has been associated with improved RFS in retrospective nonrandomized studies with no improvement in OS.<sup>201,211</sup> In one study, the combined use of preoperative RT and postoperative brachytherapy resulted in significantly better DFS and OS in patients with low-grade tumors.<sup>212</sup> In a recent retrospective study, the use of conformal postoperative RT along with aggressive surgical resection was associated with a trend towards decreased local recurrence rate and improved RFS compared to surgery alone.<sup>213</sup> At the 5-year follow-up, the RFS rate was 60% and 47%, respectively ( $P = .02$ ); however, there was no significant difference in OS between the two groups. If postoperative RT is to be considered, a coordinated effort by the surgeon and the radiation oncologist to displace bowel from the tumor bed with omentum or other tissue displacers is recommended to reduce the risk of RT-related bowel toxicity.

#### ***IORT***

The use of IORT has provided encouraging results in patients with retroperitoneal STS.<sup>214-220</sup> In patients with retroperitoneal STS prospectively treated at a single institution with a protocol involving maximal tumor resection, high-dose-rate IORT and postoperative EBRT, the overall 5-year local control rate for the whole group was 62%; local control rate was better for patients with primary tumors than



those with recurrent tumors (74% vs. 54%;  $P = .40$ ).<sup>215</sup> The overall 5-year distant metastasis-free survival rate was 82% (100% for those with low-grade tumors vs. 70% for those with high-grade tumors;  $P = .05$ ). The 5-year DFS and OS rates were 55% and 45%, respectively. IORT with or without EBRT has been effective in terms of local control and survival in patients with primary and recurrent retroperitoneal STS.<sup>216-218,220</sup> In a study that assessed the long-term outcome of patients with retroperitoneal STS treated by preoperative RT, resection, and IORT with electron beam RT (IOERT), OS (74% and 30%, respectively) and local control (83% and 61%, respectively) were better in patients undergoing gross total resection and IOERT compared to those who had only gross total resection.<sup>216</sup>

### Evaluation and Workup

The initial evaluation and workup for retroperitoneal abdominal STS are similar to that for the extremity sarcomas. This workup involves a thorough H&P and appropriate imaging studies, including chest, abdominal, and pelvic CT with contrast with or without an MRI. Chest imaging should be done, especially for patients whose tumors warrant preoperative or postoperative chemotherapy. If possible, a multidisciplinary sarcoma panel should review the patient. Note that for staging, all retroperitoneal lesions are considered deep lesions.

The differential diagnosis of retroperitoneal abdominal soft tissue mass includes malignant lesions (such as other sarcomas, GISTs, lymphomas, or germ cell tumors), desmoids, and benign lesions. Proof of the histologic subtype by biopsy is necessary for patients before receiving preoperative chemotherapy or RT. Biopsy should be considered if there is suspicion of malignancies other than STS. Image-guided (CT or ultrasound) core needle biopsy is preferred over open surgical biopsy. The goal of this strategy is to avoid inappropriate

major resection of another tumor, such as an intra-abdominal lymphoma or germ cell tumor. If a retroperitoneal STS is encountered unexpectedly when a laparotomy is performed for some other reason, a core needle biopsy should be done to establish the diagnosis as well as the histopathologic type and grade of tumor. Then, the optimal subsequent resection could be performed.

### Resectable Disease

Surgery (to obtain oncologically appropriate margins) with or without IORT is the primary treatment for most patients with resectable disease. However, complete or macroscopic surgical resection is achieved in less than 70% of patients with primary tumors, due to their close proximity to vital structures. Local recurrence and disease progression continue to be associated with a significant cause of morbidity in the majority of patients.<sup>221-223</sup> Multimodality treatment (surgery with RT and/or chemotherapy) is therefore favored due to the inability to obtain negative surgical margins and high local recurrence rates.<sup>224</sup>

Preoperative RT is often preferred, because it reduces the risk of tumor seeding at the time of surgery and may render tumors more amenable to resection.<sup>208</sup> Preoperative chemotherapy may have advantages over postoperative chemotherapy. However, the role of preoperative chemotherapy vs. postoperative chemotherapy has not yet been evaluated in randomized clinical trials.<sup>225</sup> Little data are available for the use of combined RT and chemotherapy. Decisions about postoperative or preoperative chemotherapy or RT are left to clinical judgment.<sup>226-228</sup> The regimens listed in the guidelines are based on the extrapolation of data derived from clinical trials on STS of the extremity that have included small number of patients with retroperitoneal STS.<sup>229</sup>

In the phase III randomized study (EORTC 62961), the addition of RHT to preoperative chemotherapy with EIA was associated with a significant survival benefit.<sup>170</sup> After a median follow-up of 34 months, among 192 patients with non-extremity STS, the 2-year DFS and local PFS rates were 50% and 64% respectively for patients treated with EIA plus RHT. The corresponding survival rates were 33% and 45% for those treated with EIA alone. As is the case with STS of extremities, these results need to be confirmed in large cohort studies and the use of RHT with preoperative chemotherapy is not recommended in the guidelines for the treatment of patients with retroperitoneal or abdominal STS.

Preoperative RT or chemotherapy could be considered prior to surgery in patients whose diagnosis has been confirmed by biopsy. For patients treated with preoperative EBRT (50 Gy) followed by surgery, the guidelines recommend consideration of postoperative RT boost for patients with positive margins, if this can be done within the constraints of adjacent normal tissue. The guidelines recommend an EBRT boost of 16 to 18 Gy for microscopic residual disease, and 20 to 26 Gy for grossly positive margins. Alternatively, IORT (10 to 12.5 Gy for microscopic residual disease and 15 Gy for gross residual disease) can be delivered immediately after resection to the area at risk, avoiding the uninvolved organs.

Postoperative treatment options are dependent on surgical outcomes and clinical or pathologic findings following surgery. Postoperative RT should not be administered routinely. Postoperative RT could be considered for patients with microscopically positive margins (R1 resection) if they have not received preoperative RT and following negative margin resection (R0 resection) in highly selected patients (eg, patients with pathologic findings of high-grade disease, extremely large tumors, close surgical margins, or high risk of recurrence).

Re-resection, if feasible, should be considered for patients with macroscopically positive margins (R2 resection). Alternatively, these patients could also be managed as described below for unresectable disease. The options for postoperative RT include EBRT (50 Gy irrespective of surgical margins) or IORT (10 Gy followed by EBRT). For patients treated with postoperative EBRT, the guidelines recommend postoperative RT boost to the original tumor bed based on the margin status (10 Gy for negative surgical margin if normal tissue can be adequately spared by tissue displacement with omentum or other biologic or synthetic spacer; 16 to 18 Gy for microscopic residual disease; and 20 to 26 Gy for gross residual disease). The dose recommendations above must be balanced and considered in the context of the adjacent normal tissue tolerance to RT.

### Unresectable or Stage IV Disease

Unresectable tumors are defined as those that involve vital structures or tumors whose removal would cause unacceptable morbidity. Patients who are medically unresectable (ie, not medically fit to tolerate a major retroperitoneal STS resection) are also included in this category.

Biopsy is recommended before any treatment for a patient with unresectable or metastatic disease. Patients with unresectable or stage IV disease could be treated with chemotherapy or RT in an attempt to downstage tumors. For patients undergoing definitive high-dose RT, there has been favorable experience reported in the literature with the use of tissue displacement spacers to keep bowel out of the high-dose RT volume.<sup>230</sup> Patients whose tumors become resectable following primary treatment should be managed as described above for resectable disease. If the tumor remains unresectable or if there is disease progression following primary treatment, management

decisions depend on whether patients are symptomatic or asymptomatic. Asymptomatic patients can be observed, whereas symptomatic patients can be treated with palliative therapy (chemotherapy, RT, or surgery) for symptom control or best supportive care. In patients with stage IV disease, resection should always be considered for resectable metastatic disease. Palliative RT involves expedient treatment with sufficient dose to halt tumor growth or cause tumor regression. The outcome of this approach depends on the rapidity of growth and the status of systemic disease.

### Surveillance

Patients should have a follow-up physical examination with imaging (chest/abdominal/pelvic CT) every 3 to 6 months for 2 to 3 years, then every 6 months for the next 2 years, and then annually.

### Recurrent Disease

For patients with resectable, unresectable, or disseminated recurrences, the guidelines recommend the same management after biopsy, as outlined for primary disease. Preoperative RT and/or chemotherapy should be considered for recurrent disease, if not administered previously. Palliative treatment for symptom control (RT, chemotherapy, or surgery) and best supportive care are potential options that oncologists should discuss with symptomatic patients. Enrollment in a clinical trial is preferred and should be considered if an appropriate trial is available.

### Gastrointestinal Stromal Tumors

GISTs are the most common STS of the gastrointestinal (GI) tract, resulting most commonly from *KIT* or *PDGFRA* activating mutations.<sup>231</sup> GISTs can arise anywhere along the GI tract, but stomach (60%) and small intestine (30%) are the most common

primary sites.<sup>232</sup> Duodenum (4% to 5%) and rectum (4%) are the less common primary sites, and only a small number of cases have been reported in the esophagus (<1%) and colon and appendix (1% to 2%).<sup>232</sup> Patients with a suspected GIST may present with a variety of symptoms, which may include early satiety, abdominal discomfort due to pain or swelling, intraperitoneal hemorrhage, GI bleeding, or fatigue related to anemia. Some patients may present with an acute abdomen (as a result of tumor rupture, GI obstruction, or appendicitis-like pain), which requires immediate medical attention.<sup>233</sup> Liver metastases and/or dissemination within the abdominal cavity are the most common clinical manifestations of malignancy. Lymph node metastases are extremely rare. Metastases in the lungs and other extra-abdominal locations are observed only in advanced cases.

### Principles of Biopsy and Pathologic Assessment

GISTs are soft and fragile tumors. The decision to obtain a biopsy should be based on the suspected tumor type and the extent of disease. Biopsy is necessary to confirm the diagnosis of primary GIST prior to the initiation of preoperative therapy.<sup>233</sup> Recent reports have suggested that definitive diagnosis of GIST requires tissue acquisition via EUS-guided FNA.<sup>234</sup> Endoscopic ultrasound (EUS)-guided FNA (EUS-FNA) biopsy of primary site is preferred over percutaneous biopsy due to the risk of tumor hemorrhage and intra-abdominal tumor dissemination. Percutaneous image-guided biopsy may be appropriate for confirmation of metastatic disease.

Morphologic diagnosis based on careful microscopic examination of adequate tumor tissue is essential to confirm the diagnosis of GIST. Pathology report should include anatomic location, size, and an accurate assessment of the mitotic rate measured in the most proliferative area of the tumor and reported as the number of mitoses in

50 high-power fields (equivalent to 5 mm<sup>2</sup> of tissue). The differential diagnosis of GIST should be considered for any GI sarcoma, as well as for any other intra-abdominal sarcoma. The panel recommends referral to centers with expertise in sarcomas for cases with complex or unusual histopathologic features.

Most GISTs (95%) express *KIT* (CD117). Approximately 80% of GISTs have a mutation in the gene encoding the *KIT* receptor tyrosine kinase; another 5% to 10% of GISTs have a mutation in the gene encoding the related *PDGFRA* receptor tyrosine kinase.<sup>3,235,236</sup> About 10% to 15% of GISTs have no detectable *KIT* or *PDGFRA* mutations (wild-type GIST). Other commonly expressed markers include CD34 antigen (70%), smooth muscle actin, 25%), and desmin (less than 5%).<sup>237</sup>

Most of the *KIT* mutations occur in the juxtamembrane domain encoded by *KIT* exon 11 and some are detected in the extracellular domain encoded by exon 9.<sup>238</sup> *KIT* mutations have also been identified in the tyrosine kinase domain (exon 13 and exon 17), although they are very rare.<sup>239</sup> The majority of the *PDGFRA* mutations affect exon 18 in the tyrosine kinase domain 2.<sup>238</sup> Few mutations also occur in exon 12 (juxtamembrane domain) and exon 14 (tyrosine kinase domain 1), although they are rare.<sup>240</sup> *KIT* exon 11 mutations are most common in GISTs of all sites, whereas *KIT* exon 9 mutations are specific for intestinal GISTs and *PDGFRA* exon 18 mutations are common in gastric GISTs.<sup>238</sup>

Immunohistochemical staining for CD117 and molecular genetic testing to identify *KIT* and/or *PDGFRA* mutations are useful in the diagnosis of GIST. However, *KIT* positivity alone may not be sufficient to confirm the diagnosis and, conversely, the absence of *KIT* and/or *PDGFRA* mutations does not exclude the diagnosis of GIST. In GISTs with *PDGFRA* mutations, immunostaining with *PDGFRA* has been shown to

be helpful in discriminating between *KIT*-negative GIST and other gastrointestinal mesenchymal lesions.

Loss-of-function mutations in the *SDH* gene subunits or loss of SDHB protein expression by IHC have been identified in wild-type GIST lacking *KIT* and *PDGFRA* mutations; these findings have led to the use of the term *SDH*-deficient GIST, which is preferred over the older term, wild-type GIST, for this subset of GIST.<sup>241-245</sup> *SDHB* IHC can be useful for the diagnosis of *SDH*-deficient GIST. *BRAF* exon 15 mutation (V600E) has also been reported in a small subset of patients with intestinal high-risk GISTs lacking *KIT/PDGFRA* mutations.<sup>246,247</sup> DOG1 is calcium dependent, receptor activated chloride channel protein and it is expressed in GISTs independent of mutation type. DOG1 expression was not different between the *KIT/PDGFRA* mutant or wild-type GIST, but there was a clear distinction between tumors with *PDGFRA* and *KIT* mutations. GISTs with *PDGFRA* mutations had a low *KIT* expression and high DOG1 expression, which can be used in the diagnosis of *KIT*-negative tumors.<sup>248</sup> DOG1 immunostaining may be useful for cases that cannot be categorized as GIST based on CD117 immunostaining and mutation testing for *KIT* and *PDGFRA*. DOG1 and *KIT* could be used together in difficult cases exhibiting unexpected *KIT* negativity or positivity.<sup>233</sup>

Tumors lacking *KIT* and *PDGFRA* mutations should be considered for further evaluations such as *SDHB* immunostaining, *BRAF* mutational analysis and *SDH* gene mutational analysis.

### Prognostic Factors

Tumor size and the mitotic rate are the most widely used pathologic features for the risk stratification of GIST. However, it is difficult to predict the malignant potential of GIST based on these features alone. In a long-term follow-up of 1765 patients with gastric GISTs, Miettinen

and colleagues reported that the metastatic rate was 86% for tumors >10 cm with a mitotic index of >5 mitoses/50 high-power fields (HPFs), whereas tumors of the same size with a mitotic index of <5 mitoses/50 HPFs have a relatively low metastatic rate of 11%.<sup>249</sup> In a subsequent report involving 906 patients with small intestinal GIST, tumors >10 cm with a mitotic index of ≤5 mitoses/50 HPF had a metastatic rate of 50%, which is a contrast to that reported for gastric GIST with similar tumor parameters.<sup>250</sup> Therefore, in addition to the tumor size and mitotic rate, tumor site has also been included in the guidelines developed by Miettinen and colleagues for the risk stratification of primary GIST.<sup>232</sup> According to these guidelines, gastric GISTs have an overall indolent behavior and those that are ≤2 cm (irrespective of the mitotic index) are essentially benign, whereas small intestinal GISTs tend to be more aggressive than gastric GISTs. Rectal GISTs are also very aggressive and tumors <2 cm with a mitotic index of >5 mitoses/50 HPFs have a higher risk of recurrence and malignant potential.

Although specific *KIT* and *PDGFRA* mutations show some correlation with tumor phenotype, the mutational status is not strongly correlated with the biologic potential of individual tumors. Available data indicate that *KIT* mutations can be found in high-grade tumors as well as in small incidental GIST and tumors that have a benign course. Therefore, *KIT* mutational status is not used to in the routine prognostic assessment of a primary GIST. Similarly, *PDGFRA* mutational status also cannot be used to predict the biological behavior of individual tumors. However, the presence and the type of *KIT* or *PDGFRA* mutation status are predictive of response to TKI therapy in patients with advanced or metastatic GIST. See *Impact of Mutational Status on Response to Imatinib or Sunitinib in Advanced or Metastatic GIST* in this Discussion.

### Principles of Surgery

Surgery is the primary treatment of choice for patients with localized or potentially resectable GIST lesions. While imatinib is the primary therapy for patients with metastatic GIST, surgery may be indicated for locally advanced or previously unresectable disease after a favorable response to preoperative imatinib and for limited disease progression on systemic therapy. If persistent metastatic or residual tumor remains after surgery, then imatinib should be continued as soon as the patient is able to tolerate oral intake.

GISTs are fragile and should be handled with care to avoid tumor rupture. The goal is to achieve complete gross resection of the tumor with an intact pseudocapsule. After removal of any suspected GIST, postoperative pathology assessment is essential to confirm the diagnosis. Segmented or wedge resection to obtain negative margins is often appropriate. Lymphadenectomy is usually not required given the low incidences of nodal metastases. Resection should be accomplished with minimal morbidity and complex multivisceral resection should be avoided. Re-resection is generally not indicated for microscopically positive margins on final pathology. If abdominoperineal resection would be necessary to achieve a negative margin, then preoperative imatinib should be considered. If the surgeon feels that a complex surgical procedure is required, then a multidisciplinary consultation regarding the use of preoperative imatinib is recommended.

Sphincter-sparing surgery and esophagus-sparing surgery should be considered for rectal and gastroesophageal junction GISTs, respectively. Several case reports have demonstrated that the use of preoperative imatinib enables organ-sparing surgery and improves surgical outcomes in patients with rectal GISTs.<sup>233</sup>

The role for laparoscopy in the resection of GISTs continues to expand. Although prospective studies are lacking, literature reports based on small series of patients and retrospective analyses have demonstrated that not only are laparoscopic or laparoscopic-assisted resections possible, but they are also associated with low recurrence rates, short hospital stay duration, and low morbidity.<sup>233</sup> Laparoscopic approach may be considered for selected GISTs in favorable anatomic locations such as anterior wall of the stomach, jejunum, and ileum. The same surgical principles of complete macroscopic resection including the preservation of the pseudocapsule and avoidance of tumor rupture should be followed during laparoscopy. Resection specimen should be removed from the abdomen in a plastic bag to avoid spillage or seeding of port sites. Laparoscopic surgery could be feasible in other anatomic sites, such as smaller rectal GISTs. However, data on laparoscopic resection of GISTs at other sites are limited.

### Targeted Therapy

GISTs have previously been documented to be resistant to conventional chemotherapies. Since *KIT* activation occurs in the majority of cases of GISTs, *KIT*-inhibition has emerged as the primary therapeutic modality along with surgery for the treatment of GISTs.

#### *Imatinib*

Imatinib, a selective inhibitor of the *KIT* protein tyrosine kinase, has produced durable clinical benefit and objective responses in most patients with GIST. In phase II and III studies, imatinib has resulted in high overall response rates and exceptionally good PFS in patients with unresectable and/or metastatic GIST, inducing objective responses in more than 50% of the patients.<sup>251-255</sup> In February 2002, the FDA approved of imatinib for the treatment of patients with *KIT*-positive unresectable and/or metastatic malignant GIST. Long-term follow-up results of the B2222 study (n = 147, randomly assigned to received 400

or 600 mg of imatinib daily) confirmed that imatinib induces durable disease control in patients with advanced GIST.<sup>256</sup> The estimated 9-year OS rate for all patients was 35%, 38% for those with CR or PR, and 49% for those with stable disease. Low tumor bulk at baseline predicted for longer TTP and improved OS.

Two separate phase III studies (EORTC 62005 study and the S0033/CALGB 150105 study) have assessed the efficacy of imatinib at two initial dose levels (400 mg daily vs. 800 mg daily, given as 400 mg twice a day) in patients with metastatic or unresectable GIST.<sup>252,253,255</sup> Both studies showed equivalent response rates and OS for both dose levels. Higher dose of imatinib was associated with more side effects than the lower dose in both studies. The EORTC 62005 study (n = 946) documented an earlier TTP for patients receiving 400 mg daily.<sup>252</sup> At a median follow-up of 760 days, 56% of patients allocated to imatinib once a day had progressed compared with 50% of those who were assigned to treatment twice a day. The S0033/CALGB 150105 study (n = 746) reported identical response rates (40% vs. 42%, respectively) at a median follow-up of 4.5 years and there were no statistical differences in PFS (18 months for low-dose arm vs. 40 months for higher dose arm) and median OS (55 and 51 months, respectively).<sup>255</sup> Following progression on 400 mg daily, 33% of patients who crossed over to the higher dose achieved objective response rates and stable disease. This finding is consistent with that of the EORTC 62005 study, in which 133 (55%) patients who progressed on low-dose imatinib crossed over to high-dose imatinib; subsequently, 2% of patients had PR and 27% had stable disease.<sup>253</sup> However, the small advantage in PFS observed for high-dose imatinib in the EORTC 62005 study was not corroborated by the S0033/CALGB 150105 study.

Available data confirm the safety and efficacy of imatinib at 400 mg/day as the initial standard dose to achieve response induction.<sup>252,255</sup> Dose



escalation to 800 mg/day is a reasonable option for patients progressing on 400 mg/day.<sup>253</sup>

#### *Preoperative Imatinib*

The RTOG 0132/ACRIN 6665 is the first prospective study that evaluated the efficacy of preoperative imatinib (600 mg/day) in patients with potentially resectable primary disease (30 patients) or potentially resectable recurrent or metastatic disease (22 patients).<sup>257</sup> Among patients with primary GIST, PR, and stable disease were observed in 7% and 83% of patients, respectively. In patients with recurrent or metastatic GIST, PR, and stable disease were observed in 4.5% and 91% of patients, respectively. The estimated 2-year OS rate was 93% and 91% for patients with primary GIST and those with recurrent or metastatic GIST, respectively. The estimated 2-year PFS rate was 83% and 77%, respectively.

In a study conducted at the MD Anderson Cancer Center, 19 patients undergoing surgical resection for primary GIST (with or without metastases) or recurrent disease (local or metastatic) were randomized to receive 3, 5, or 7 days of preoperative imatinib (600 mg daily).<sup>258</sup> The response rate assessed by FDG-PET and dynamic CT was 69% and 71%, respectively. Median DFS of patients treated with surgery and imatinib was 46 months. Tumor size was a predictor of recurrence after postoperative imatinib. However, in this study, there was no histologic evidence of cytoreduction within 3 to 7 days of preoperative imatinib.

In another prospective study, Fiore and colleagues reported that preoperative imatinib improved resectability and reduced surgical morbidity in patients with primary GISTs, unresectable or resectable through a major surgical procedure with significant surgical morbidity. Median size reduction was 34% and the estimated 3-year PFS rate was

77%.<sup>259</sup> Imatinib was continued postoperatively for 2 years in all patients.

In the subgroup analysis of patients with non-metastatic, locally advanced, primary GIST treated with imatinib within the prospective BFR14 phase III study, preoperative imatinib was associated with a PR rate of 60% (15 of 25 patients), and 36% (9 of 25 patients) of patients underwent surgical resection of primary tumor after a median of 7.3 months of imatinib treatment.<sup>260</sup> All patients who underwent resection were treated with postoperative imatinib. The 3-year PFS and OS rates were 67% and 89%, respectively, for patients who underwent resection. All patients who underwent resection were treated with postoperative imatinib.

While the results of these prospective studies have demonstrated the safety and efficacy of preoperative imatinib in patients undergoing surgical resection, survival benefit could not be determined since all patients included in 3 of these studies also received postoperative imatinib postoperatively for 2 years.<sup>257,258,260</sup> At the present time, the decision to use preoperative imatinib for patients with resectable primary or locally advanced or recurrent GIST should be made on an individual basis.

#### *Postoperative Imatinib*

Surgery does not routinely cure GIST. Complete resection is possible in approximately 85% of patients with primary tumors. At least 50% of these patients will develop recurrence or metastasis following complete resection and the 5-year survival rate is about 50%.<sup>261-263</sup> Median time to recurrence after resection of primary high-risk GIST is about 2 years.

In the single arm multicenter phase II intergroup study conducted by the American College of Surgeons Oncology Group (ACOSOG),

postoperative imatinib (400 mg/day) for one year following complete resection prolonged RFS and improved OS compared to historical controls in patients (n = 106) with primary GIST at high risk of recurrence based on clinicopathologic factors.<sup>264</sup>

These findings were confirmed in a subsequent phase III, double-blind, randomized study (ACOSOG Z9001), which randomized patients with primary localized GISTs (3 cm or greater in size) to postoperative imatinib 400 mg (359 patients) or placebo (354 patients) for one year after complete resection.<sup>265</sup> At a median follow-up of 19.7 months, the RFS rate at one year was significantly higher in the imatinib arm compared to placebo (98% and 83%, respectively,  $P < .001$ ). OS was not different in both arms (99.2% vs. 99.7%, respectively;  $P = .47$ ).<sup>265</sup> In the subset analysis, RFS was statistically in favor of the imatinib arm in patients with intermediate-risk (6 cm or greater and less than 10 cm; 98% vs. 76% for placebo;  $P = .05$ ) and high-risk tumors (10 cm or greater; 77% vs. 41% for placebo;  $P < .0001$ ).<sup>265</sup> Long-term follow-up is ongoing to determine the appropriate duration of treatment and the impact of mutational status on the outcome of patients treated with postoperative imatinib.

The results of another randomized phase III study (SSGXVIII/AIO) suggest that postoperative imatinib administered for 36 months improves RFS and OS compared to 12 months for patients with a high estimated risk of recurrence after surgery.<sup>266</sup> In this study, patients with a high risk for GIST recurrence after surgery (tumor greater than 10 cm in size with a mitotic rate of >10 mitoses/50 HPF or tumor greater than 5 cm in size with a mitotic rate of >5 mitoses/50 HPF or a risk of recurrence of greater than 50%) were randomized to 12 months (n = 200) or 36 months (n = 200) of postoperative imatinib. The median follow-up was 54 months. The RFS and OS were longer in the 36-month group compared to the 12-month group (5-year RFS: 66% vs.

48%, respectively;  $P < .0001$ ; 5-year OS: 92 % vs. 82% respectively;  $P = .019$ ).

### *Management of Toxicities*

The most common side effects of imatinib include fluid retention, diarrhea, nausea, fatigue, muscle cramps, abdominal pain, and rash. The side effect profile may improve with prolonged therapy.<sup>267</sup> Serious side effects (such as liver function test [LFT] abnormalities, lung toxicity, low blood counts, and GI bleeding) have rarely been reported and often improve after imatinib is withheld. LFT abnormalities are seen in fewer than 5% of patients. Leukopenia is quite rare and imatinib has only rarely been associated with neutropenic fever. The side effect profile may improve with prolonged therapy and can be managed with appropriate supportive care measures. If life-threatening side effects occur with imatinib that cannot be managed by maximum supportive treatment, then sunitinib should be considered, after discontinuing imatinib.

A recent report described congestive heart failure (CHF) as a potential side effect of imatinib. However, in a retrospective analysis of 219 consecutive patients treated with imatinib, grade 3 or 4 cardiotoxicity occurred in 8.2% of patients, who were manageable with medical therapy, and infrequently required dose reduction or discontinuation of imatinib.<sup>268</sup> Arrhythmias, acute coronary syndromes, or heart failure were uncommon, occurring in less than 1% of treated patients. The authors concluded that imatinib is an uncommon cause of cardiotoxicity, and that the cardiovascular adverse events that occur are manageable when recognized and treated. However, patients on imatinib who present with significant fluid retention should be evaluated carefully.

### Sunitinib

Sunitinib is a multi-targeted TKI that can induce objective responses and control progressive disease in patients with imatinib-resistant GIST.

In a randomized phase III placebo-controlled study, sunitinib produced significant, sustained clinical benefit in patients with imatinib-resistant or imatinib-intolerant GIST.<sup>269</sup> In patients with imatinib-resistant GIST, sunitinib resulted in a significant improvement in median time to progression (27.3 vs. 6.4 weeks) and significantly greater estimated OS. Sunitinib treatment induced PR in 14 patients (6.8%) and stable disease (22 weeks or more) in 36 patients (17.4%) versus no PRs and stable disease in 2 patients (1.9%) on placebo. In the imatinib-intolerant group, 4 out of 9 patients randomized to sunitinib achieved PR and one patient had progressive disease. In contrast, three of the four patients randomized to placebo had progressive disease at the time of analysis and no PR was observed. Sunitinib was generally well tolerated. In January 2006, sunitinib received FDA approval for the treatment of GIST, after disease progression on or intolerance to imatinib.

The safety and efficacy of sunitinib on a continuous daily dosing schedule at 37.5 mg was evaluated in an open-label, multicenter, randomized phase II study in patients with advanced GIST after imatinib failure.<sup>270</sup> Patients were randomized (1:1) to receive continuous daily sunitinib (37.5 mg/day) either in the morning or in the evening for 28 days (one cycle). The primary endpoint was the clinical benefit rate (CBR) defined as the percentage of patients with CRs, PRs, or stable disease for 24 weeks or more based on RECIST. The overall CBR was 53% (13% of patients had PRs and 40% had stable disease). Median PFS and OS were 34 weeks and 107 weeks, respectively. The most commonly reported treatment-related adverse events (diarrhea, fatigue, and nausea) were consistent with those known to be associated with sunitinib intermittent dosing. Treatment-related hypertension and

hypothyroidism (experienced by 28% and 12% of patients, respectively) were successfully managed with appropriate supportive care measures. Both of these adverse events have also been associated with the long-term use of sunitinib on intermittent dosing. The results of this study suggest that continuous daily dosing appears to be an effective alternative dosing strategy with acceptable safety for patients with imatinib-resistant/-intolerant GIST.

### Management of Toxicities

Sunitinib-related toxicities can often be managed with dose interruptions or reductions. Fatigue, nausea, and vomiting were dose-limiting toxicities for sunitinib in clinical trials. Other common toxicities include hematologic toxicities (anemia, neutropenia), diarrhea, abdominal pain, mucositis, anorexia, and skin discoloration. Sunitinib is associated with a significant risk of developing hand-foot skin reaction (HFSR).<sup>271</sup> Early detection and proper management of HFSR is vital during treatment with sunitinib. HFSR can be prevented with routine application of emollient lotions. If it is significant, interruption of therapy is indicated; if it is severe, dose reduction should be considered.

Hypertension is a common side effect reported in clinical trials, since sunitinib targets vascular endothelial growth factor receptor (VEGFR). However, the risk is higher in patients with renal cell carcinoma (RCC) compared to those with non-RCC.<sup>272</sup> Recent reports have shown that sunitinib is also associated with cardiotoxicity and hypothyroidism.<sup>273,274</sup> In a retrospective analysis of the data from phase I-II studies, 11% of the patients had an adverse cardiovascular event including CHF in 8% of patients and absolute reduction in the left ventricular ejection fraction (LVEF) in 28% of patients.<sup>273</sup> In a prospective, observational cohort study, abnormal serum thyroid-stimulating hormone (TSH) concentrations were documented in 62% of patients and the risk for hypothyroidism increased with the duration of therapy.<sup>274</sup>



Close monitoring for hypertension and LVEF is essential in patients receiving sunitinib, especially in patients with a history of heart disease or cardiac risk factors. Routine monitoring (every 3–6 months) of TSH is indicated. If hypothyroidism is suggested, patients should receive thyroid hormone replacement therapy. Patients should monitor their blood pressure closely and those who experience an increase in blood pressure should be treated with antihypertensives.<sup>233</sup>

#### ***Impact of Mutational Status on Response to Imatinib or Sunitinib in Patients with Advanced or Metastatic GIST***

The presence and type of *KIT* or *PDGFRA* mutation has been identified as the predictor of response to imatinib. In randomized clinical trials, the presence of a *KIT* exon 11 mutation was associated with better response rates, PFS, and OS compared to *KIT* exon 9 mutations or wild-type GIST.<sup>275-278</sup>

In the US-Finnish B2222 phase II study, PR rates, event-free survival (EFS), and OS rates were better for patients with *KIT* exon 11 mutations than those with *KIT* exon 9 mutations or had no detectable kinase mutations.<sup>275</sup> The PR rates for patients with *KIT* exon 11 mutations, *KIT* exon 9 mutations, or no detectable kinase mutations were 83.5%, 48%, and no responses, respectively. The presence of *KIT* exon 11 mutations was the strongest prognostic factor reducing the risk of death by more than 95%.

In a randomized EORTC-62005 study, the presence of *KIT* exon 9 mutations was the strongest adverse prognostic factor for risk of progression and death.<sup>276</sup> In this trial, treatment with high-dose imatinib (800 mg/day) resulted in a significantly superior PFS with a reduction of the relative risk of 61% ( $P = .0013$ ), in patients whose tumors expressed a *KIT* exon 9 mutation.<sup>277</sup> In addition, the response rate after crossover from 400 mg daily to 400 mg twice daily imatinib was much

higher among patients with *KIT* exon 9 mutations (57%) than among patients with *KIT* exon 11 mutations (7%).

The North American Intergroup phase III trial (SWOG S0033/CALGB 150105) also confirmed the findings from B2222 and EORTC-62005 studies. Patients with *KIT* exon 9 mutation treated with 800 mg imatinib had improved response rates compared to those treated with 400 mg imatinib (67% vs. 17%, respectively).<sup>278</sup> However, the PFS advantage observed in the EORTC-62005 study in patients with *KIT* exon 9 mutations treated with high-dose imatinib was not confirmed in the S0033/CALGB 150105 study. The results of the North American Intergroup phase III trial also showed that patients with CD117-negative GIST have similar time to tumor progression but inferior OS compared to those with CD117-positive GIST, suggesting that patients with CD117-negative GIST may benefit from imatinib therapy.<sup>278</sup> Therefore, it is rational to offer *KIT*-negative GIST patients a therapeutic trial of imatinib with close evaluation and follow-up.

A meta-analysis of EORTC-62005 and SWOG S0033/CALGB 150105 phase III trials that randomized 1,640 patients with advanced GIST to standard-dose imatinib (400 mg daily) or high-dose imatinib (800 mg daily) showed a benefit in PFS for patients with *KIT* exon 9 mutations treated with 800 mg of imatinib.<sup>279</sup> In a recent international survey that reported the outcome of GIST patients with *PDGFRA* mutations, none of 31 evaluable patients with D842V mutation had a response, whereas 21 of 31 (68%) had disease progression.<sup>280</sup> Median PFS was 2.8 months for patients with D842V substitution and 28.5 months for patients with other *PDGFRA* mutations. With 46 months of follow-up, median OS was 14.7 months for patients with D842V substitutions and was not reached for patients with other *PDGFRA* mutations.

Heinrich and colleagues reported that sunitinib induced higher response rates in patients with primary *KIT* exon 9 mutations than those with *KIT* exon 11 mutations (58% vs. 34%, respectively). PFS and OS were significantly longer for patients with *KIT* exon 9 mutations or with wild-type GIST compared to those with *KIT* exon 11 mutations. There were only 4 patients with *PDGFRA* mutations; of these 2 had a primary and one had a secondary D842V mutation and did not respond to treatment. In patients with *KIT* exon 11 mutations, PFS and OS were longer for those with secondary exon 13 or 14 mutations compared to those with exon 17 or 18 mutations. Additional studies are needed to confirm these findings.

### **Resistance to Imatinib and Sunitinib**

While imatinib benefits most patients with advanced GIST, some patients develop resistance to the drug. Primary resistance is defined as the evidence of clinical progression developing during the first 6 months of imatinib therapy and it is most commonly seen in patients with *KIT* exon 9 mutations treated with imatinib at 400 mg daily, *PDGFRA* exon 18 D842V mutations, or those with tumors that lack identifiable activating mutations in *KIT* or *PDGFRA*, the majority of which are *SDH*-deficient GIST.<sup>275,276,278,281</sup> Secondary resistance is seen in patients who have been on imatinib for more than 6 months with an initial response or disease stabilization followed by progression, most commonly because of the outgrowth of tumor clones with secondary mutations in *KIT*.<sup>282-285</sup> Dose escalation to 800 mg/day or switching to sunitinib is a reasonable option for patients progressing on imatinib 400 mg/day.<sup>253,269,270</sup>

Comprehensive molecular studies investigating the mechanisms of resistance to sunitinib are limited due to the small number of patients who are surgical candidates after failing two TKI therapies. Nevertheless, available evidence (both clinical and preclinical)

indicates that while sunitinib is very sensitive to ATP-binding pocket mutations that confer resistance to imatinib, it has little activity against other imatinib-resistant mutations in the *KIT* activation loop.<sup>286-288</sup>

### **Management of Resistance to Imatinib and Sunitinib**

Regorafenib, a multikinase inhibitor with activity against *KIT*, PDGFR, and VEGFR, was recently approved by the FDA for the treatment of patients with locally advanced, unresectable, or metastatic GIST previously treated with imatinib and sunitinib. In a phase III randomized study, 199 patients with metastatic and/or unresectable GIST progressing on prior therapy with imatinib and sunitinib were randomized to regorafenib (n = 133) or placebo (n = 66).<sup>289</sup> The median PFS (4.8 months vs. 0.9 months;  $P < .0001$ ) and the disease control rate (DCR; 53% vs. 9%) were significantly higher for regorafenib compared to placebo. The PFS rates at 3 and 6 months were 60% and 38%, respectively, for regorafenib compared to 11% and 0%, respectively, for placebo. The HR for OS was 0.77 with 85% of patients in the placebo arm crossing over to regorafenib due to disease progression. The most common treatment-related adverse events (grade 3 or higher) were hypertension (23%), HFSR (20%), and diarrhea (5%).

Sorafenib,<sup>290-293</sup> nilotinib,<sup>294-298</sup> dasatinib,<sup>299,300</sup> and pazopanib<sup>301</sup> have also shown activity in patients with GIST resistant to imatinib and sunitinib. Much of the data on these TKIs comes from phase II studies and retrospective analyses involving a small number of patients.

In a prospective, multicenter, phase II study of 38 patients with unresectable, *KIT*-positive GIST that had progressed on imatinib and sunitinib, sorafenib resulted in a DCR of 68% (55% of patients who had stable disease and 13% who had PR).<sup>290</sup> Median PFS and OS were 5.2 months and 11.6 months, respectively; 1-year and 2-year

survival rates were 50% and 29%, respectively. In a retrospective analysis of 124 patients with metastatic GIST resistant to imatinib and sunitinib, sorafenib also demonstrated activity resulting in median PFS and OS of 6.4 months and 13.5 months, respectively.<sup>292</sup> It should be noted that patients included in this study had not been treated with regorafenib, and the efficacy of sorafenib following regorafenib therapy in patients with metastatic GIST resistant to imatinib and sunitinib has not been studied.

In a retrospective analysis of 52 patients with advanced GIST resistant to imatinib and sunitinib, nilotinib resulted in a 10% response rate and 37% DCR.<sup>295</sup> Median PFS and OS were 12 weeks and 34 weeks, respectively. In a randomized phase III study of nilotinib as third-line therapy and best supportive care (with or without a TKI) in patients with GIST resistant or intolerant to imatinib and sunitinib (248 patients), the PFS on nilotinib was not found to be superior to best supportive care (109 days vs. 111 days;  $P = .56$ ). In a post hoc subset analysis, patients progressing on both imatinib and sunitinib who had not received any other therapy had an improved OS (>4 months) with nilotinib compared to best supportive care (405 vs. 280 days;  $P = .02$ ). The clinical benefit associated with nilotinib may be specific to subsets of patients with *KIT* exon 17 mutations, previously treated with imatinib and sunitinib.<sup>298</sup>

Dasatinib has demonstrated activity against *PDGFRA* D842V mutation that confers the highest resistance to imatinib, and it could be an effective treatment option for this group of patients with imatinib-resistant GIST.<sup>299</sup> In the phase II study of 50 patients with advanced GIST resistant to imatinib, dasatinib was associated with a median PFS and OS of 2 and 19 months, respectively, with response assessment by Choi criteria.<sup>300</sup> Median PFS for patients with wild-type GIST was 8.4 months.

Pazopanib has also shown marginal activity in unselected, heavily pretreated patients with advanced GIST. In a multicenter phase II study of patients with advanced GIST following failure of at least imatinib and sunitinib ( $n = 25$ ), pazopanib was well tolerated resulting in stable disease in 48% of patients, with a 24-week non-progression (CR + PR + stable disease) rate of 17%.<sup>301</sup> The median PFS and OS were 1.9 months and 10.7 months, respectively.

### Initial Evaluation and Workup

All patients should be managed by a multidisciplinary team with expertise in sarcoma. Essential elements of the workup include the H&P, abdominal/pelvic CT scan with contrast and/or MRI, chest imaging, EUS in selected patients, endoscopy as indicated (if not previously done), and surgical assessment.

### Imaging of GISTs

In patients with GIST, imaging is used for diagnosis, initial staging, restaging, monitoring response to therapy, and performing follow-up surveillance of possible recurrence. Contrast-enhanced CT is the imaging modality of choice to characterize an abdominal mass, as well as to evaluate its extent and the presence or absence of metastasis at the initial staging workup for biopsy-proven GIST. PET scan helps to differentiate active tumor from necrotic or inactive scar tissue, malignant from benign tissue, and recurrent tumor from nondescript benign changes. PET provides significant value to the standard CT images, because changes in the metabolic activity of tumors often precede anatomic changes on CT. However, PET scan is not a substitute for CT. PET scans may be used to clarify ambiguous findings seen on CT or MRI. PET may also be useful to assess complex metastatic disease in patients who are being considered for surgery. Even in this clinical setting there is no clear evidence that PET provides

significant information that cannot be obtained using IV contrast-enhanced CT. PET may be of benefit in patients with IV contrast allergy, particularly for peritoneal disease; MRI with or without contrast usually yields excellent anatomical definition of liver metastases.<sup>233</sup> Many imaging centers are also equipped with combined PET-CT scanners, which may facilitate both anatomic and functional tumor evaluation in one step.<sup>302</sup> If clinicians consider using PET scan to monitor therapy, a baseline PET should be obtained prior to the start of therapy.

### Response Assessment

The CT response criteria proposed by Choi are much better than RECIST criteria to assess the response of GIST to TKI therapy. Choi criteria have been validated in one center in patients with GIST who had not previously received TKI therapy.<sup>303</sup> However, these criteria are not universally accepted, they have not been validated for patients who have received several targeted therapies, and the ease of use outside specialized centers is unknown. The EORTC has developed metabolic response criteria for tumors evaluated with PET that provide definitions for complete metabolic response, partial metabolic response, stable metabolic disease, or disease metabolic progression.<sup>304</sup> However, since there is a 95% correlation between the information from regular contrast-enhanced CT and PET-CT scans, CT scans with IV contrast are the preferred routine imaging modality for patients with GIST on TKI therapy. Early assessment of treatment response to sunitinib has been shown to be a predictor of clinical outcome. However, the preliminary findings from this study need to be confirmed in larger prospective studies.<sup>305</sup>

### Resectable Disease

#### *Primary/Preoperative Treatment*

Surgery is the primary treatment for all patients with GISTs (2 cm or greater) that are resectable without significant risk of morbidity. Preoperative imatinib is recommended as primary treatment for patients with GIST that is resectable with negative margins but with a significant risk of morbidity.<sup>257,259</sup> The use of preoperative imatinib may however prohibit the accurate assessment of recurrence risk. Preoperative imatinib should be considered only if surgical morbidity could be reduced by downstaging the tumor prior to resection. Close monitoring is essential, because some patients may rapidly become unresectable. In prospective studies, preoperative imatinib has been tested at a daily dose of either at 400 mg<sup>259,260</sup> or 600 mg.<sup>257,258</sup> The guidelines recommend an initial dose of 400 mg daily. Patients with documented *KIT* exon 9 mutations may benefit from dose escalation up to 800 mg daily (given as 400 mg twice daily), as tolerated.

Baseline CT with or without MRI is recommended prior to the start of preoperative imatinib. Since the optimal duration of preoperative therapy remains unknown, in patients responding to therapy, imatinib should be continued until maximal response (defined as no further improvement between 2 successive CT scans, which can take as long as 6–12 months). However, it is not always necessary to wait for a maximal response to perform surgery. Surgery is recommended if bleeding and/or symptoms are present. PET may give an indication of imatinib activity after 2 to 4 weeks of therapy when rapid readout of activity is necessary. Diagnostic CT is indicated every 8 to 12 weeks. If there is no progression, continuation of the same dose of imatinib is recommended and resection should be considered, if possible. If there is progression, as confirmed with CT scan, surgery is recommended after discontinuing imatinib. In patients taking preoperative imatinib,

dosing can be stopped right before surgery and resumed as soon as the patient is able to tolerate oral medications following surgery regardless of surgical margins. Collaboration between the medical oncologist and the surgeon is necessary to determine the appropriateness of surgery following major response or stable disease.

However, the management of incidentally encountered small GISTs less than 2 cm remains controversial.<sup>233</sup> At present, there are insufficient data to guide the management of very small GISTs (less than 2 cm) discovered incidentally on endoscopy and the usefulness of regular EUS surveillance has not been established. Complete surgical resection is the mainstay of treatment in symptomatic patients. For a subset of patients with very small gastric GISTs (less than 2 cm) with no high-risk EUS features (irregular extra-luminal border, heterogeneous echo pattern, presence of cystic spaces and echogenic foci), endoscopic surveillance at 6- to 12-month intervals may be considered.<sup>234</sup> The panel has included this approach with a category 2B recommendation.

### **Postoperative Treatment**

Based on results of the ACOSOG Z9001 study and the randomized phase III study (SSGXVIII/AIO), the guidelines recommend postoperative imatinib following complete resection for primary GIST with no preoperative imatinib for patients at intermediate or high risk of recurrence (category 1).<sup>265,266</sup> The panel recommends that postoperative imatinib for at least 36 months should be considered for patients with high-risk GIST.<sup>266</sup>

Estimation of risk of recurrence is important in selecting patients who would benefit from postoperative therapy following complete resection. In the ACOSOG Z9001 study, risk stratification was based only on tumor size and postoperative imatinib improved RFS in patients with

GIST 3 cm or larger; however, it was statistically significant in patients with intermediate (6 cm or greater and less than 10 cm) and high risk (greater than 10 cm) of recurrence.<sup>265</sup> In the SSGXVIII/AIO study, risk stratification was based on tumor size, site, mitotic count, and rupture; survival benefit was seen in patients with high risk of recurrence (mitotic index of >5 mitoses/50 HPF, size >5 cm, non-gastric location, and tumor rupture).<sup>266</sup>

Risk stratification after surgical resection should be based on tumor mitotic rate, size, and location.<sup>306</sup> Gold and colleagues have developed a nomogram, taking into account tumor size, site, and mitotic index, to predict RFS after resection of localized primary GIST.<sup>307</sup> This nomogram accurately predicts RFS after resection of localized primary GIST and might be useful for patient care, interpretation of study results, and selection of patients for postoperative imatinib therapy.

For patients with complete resection following preoperative imatinib, the panel agreed that continuation of imatinib (at the same dose that induced objective response) is warranted. The panel acknowledged that while data from single and multi-institutional studies support the continuation of postoperative imatinib for two years following surgery, the exact duration of postoperative imatinib in this group of patients has not been studied in randomized studies.<sup>257-260</sup> The long-term analysis of the RTOG 0132 study suggested that a high percentage of patients progressed after discontinuation of 2-year postoperative imatinib therapy.<sup>308</sup>

In patients who have received preoperative imatinib, if there is persistent gross disease following resection (R2 resection), additional resection may be considered to remove residual disease. Imatinib treatment should be continued following re-resection regardless of surgical margins until progression. Postoperative imatinib should be



initiated following resection, if the patient had not received prior imatinib therapy.

### **Unresectable, Metastatic, or Recurrent Disease**

Imatinib (category 1) is the primary treatment for patients with advanced, unresectable, or metastatic GIST. Imatinib has been shown to improve resectability and reduce surgical morbidity in patients with documented unresectable GIST or in patients for whom resection would carry the risk of severe postoperative functional deficit.<sup>259,260</sup> Several retrospective studies have demonstrated survival benefit of cytoreductive surgery following preoperative imatinib in patients with advanced or metastatic GIST responding to preoperative imatinib.<sup>309-316</sup> No definitive data exist to prove whether surgical resection improves clinical outcome in addition to TKI therapy for patients with resectable metastatic GIST. Prospective phase III studies are underway to assess whether or not resection changes outcome in patients with unresectable metastatic GIST responding to TKI therapy.

Patients should be assessed within 3 months of initiating imatinib to determine if their GIST has become resectable. In selected patients, imaging can be done prior to 3 months. If there is no progression, resection can be considered following surgical consultation. Imatinib should be continued if resection is not feasible. At this time, continuous use of imatinib is recommended for metastatic GIST until progression. The patient should be maintained on the same dose, and the dose of imatinib should not be increased if patients remain stable without objective progression of the disease. Termination of imatinib in patients with GIST that is refractory to imatinib has been shown to result in a flare phenomenon, which in turn indicates that even in patients with progressive disease on imatinib therapy, there are some tumor cells for which imatinib may still be effective.<sup>317</sup>

Recurrence following complete resection should be managed as described for unresectable or metastatic disease, because recurrent disease represents locoregional metastatic or infiltrative spread of the malignancy and carries essentially the same prognosis as distant metastases overall.

### **Progressive Disease**

Progression is defined as the appearance of a new lesion or an increase in tumor size. It may be determined using CT or MRI with clinical interpretation; PET may be used if the CT findings are ambiguous.

Dose escalation of imatinib up to 800 mg daily (given as 400 mg twice daily) as tolerated or switching to sunitinib (category 1) are included as options for patients with progressive disease (limited disease or widespread systemic disease in patients with good performance status) on standard-dose imatinib.<sup>253,269,270</sup> All clinical and radiological data, including lesion density on CT and patient compliance to treatment with standard-dose imatinib, should be assessed prior to dose escalation of imatinib or switching to sunitinib.

For patients with limited progressive disease on standard-dose imatinib, second-line therapy with sunitinib should be initiated only if the majority of disease is no longer controlled by imatinib; consideration of other therapeutic interventions for progressing lesion(s) is warranted. Surgical resection should be considered in carefully selected patients with limited progressive disease that is potentially easily resectable.<sup>309,314,318</sup> However, incomplete resections are frequent with high complication rates. The guidelines have included, only for patients with limited progressive disease, continuation of imatinib at the same initial dose and treatment of



# NCCN Guidelines Version 2.2014

## Soft Tissue Sarcoma

progressing lesions with resection, RFA, chemoembolization, or palliative RT (for rare patients with bone metastases) as an option.<sup>233</sup>

Regorafenib (category 1) is recommended for patients with disease progression on imatinib and sunitinib.<sup>289</sup> Based on limited data,<sup>290-300</sup> the guidelines have also included sorafenib, dasatinib, or nilotinib as additional options for patients who are no longer receiving clinical benefit from imatinib, sunitinib, or regorafenib, although all data regarding the potential benefit of these agents are in the pre-regorafenib era.

In patients with progressive disease no longer receiving benefit from current TKI therapy, re-introduction of previously tolerated and effective TKI therapy for palliation of symptoms can be considered.<sup>319,320</sup> The results of a recent randomized study demonstrated that imatinib rechallenge significantly improved PFS and DCR in patients with advanced GIST after failure of at least imatinib and sunitinib.<sup>320</sup> However, the duration of survival benefit was brief due to continued progression of TKI-resistant clones.

Any patient who has disease progression despite prior therapy or who has a recurrence, regardless of presentation, should be considered for enrollment in a clinical trial, if an appropriate trial is available.

### Continuation of TKI Therapy

The optimal duration of TKI therapy in patients with responding or stable disease is not known. The results of a prospective, multicenter, randomized phase III study (BFR14) show that there was significant increase in the rate of progressive disease when imatinib therapy was interrupted in patients with advanced disease who were stable or responding to imatinib therapy.<sup>321,322</sup> A recent report from this study confirmed that patients with rapid disease progression after interruption

of imatinib had a poorer prognosis.<sup>323</sup> More importantly, the quality of response upon reintroduction of imatinib did not reach the tumor status observed at randomization.

The panel strongly recommends that TKI therapy at the prescribed daily dose should be continued as long as patients are receiving clinical benefit (response or stable disease). The panel also feels that continuation of TKI therapy life-long for palliation of symptoms should be an essential component of best supportive care. However, short interruptions for one to two weeks, when medically necessary, have not been shown to negatively impact disease control or other outcomes.

### Surveillance

Every patient with a resected, localized GIST should have a thorough H&P every 3 to 6 months; these patients should also have an abdominopelvic CT scan every 3 to 6 months. An identical schedule is used for patients who have persistent gross residual disease that is unresectable or for completely resected disease.

### Desmoid Tumors (Aggressive Fibromatoses)

Desmoid tumors, also known as aggressive fibromatoses, are unique mesenchymal neoplasms, which are often considered “benign malignancies.” Specifically, these tumors are an aggressive fibroblastic proliferation of well-circumscribed, locally invasive, and differentiated fibrous tissue. Desmoid tumors can cause functional morbidity and are often locally invasive, but they rarely metastasize. The location and presentation of desmoids vary, from the abdominal wall of young pregnant females, to intra-abdominal mesenteric masses, and to large extremity masses in older men and women.

Desmoid tumors often pose difficult decisions for patients because of the extent of surgery required for optimal control, their high recurrence rate, and their long natural history. Although they do not exhibit the histopathologic features to classify them as sarcomas, desmoid tumors are often categorized as low-grade sarcomas because of their high tendency to recur locally after excision.

Desmoid tumors have been reported to occur in 7.5% to 16% of patients with FAP and the relative risk of developing desmoid tumors is much higher in patients with FAP than the general population.<sup>22-25</sup> Abdominal desmoids may be a component of FAP and may also arise through elective surgical intervention (eg, colectomy) in susceptible patients.<sup>22,324,325</sup> In patients who have been treated with prophylactic colectomy, desmoids now represent a more significant cause of morbidity than carcinoma of the colon.<sup>326</sup>

Mutations in the *CTNNB1* gene encoding the  $\beta$ -catenin pathway have been identified in sporadic desmoid tumors, although the correlation of *CTNNB1* mutation status with the clinical outcome remains uncertain.<sup>327-331</sup> Lazar and colleagues identified mutations in the *CTNNB1* gene in 85% of patients with desmoid tumors.<sup>327</sup> Three distinct mutations, 41A, 45F, and 45P, were identified in 59%, 33%, and 8% of cases, respectively. Mutation 45F was associated with a high risk of recurrence; 5-year RFS rate was 23% for patients harboring 45F mutation compared to 57% for those with 41A and 68% for those with no mutations.<sup>327</sup> In a retrospective study of patients with extra-abdominal desmoid tumors, Domont and colleagues reported *CTNNB1* mutations in 87% of patients, and the 5-year RFS rate was significantly worse in patients with  $\beta$ -catenin mutations, regardless of the genotype, compared with wild-type tumors (49% vs. 75%, respectively).<sup>328</sup> Columbo and colleagues also reported that mutation 45F was associated with higher rates of local recurrence among

patients with primary, completely resected, sporadic desmoid tumors and mutation 45F was more prevalent in extra-abdominal desmoid tumors compared to other sites.<sup>330</sup> In contrast to these findings, Mullen and colleagues reported that *CTNNB1* mutation status or the specific *CTNNB1* mutation was not associated with any statistically significant difference in recurrence risk in a subset of 115 patients with desmoid tumors who underwent macroscopically complete surgical resection.<sup>331</sup> At a median follow-up of 31 months, the 5-year RFS rates were 58% and 74%, respectively, for patients with *CTNNB1* mutations and for those with wild-type tumors. Additional prospective studies are needed to confirm whether genotyping of *CTNNB1* may provide important information regarding the risk of recurrence and the selection of patients for adjuvant treatment options.

### Evaluation and Workup

The workup for desmoid tumors includes H&P (with evaluation for Gardner's syndrome), chest imaging, and appropriate imaging of the primary site with CT or MRI as clinically indicated. All patients should be managed by a multidisciplinary team. Biopsy should be performed for suspicious masses to confirm the diagnosis, and may not be necessary if complete resection is planned. The differential diagnosis for desmoids depends on location; it includes other sarcomas, other malignant carcinomas, and benign lesions. Desmoid tumors of the breast are difficult to differentiate from carcinomas, because they resemble carcinomas clinically and radiologically.<sup>332-335</sup>

### Resectable Tumors

Surgery is the primary treatment for patients with resectable desmoid tumors.<sup>336-339</sup> Tumor location and size, patients' age, and margin status have been identified as factors associated with recurrence following resection. Extra-abdominal tumors have a higher risk of recurrence

than abdominal tumors. In an analysis of 203 patients with desmoid tumors treated with surgery, Gronchi and colleagues reported significantly higher DFS rates for patients with abdominal wall tumors than those with extremity tumors. The 10-year DFS rates were 88% and 62%, respectively ( $P < .01$ ).<sup>340</sup> In a more recent report involving 211 patients with desmoid tumors treated with surgery, Peng and colleagues also reported similar findings.<sup>341</sup> The median RFS was not reached following resection for patients with either abdominal wall or intra-abdominal tumors, whereas the median RFS was 29.4 months for patients with extra-abdominal tumors ( $P < 0.001$ ). However, the impact of positive resection margins on local control and risk of recurrence remains controversial.<sup>342</sup> Some studies have reported margin status as an independent prognostic factor of recurrence.<sup>341,343-345</sup> Other studies have failed to demonstrate any clear association between resection margins and risk of recurrence.<sup>340,346,347</sup> Several retrospective series have reported that postoperative RT significantly improves local control and PFS compared to surgery alone, suggesting that postoperative RT could be considered for patients who are at high risk of local recurrence.<sup>346,348-352</sup>

The results of recent retrospective analyses suggest that observation may be appropriate for selected patients with resectable tumors (small size, asymptomatic, and tumors located at sites where increase in size will not alter the outcome of surgery or lead to functional limitation).<sup>353,354</sup> In a retrospective analysis of 142 patients with desmoid fibromatoses (74 with primary tumor and 68 with recurrence) reported by Fiore and colleagues, the 5-year PFS rates for patients with primary tumors were 47% for those who were treated with a “wait and see” approach (no surgery or RT) and 54% for those who received medical therapy (chemotherapy or hormonal therapy;  $P = .70$ ).<sup>354</sup> The corresponding survival rates were 54% and 61% ( $P = .48$ ) for patients

with recurrence. Large tumors (greater than 10 cm in size) and tumors located on the trunk were associated with a high risk of recurrence.

Based on these results, the panel concluded that patients with desmoid fibromatoses can be managed appropriately with a careful “watch and wait” approach if their tumors are asymptomatic and are not located in an area that could lead to functional limitations if the tumor increases in size. The guidelines have included observation as an option for selected patients with resectable tumors. If there is progression, they can be treated with surgery and/or RT and/or systemic therapy.

For symptomatic patients with large tumors causing morbidity, pain, or functional limitation, treatment choices should be based on the location of the tumor and potential morbidity of the treatment. Options include surgery and/or RT and/or systemic therapy. Patients with resectable tumors should be treated with complete surgical resection when feasible. Microscopically positive margins may be acceptable if they achieve negative margins would produce excessive morbidity. If surgical margins are negative after resection (R0 resection) or if there is complete radiographic response, patients may only be observed. For microscopically positive margins or minimal residual disease (R1 resection), additional resection or high-dose RT (if not received prior to surgery) can be considered. Postoperative RT reduces the risk of recurrence in patients with positive margins and should be considered if a subsequent relapse might lead to increased morbidity. Patients with macroscopic surgical margins (R2 resection) are treated as described below for unresectable disease.

### Unresectable Tumors

In the case of unresectable desmoid tumors, amputation should almost never be considered. Functional outcomes are important, and alternatives to amputation may be open to patients who have



unresectable desmoid tumors.<sup>340,355</sup> RT is a reasonable treatment option for patients with unresectable tumors, depending on the possible morbidity of treatment.<sup>346,356-359</sup> In a retrospective analysis of 23 patients with extra-mesenteric desmoid tumors treated with RT for gross residual unresectable disease, 7 patients sustained local recurrence, yielding a 5-year actuarial local control rate of 69%. In another retrospective analysis that included 13 patients with unresectable tumors treated with RT alone as a definitive local therapy, the actuarial 3-year freedom-from-recurrence rate was 92.3%.<sup>346</sup> In a more recent multicenter, prospective phase II study of 44 patients with inoperable desmoid tumors of trunk and extremities treated with RT (56 Gy in 28 fractions), Keus and colleagues reported a 3-year local control rate of 81.5%, at a median follow-up of 4.8 years.<sup>359</sup> During the first 3 years, CR, PR, and stable disease were observed in 13.6%, 36.4%, and 40.9% of patients, respectively. Response to RT was slow, with continuing regression seen even after 3 years.<sup>359</sup>

Definitive RT (54–58 Gy in the absence of any prior RT only for desmoid tumors of the extremity head and neck or superficial trunk), systemic therapy, and observation are some of the options for patients with unresectable tumors. Radical surgery should be considered only if other treatment modalities fail. RT is not generally recommended for retroperitoneal/intra-abdominal desmoid tumors.

Systemic therapy using non-steroidal anti-inflammatory drugs (NSAIDs), hormonal or biological agents, or cytotoxic drugs have shown promising results in patients with desmoid tumors.<sup>360,361</sup> In a prospective study, tamoxifen in combination with sulindac resulted in disease stabilization in patients with progressive or recurrent tumors following surgery.<sup>362</sup> The results of a retrospective, non-randomized study showed that interferon alfa with or without tretinoin may be effective in prolonging the disease-free interval after intralesional or

marginal surgery in patients with extra-abdominal desmoid tumors.<sup>363</sup> In case reports, toremifene has been effective in disease stabilization following surgery.<sup>364-367</sup> Doxorubicin-based chemotherapy has been effective in patients with recurrent or unresectable tumors.<sup>368-371</sup> The combination of methotrexate and vinorelbine or vinblastine has also been associated with prolonged stable disease in patients with unresectable or recurrent tumors.<sup>370,372,373</sup>

Imatinib and sorafenib have also been evaluated in patients with unresectable, progressive, or recurrent aggressive fibromatosis.<sup>374-377</sup> In a phase II multicenter study, imatinib resulted in an objective response rate of 6% and the 1-year PFS rate was 66% in patients with unresectable tumors.<sup>375</sup> Long-term follow-up results of the phase II study by the French Sarcoma Group also showed that imatinib resulted in objective responses and stable disease in a large proportion of patients with recurrent or progressive aggressive fibromatosis.<sup>376</sup> At a median follow-up of 34 months, the 2-year PFS and OS rates were 55% and 95%, respectively. The non-progression rates at 3, 6, and 12 months were 91%, 80%, and 67%, respectively. In a study of 26 patients (11 patients received sorafenib as first-line therapy and the remaining 15 patients had received a median of 2 prior systemic therapies), sorafenib induced PR in 25% of patients and 70% of patients had stable disease, with a median follow-up of 6 months.<sup>377</sup>

The guidelines have included NSAIDs (sulindac or celecoxib), hormonal or biological agents (tamoxifen, toremifene, or low-dose interferon), chemotherapy (methotrexate and vinblastine, doxorubicin-based regimens), and TKIs (imatinib and sorafenib) as options for systemic therapy for patients with advanced or unresectable desmoid tumors. The risk of cardiovascular events may be increased in patients receiving celecoxib and patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Physicians



prescribing celecoxib should consider this information when weighing the benefits against risks for individual patients.

### Surveillance

Every patient should have an H&P with appropriate imaging every 3 to 6 months for 2 to 3 years and then annually. Disease progression or recurrence should be managed as described under primary treatment for resectable or unresectable disease.

### Rhabdomyosarcoma

RMS is more common among children and adolescents but is less common in adults accounting for 2% to 5% of all STSs.<sup>378</sup> RMS has three histologic subtypes: embryonal (including botryoid, and spindle cell variants), alveolar (including a solid variant), and pleomorphic histologies.<sup>379,380</sup> Embryonal and alveolar variants occur mainly in children and adolescents. Although pleomorphic RMS occurs predominantly in adults, embryonal and alveolar variants are also well represented.<sup>378,380-385</sup> The incidence of pleomorphic RMS increases with age and the overall prognosis of RMS in adults is poor.<sup>386</sup> In a study of 39 adult patients treated at a single institution, the incidence of pleomorphic RMS increased with age (0%, 27%, and 60%, respectively, for ages 16–19, 20–49, and 50 or older) and the median survival was 2.25 years after diagnosis.<sup>386</sup> Extremities, trunk wall, and genitourinary organs are the most common primary sites for pleomorphic RMS in adults.<sup>387-389</sup> In a recent SEER database analysis of 1,071 adults (older than 19 years) with RMS, the most common primary sites included extremities (26%) and trunk (23%) followed by genitourinary tract (17%) and head and neck (9%).<sup>384</sup> Pleomorphic histologies (19% vs. 1% in children;  $P < .0001$ ) and unfavorable sites (65% vs. 55% in children;  $P < .0001$ ) were more common in adults; the

estimated 5-year OS rates were 27% for adults compared to 63% for pediatric patients.<sup>384</sup>

Given the rarity of the clinical situation, there are very limited data (mostly from single-institution retrospective studies) available on the management of adults with RMS. Multimodality treatment (surgery, RT, and chemotherapy) has been used in all of these studies. In the largest retrospective single-institution study that evaluated 180 patients diagnosed with RMS (18 years or older; 143 patients with embryonal, alveolar, or RMS-not otherwise specified and 37 patients with pleomorphic histology), Ferrari and colleagues reported 5-year EFS and OS rates of 28% and 40%, respectively.<sup>378</sup> The overall response rate was 85% in patients with embryonal and alveolar RMS treated with chemotherapy according to the pediatric protocol. Surgery was the main treatment in patients with pleomorphic RMS (74% compared to 34% with non-pleomorphic histologies), and the EFS rate was 37% for patients who underwent complete resection compared to 0% in patients with unresectable tumors.<sup>378</sup>

Other retrospective studies from MD Anderson Cancer Center (82 adults) and Dana Farber Cancer Institute (39 patients) have also reported high overall response rates to chemotherapy (75% and 82%, respectively).<sup>382,390</sup> Survival was significantly better for patients responding to chemotherapy than those who did not. In the MD Anderson Cancer Center study, the 10-year metastasis-free survival was 72% for patients responding to chemotherapy compared to 19% for those who failed to respond.<sup>382</sup>

In the series from Dana Farber Cancer Institute, metastatic disease at presentation and poor response to chemotherapy were independent predictors of poor prognosis; the 5-year survival rate was 57% for patients with a CR to chemotherapy compared to only 7% for those with



poor response.<sup>390</sup> In this study, 5-year survival rates were also higher for patients who underwent complete resection than for those who did not (63% vs. 29% and 46% for those who underwent compromised or incomplete resections, respectively).<sup>390</sup> Hawkins and colleagues also reported that margin status after resection was predictive of disease-specific survival in adult patients (105 months for patients who underwent complete resection compared to 9 months for those with positive margins).<sup>381</sup>

Chemotherapy regimens used in adults with RMS are usually derived from the pediatric clinical trials on RMS conducted by international cooperative groups.<sup>391</sup> Vincristine, dactinomycin, and cyclophosphamide (VAC) has been the standard chemotherapy for pediatric nonmetastatic RMS (intermediate or high risk).<sup>392</sup> In a randomized study (D9803) from the Children's Oncology Group, there was no significant survival benefit of adding topotecan to standard VAC regimen in children with intermediate-risk RMS. In this study, at a median follow-up of 4.3 years, the 4-year failure-free-survival (FFS) rate was 73% and 68%, respectively, for patients treated with VAC and VAC alternating with vincristine, topotecan, and cyclophosphamide ( $P = .30$ ).<sup>392</sup> The results of the Intergroup RMS Study (D9602) showed that newly diagnosed patients with low-risk RMS treated with vincristine and dactinomycin had similar 5-year failure-free survival rates compared to those patients treated with vincristine, dactinomycin, and cyclophosphamide (89% and 85%, respectively), suggesting that vincristine and dactinomycin could be an appropriate option for patients with newly diagnosed, low-risk RMS.<sup>393</sup> Vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide was found to be effective for patients with intermediate-risk RMS.<sup>394</sup> Newer agents such as carboplatin,<sup>395</sup> irinotecan,<sup>396-399</sup> topotecan,<sup>400-402</sup> and

vinorelbine<sup>403,404</sup> have also shown activity in the treatment of patients with metastatic, relapsed, or refractory RMS.

Retrospective studies on adults with RMS have used a variety of multidrug chemotherapy regimens including cyclophosphamide or ifosfamide, doxorubicin, and/or dactinomycin with or without vincristine or other drugs such as cisplatin, carboplatin, and etoposide.<sup>378,382,386,390,405</sup> In the MD Anderson Cancer Center study, the 10-year overall, disease-free, and metastasis-free survival rates were 47%, 45%, and 59%, respectively, for adult patients treated with chemotherapy regimens containing vincristine and cyclophosphamide with dactinomycin or doxorubicin.<sup>382</sup> Esnaola and colleagues reported an overall response rate of 82%, with a CR rate of 45% in adults with RMS treated with vincristine, doxorubicin, and cyclophosphamide or other doxorubicin-based chemotherapy regimens.<sup>390</sup> Recently, Ogilvie and colleagues also reported that chemotherapy with vincristine, doxorubicin, and ifosfamide resulted in an overall response rate of 86% in 11 adult patients with pleomorphic RMS; the 2-year OS and DFS rates were 55% and 64%, respectively.<sup>405</sup>

These guidelines strongly recommend that all patients should be referred to institutions with expertise in treating patients with RMS. Evaluation by a multidisciplinary team involving pediatric, medical, surgical, and radiation oncologists is strongly encouraged. Multimodality treatment (surgery, RT, and chemotherapy) planning and risk stratification is required for all patients.<sup>391</sup> PET imaging may be useful for initial staging because of the possibility of nodal metastases and the appearance of unusual sites of initial metastatic disease in adult patients.<sup>406</sup>

Systemic chemotherapy options for RMS may be different than those used with other STS histologies. Pleomorphic RMS is usually excluded



from RMS randomized clinical trials. Consideration to treat according to STS guidelines may be warranted for this group of patients. In the absence of data from prospective clinical trials, there is no optimal chemotherapy for the management of adults with RMS. In the guidelines, vincristine and dactinomycin (with or without cyclophosphamide);<sup>392,393</sup> vincristine, doxorubicin, and cyclophosphamide (alone or alternating with ifosfamide and etoposide);<sup>327,394</sup> and vincristine, doxorubicin, and ifosfamide<sup>405</sup> are included as options for systemic chemotherapy. High-dose methotrexate may be useful for selected patients with CNS or leptomeningeal involvement when RT is not feasible.<sup>407</sup> See *Systemic Therapy Agents and Regimens with Activity in Soft Tissue Sarcoma* in the guidelines for a list of other chemotherapy regimens that are recommended for the management of adults with RMS.



## References

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. *CA Cancer J Clin* 2014;64:9-29. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24399786>.
2. D'Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumors. *Cancer Control* 2005;12:44-56. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15668652>.
3. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. *Hum Pathol* 2002;33:459-465. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12094370>.
4. Brady MS, Gaynor JJ, Brennan MF. Radiation-associated sarcoma of bone and soft tissue. *Arch Surg* 1992;127:1379-1385. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1365680>.
5. Zahm S, Fraumeni JJ. The epidemiology of soft tissue sarcoma. *Semin Oncol* 1997;24:504-514. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9344316>.
6. Penel N, Grosjean J, Robin YM, et al. Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 cases. *Sarcoma* 2008;2008:459386. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18497869>.
7. Coindre J, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. *Cancer* 2001;91:1914-1926. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11346874>.
8. Pisters PWT, Weiss M, Maki R. Soft-Tissue Sarcomas In: Haller DG, Wagman LD, Camphausen C, Hoskins WJ, eds. *Cancer Management: A Multidisciplinary Approach Medical, Surgical, & Radiation Oncology* (ed 14): UBM Medica LLC; 2011.
9. Clasby R, Tilling K, Smith MA, Fletcher CD. Variable management of soft tissue sarcoma: regional audit with implications for specialist care. *Br J Surg* 1997;84:1692-1696. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9448617>.
10. Li FP, Fraumeni JF, Jr., Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. *Cancer Res* 1988;48:5358-5362. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3409256>.
11. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. *Am J Gastroenterol* 2006;101:385-398. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16454848>.
12. Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. *J Natl Cancer Inst* 2007;99:24-31. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17202110>.
13. Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. *Orphanet J Rare Dis* 2009;4:22. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19822006>.
14. Postow MA, Robson ME. Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications. *Clin Sarcoma Res* 2012;2:16. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23036227>.
15. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science* 1990;250:1233-1238. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1978757>.
16. Nichols KE, Malkin D, Garber JE, et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. *Cancer Epidemiol Biomarkers Prev* 2001;10:83-87. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11219776>.



17. Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Sarcomas in TP53 germline mutation carriers. *Cancer* 2012;118:1387-1396. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21837677>.

18. Kleihues P, Schauble B, zur Hausen A, et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. *Am J Pathol* 1997;150:1-13. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9006316>.

19. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. *Cancer Res* 2003;63:6643-6650. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14583457>.

20. Mitchell G, Ballinger ML, Wong S, et al. High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort. *PLoS One* 2013;8:e69026. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23894400>.

21. Bisgaard ML, Bulow S. Familial adenomatous polyposis (FAP): genotype correlation to FAP phenotype with osteomas and sebaceous cysts. *Am J Med Genet A* 2006;140:200-204. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16411234>.

22. Gurbuz AK, Giardiello FM, Petersen GM, et al. Desmoid tumours in familial adenomatous polyposis. *Gut* 1994;35:377-381. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8150351>.

23. Fallen T, Wilson M, Morlan B, Lindor NM. Desmoid tumors -- a characterization of patients seen at Mayo Clinic 1976-1999. *Fam Cancer* 2006;5:191-194. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16736290>.

24. Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM, et al. A nationwide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. *Int J Cancer* 2011;129:256-261. Available at:

25. Nieuwenhuis MH, Lefevre JH, Bulow S, et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. *Dis Colon Rectum* 2011;54:1229-1234. Available at:

26. Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. *Am J Med Genet* 2002;108:132-139. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11857563>.

27. Pasini B, McWhinney SR, Bei T, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. *Eur J Hum Genet* 2008;16:79-88. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17667967>.

28. Gill AJ, Chou A, Vilain R, et al. Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. *Am J Surg Pathol* 2010;34:636-644. Available at:

29. Gaal J, Stratakis CA, Carney JA, et al. SDHB immunohistochemistry: a useful tool in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors. *Mod Pathol* 2011;24:147-151. Available at:

30. Kleinerman RA, Schonfeld SJ, Tucker MA. Sarcomas in hereditary retinoblastoma. *Clin Sarcoma Res* 2012;2:15. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23036192>.

31. Domanski HA. Fine-needle aspiration cytology of soft tissue lesions: diagnostic challenges. *Diagn Cytopathol* 2007;35:768-773. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18008345>.

32. Antonescu CR. The role of genetic testing in soft tissue sarcoma. *Histopathology* 2006;48:13-21. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16359533>.

33. Pfeifer JD, Hill DA, O'Sullivan MJ, Dehner LP. Diagnostic gold standard for soft tissue tumours: morphology or molecular genetics? *Histopathology* 2000;37:485-500. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11122430>.
34. Hill DA, O'Sullivan MJ, Zhu X, et al. Practical application of molecular genetic testing as an aid to the surgical pathologic diagnosis of sarcomas: a prospective study. *Am J Surg Pathol* 2002;26:965-977. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12170083>.
35. Sorensen PHB, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. *J Clin Oncol* 2002;20:2672-2679. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12039929>.
36. Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. *J Clin Oncol* 2004;22:4040-4050. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15364967>.
37. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. *Cancer Res* 2002;62:135-140. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11782370>.
38. Antonescu CR, Tschernyavsky SJ, Decuseara R, et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. *Clin Cancer Res* 2001;7:3977-3987. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11751490>.
39. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. *J Clin Oncol* 1997;15:350-362. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8996162>.
40. Riad S, Griffin AM, Liberman B, et al. Lymph node metastasis in soft tissue sarcoma in an extremity. *Clin Orthop Relat Res* 2004;129-134. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15346063>.
41. Al-Refaie WB, Andtbacka RH, Ensor J, et al. Lymphadenectomy for isolated lymph node metastasis from extremity soft-tissue sarcomas. *Cancer* 2008;112:1821-1826. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18306370>.
42. Edge SB, Byrd DR, Compton CC, et al. *AJCC cancer staging manual* (ed 7). New York, NY: Springer; 2010.
43. Zagars GK, Ballo MT, Pisters PWT, et al. Surgical margins and resection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. *Cancer* 2003;97:2544-2553. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12733154>.
44. Pohar S, Haq R, Liu L, et al. Adjuvant high-dose-rate and low-dose-rate brachytherapy with external beam radiation in soft tissue sarcoma: a comparison of outcomes. *Brachytherapy* 2007;6:53-57. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17284387>.
45. Leibel SA, Fuks Z, Zelefsky MJ, et al. Intensity-modulated radiotherapy. *Cancer J* 2002;8:164-176. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12004802>.
46. Tran PT, Hara W, Su Z, et al. Intraoperative radiation therapy for locally advanced and recurrent soft-tissue sarcomas in adults. *Int J Radiat Oncol Biol Phys* 2008;72:1146-1153. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18394818>.
47. Kuklo TR, Temple HT, Owens BD, et al. Preoperative versus postoperative radiation therapy for soft-tissue sarcomas. *Am J Orthop*



(Belle Mead NJ) 2005;34:75-80. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/15789525>.

48. Al-Absi E, Farrokhyar F, Sharma R, et al. A systematic review and meta-analysis of oncologic outcomes of pre- versus postoperative radiation in localized resectable soft-tissue sarcoma. *Ann Surg Oncol* 2010;17:1367-1374. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20217260>.

49. Sampath S, Schultheiss TE, Hitchcock YJ, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma: multi-institutional analysis of 821 patients. *International journal of radiation oncology, biology, physics* 2011;81:498-505. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20888702>.

50. Cheng EY, Dusenbery KE, Winters MR, Thompson RC. Soft tissue sarcomas: preoperative versus postoperative radiotherapy. *J Surg Oncol* 1996;61:90-99. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/8606553>.

51. Davis AM, O'Sullivan B, Bell RS, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. *J Clin Oncol* 2002;20:4472-4477. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/12431971>.

52. Zagars GK, Ballo MT, Pisters PWT, et al. Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. *Int J Radiat Oncol Biol Phys* 2003;56:482-488. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/12738324>.

53. Wilson AN, Davis A, Bell RS, et al. Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. *Eur J Cancer* 1994;30A:746-751. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/7917531>.

54. Delaney TF, Kepka L, Goldberg SI, et al. Radiation therapy for control of soft-tissue sarcomas resected with positive margins. *Int J Radiat Oncol Biol Phys* 2007;67:1460-1469. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/17394945>.

55. Al Yami A, Griffin AM, Ferguson PC, et al. Positive surgical margins in soft tissue sarcoma treated with preoperative radiation: is a postoperative boost necessary? *Int J Radiat Oncol Biol Phys* 2010;77:1191-1197. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20056340>.

56. Pisters PW, Patel SR, Varma DG, et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. *J Clin Oncol* 1997;15:3481-3487. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/9396401>.

57. Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. *Eur J Cancer* 2001;37:1096-1103. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/11378339>.

58. Cormier JN, Huang X, Xing Y, et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. *J Clin Oncol* 2004;22:4567-4574. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/15542808>.

59. Grobmyer SR, Maki RG, Demetri GD, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. *Ann Oncol* 2004;15:1667-1672. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/15520069>.

60. Edmonson JH, Petersen IA, Shives TC, et al. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. *Cancer* 2002;94:786-792. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/11857314>.

61. Pisters PWT, Ballo MT, Patel SR. Preoperative chemoradiation treatment strategies for localized sarcoma. *Ann Surg Oncol* 2002;9:535-542. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12095968>.
62. DeLaney TF, Spiro IJ, Suit HD, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. *Int J Radiat Oncol Biol Phys* 2003;56:1117-1127. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12829150>.
63. Mack LA, Crowe PJ, Yang JL, et al. Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcoma. *Ann Surg Oncol* 2005;12:646-653. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15965732>.
64. Kraybill WG, Harris J, Spiro IJ, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. *J Clin Oncol* 2006;24:619-625. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16446334>.
65. Kraybill WG, Harris J, Spiro IJ, et al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. *Cancer* 2010;116:4613-4621. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20572040>.
66. Mullen JT, Kobayashi W, Wang JJ, et al. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas. *Cancer* 2012;118:3758-3765. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22180344>.
67. Look Hong NJ, Hornicek FJ, Harmon DC, et al. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study. *Eur J Cancer* 2013;49:875-883. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23092789>.
68. Tierney JF, Mosseri V, Stewart LA, et al. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. *Br J Cancer* 1995;72:469-475. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7640234>.
69. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. *Sarcoma Meta-analysis Collaboration. Lancet* 1997;350:1647-1654. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9400508>.
70. Maki RG. Role of chemotherapy in patients with soft tissue sarcomas. *Expert Rev Anticancer Ther* 2004;4:229-236. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15056053>.
71. Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. *Cancer* 2008;113:573-581. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18521899>.
72. Italiano A, Delva F, Mathoulin-Pelissier S, et al. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. *Ann Oncol* 2010;21:2436-2441. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20439343>.
73. Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *J Clin Oncol* 1994;12:1137-1149. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8201375>.
74. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of



the Italian randomized cooperative trial. *J Clin Oncol* 2001;19:1238-1247. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11230464>.

75. Petrioli R, Coratti A, Correale P, et al. Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. *Am J Clin Oncol* 2002;25:468-473. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12393986>.

76. Woll PJ, van Glabbeke M, Hohenberger P, et al. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): Interim analysis of a randomised phase III trial [abstract]. *J Clin Oncol* 2007;25(18\_Suppl):Abstract 10008. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/25/18\\_suppl/10008](http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/10008).

77. Fakhrai N, Ebm C, Kostler WJ, et al. Intensified adjuvant IFADIC chemotherapy in combination with radiotherapy versus radiotherapy alone for soft tissue sarcoma: long-term follow-up of a prospective randomized feasibility trial. *Wien Klin Wochenschr* 2010;122:614-619. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20963638>.

78. Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. *Oncology* 2003;65 Suppl 2:80-84. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14586155>.

79. Mouridsen HT, Bastholt L, Somers R, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer Clin Oncol* 1987;23:1477-1483. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3479329>.

80. Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. *J Clin Oncol* 1989;7:1208-1216. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2504890>.

81. Antman KH, Elias A. Dana-Farber Cancer Institute studies in advanced sarcoma. *Semin Oncol*. 1990;1:7-15. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2106162>

82. Buesa JM, Mouridsen HT, van Oosterom AT, et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. *Ann Oncol* 1991;2:307-309. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1868027>.

83. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. *J Clin Oncol* 1993;11:1276-1285. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8315425>.

84. Bramwell VHC, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. *Cochrane Database Syst Rev* 2003. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12917960>.

85. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. *J Clin Oncol* 1993;11:1269-1275. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8315424>.

86. Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. *J Natl Cancer Inst* 1991;83:926-932. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2067035>.

87. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and

Bone Sarcoma Group. J Clin Oncol 1995;13:1537-1545. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7602342>.

88. Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998;16:1438-1443. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9552049>.

89. Palumbo R, Neumaier C, Cosso M, et al. Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. Eur J Cancer 1999;35:66-72. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10211090>.

90. Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007;25:3144-3150. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17634494>.

91. Bay JO, Ray-Coquard I, Fayette J, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: A retrospective analysis. International Journal of Cancer 2006;119:706-711. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16496406>.

92. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007;25:2755-2763. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17602081>.

93. Dileo P, Morgan JA, Zahrieh D, et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer 2007;109:1863-1869. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17385194>.

94. Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011;29:2528-2533. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21606430>.

95. Talbot SM, Keohan ML, Hesdorffer M, et al. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer 2003;98:1942-1946. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14584078>.

96. Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003;98:2693-2699. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14669291>.

97. Garcia del Muro X, Lopez-Pousa A, Martin J, et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 2005;104:1706-1712. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16134177>.

98. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870-877. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11313175>.

99. Anderson SE, Keohan ML, D'Adamo DR, Maki RG. A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. Sarcoma 2006;2006:15947. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17496991>.

100. Kuttlesch JF, Jr., Krailo MD, Madden T, et al. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study. Pediatr



Blood Cancer 2009;53:590-593. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19533657>.

101. Laverdiere C, Kolb EA, Supko JG, et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003;98:832-840. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/12910529>.

102. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890-899. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/14990645>.

103. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23:576-584. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/15659504>.

104. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naïve patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005;23:5484-5492. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/16110008>.

105. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009;27:4188-4196. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19652065>.

106. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27:3126-3132. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19451427>.

107. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-1886. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22595799>.

108. Cassier PA, Gelderblom H, Stacchiotti S, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 2012;118:1649-1655. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/21823110>.

109. Stacchiotti S, Negri T, Libertini M, et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol 2012;23:3171-3179. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22711763>.

110. Stacchiotti S, Negri T, Zaffaroni N, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol 2011;22:1682-1690. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/21242589>.

111. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010;363:1727-1733. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20979472>.

112. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangiomyomatosis. N Engl J Med 2008;358:140-151. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18184959>.

113. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010;28:835-840. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20048174>.

114. Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic

lymphangiomyomatosis: a phase 2 trial. Clin Cancer Res 2011;17:4071-4081. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21525172>.

115. McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangiomyomatosis. N Engl J Med 2011;364:1595-1606. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21410393>.

116. Gennatas C, Michalaki V, Kairi PV, et al. Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor. World J Surg Oncol 2012;10:181. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22943457>.

117. Park MS, Patel SR, Ludwig JA, et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer 2011;117:4939-4947. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21480200>.

118. Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 2013;24:257-263. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22910841>.

119. Pisters PW, Leung DH, Woodruff J, et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14:1679-1689. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8622088>.

120. Fleming JB, Berman RS, Cheng SC, et al. Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol 1999;17:2772-2780. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10561352>.

121. Gerrand CH, Wunder JS, Kandel RA, et al. Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence. J Bone Joint Surg Br

2001;83:1149-1155. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11764430>.

122. McKee MD, Liu DF, Brooks JJ, et al. The prognostic significance of margin width for extremity and trunk sarcoma. J Surg Oncol 2004;85:68-76. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14755506>.

123. Biau DJ, Ferguson PC, Chung P, et al. Local recurrence of localized soft tissue sarcoma: a new look at old predictors. Cancer 2012;118:5867-5877. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22648518>.

124. Alamanda VK, Crosby SN, Archer KR, et al. Predictors and clinical significance of local recurrence in extremity soft tissue sarcoma. Acta Oncol 2013;52:793-802. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22877243>.

125. Clark MA, Thomas JM. Amputation for soft-tissue sarcoma. Lancet Oncol 2003;4:335-342. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12788405>.

126. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196:305-315. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7114936>.

127. Baldini EH, Goldberg J, Jenner C, et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol 1999;17:3252-3259. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10506627>.

128. Lin PP, Guzel VB, Pisters PW, et al. Surgical management of soft tissue sarcomas of the hand and foot. Cancer 2002;95:852-861. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12209730>.



129. Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. *Ann Surg* 1992;215:269-275. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1543400>.

130. Stojadinovic A, Jaques DP, Leung DH, et al. Amputation for recurrent soft tissue sarcoma of the extremity: indications and outcome. *Ann Surg Oncol* 2001;8:509-518. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11456050>.

131. Ghert MA, Abudu A, Driver N, et al. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. *Ann Surg Oncol* 2005;12:10-17. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15827772>.

132. Alamanda VK, Crosby SN, Archer KR, et al. Amputation for extremity soft tissue sarcoma does not increase overall survival: a retrospective cohort study. *Eur J Surg Oncol* 2012;38:1178-1183. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22985713>.

133. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. *J Clin Oncol* 1998;16:197-203. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9440743>.

134. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. *Lancet* 2002;359:2235-2241. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12103287>.

135. Alektiar KM, Velasco J, Zelefsky MJ, et al. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. *Int J Radiat Oncol Biol Phys* 2000;48:1051-1058. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11072162>.

136. Jepsen NL, Trovik CS, Bauer HC, et al. Radiotherapy to improve local control regardless of surgical margin and malignancy grade in

extremity and trunk wall soft tissue sarcoma: a Scandinavian sarcoma group study. *Int J Radiat Oncol Biol Phys* 2008;71:1196-1203. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18207661>.

137. Kim B, Chen YL, Kirsch DG, et al. An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control. *Int J Radiat Oncol Biol Phys* 2010;77:843-850. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20005638>.

138. Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. *J Clin Oncol* 1996;14:859-868. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8622034>.

139. Alektiar KM, Leung D, Zelefsky MJ, et al. Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity. *Ann Surg Oncol* 2002;9:48-56. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11829430>.

140. Alektiar KM, Brennan MF, Healey JH, Singer S. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. *J Clin Oncol* 2008;26:3440-3444. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18612160>.

141. Alektiar KM, Brennan MF, Singer S. Local control comparison of adjuvant brachytherapy to intensity-modulated radiotherapy in primary high-grade sarcoma of the extremity. *Cancer* 2011;117:3229-3234. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21264834>.

142. O'Sullivan B, Davis A, Turcotte R, et al. Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma [abstract]. *J Clin Oncol* 2004;22(14\_Suppl):Abstract 9007. Available at: [http://meeting.jco.org/cgi/content/abstract/22/14\\_suppl/9007](http://meeting.jco.org/cgi/content/abstract/22/14_suppl/9007).

143. Davis AM, O'Sullivan B, Turcotte R, et al. Late radiation morbidity following randomization to preoperative versus postoperative

radiotherapy in extremity soft tissue sarcoma. *Radiother Oncol* 2005;75:48-53. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15948265>.

144. O'Sullivan B, Griffin AM, Dickie CI, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. *Cancer* 2013;119:1878-1884. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23423841>.

145. Cahlon O, Spierer M, Brennan MF, et al. Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy. *Cancer* 2008;112:2774-2779. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18429001>.

146. Tran QNH, Kim AC, Gottschalk AR, et al. Clinical outcomes of intraoperative radiation therapy for extremity sarcomas. *Sarcoma* 2006;2006:91671-91671. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17040093>.

147. Call JA, Stafford SL, Petersen IA, Haddock MG. Use of intraoperative radiotherapy for upper-extremity soft-tissue sarcomas: analysis of disease outcomes and toxicity. *Am J Clin Oncol* 2014;37:81-85. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23111357>.

148. Sadoski C, Suit HD, Rosenberg A, et al. Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues. *J Surg Oncol* 1993;52:223-230. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8468983>.

149. Demas BE, Heelan RT, Lane J, et al. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. *AJR Am J Roentgenol* 1988;150:615-620. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3257620>.

150. Hanna SL, Fletcher BD. MR imaging of malignant soft-tissue tumors. *Magn Reson Imaging Clin N Am* 1995;3:629-650. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8564687>.

151. Heslin MJ, Smith JK. Imaging of soft tissue sarcomas. *Surg Oncol Clin N Am* 1999;8:91-9107. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9824363>.

152. Schwab JH, Boland P, Guo T, et al. Skeletal metastases in myxoid liposarcoma: an unusual pattern of distant spread. *Ann Surg Oncol* 2007;14:1507-1514. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17252290>.

153. Schwab JH, Boland PJ, Antonescu C, et al. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. *Cancer* 2007;110:1815-1822. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17724681>.

154. Tateishi U, Hasegawa T, Beppu Y, et al. Prognostic significance of MRI findings in patients with myxoid-round cell liposarcoma. *AJR Am J Roentgenol* 2004;182:725-731. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14975976>.

155. Portera CA, Jr., Ho V, Patel SR, et al. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. *Cancer* 2001;91:585-591. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11169942>.

156. Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. *Eur J Nucl Med Mol Imaging* 2002;29:1149-1154. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12192559>.

157. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. *Cancer* 2005;103:339-348. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15578712>.

158. Schuetze SM. Utility of positron emission tomography in sarcomas. *Curr Opin Oncol* 2006;18:369-373. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16721133>.

159. Evilevitch V, Weber WA, Tap WD, et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. *Clin Cancer Res* 2008;14:715-720. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18245531>.

160. Benz MR, Czernin J, Allen-Auerbach MS, et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. *Clin Cancer Res* 2009;15:2856-2863. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19351756>.

161. Quak E, van de Luitgaarden AC, de Geus-Oei LF, et al. Clinical applications of positron emission tomography in sarcoma management. *Expert Rev Anticancer Ther* 2011;11:195-204. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21342039>.

162. Folpe AL, Lyles RH, Sprouse JT, et al. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. *Clin Cancer Res* 2000;6:1279-1287. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10778952>.

163. Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F, et al. Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. *Ann Surg* 2000;231:380-386. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10714631>.

164. Geer RJ, Woodruff J, Casper ES, Brennan MF. Management of small soft-tissue sarcoma of the extremity in adults. *Arch Surg* 1992;127:1285-1289. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1444788>.

165. Karakousis CP, Emrich LJ, Rao U, Khalil M. Limb salvage in soft tissue sarcomas with selective combination of modalities. *Eur J Surg Oncol* 1991;17:71-80. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1995362>.

166. Billing V, Mertens F, Domanski HA, Rydholm A. Deep-seated ordinary and atypical lipomas: histopathology, cytogenetics, clinical features, and outcome in 215 tumours of the extremity and trunk wall. *J Bone Joint Surg Br* 2008;90:929-933. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18591605>.

167. Sommerville SMM, Patton JT, Luscombe JC, et al. Clinical outcomes of deep atypical lipomas (well-differentiated lipoma-like liposarcomas) of the extremities. *ANZ J Surg* 2005;75:803-806. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16173997>.

168. Kooby DA, Antonescu CR, Brennan MF, Singer S. Atypical lipomatous tumor/well-differentiated liposarcoma of the extremity and trunk wall: importance of histological subtype with treatment recommendations. *Ann Surg Oncol* 2004;11:78-84. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14699038>.

169. Kang J, Botros M, Goldberg S, et al. The use of radiation therapy in the management of selected patients with atypical lipomas. *Sarcoma* 2013;2013:485483-485483. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23401663>.

170. Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. *Lancet Oncol* 2010. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20434400>.

171. Pisters PW, Pollock RE, Lewis VO, et al. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. *Ann Surg* 2007;246:675-681; discussion 681-682. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17893504>.

172. Al-Refaie WB, Habermann EB, Jensen EH, et al. Surgery alone is adequate treatment for early stage soft tissue sarcoma of the extremity. *Br J Surg* 2010;97:707-713. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20235085>.

173. Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. *Ann Surg* 1993;217:72-77. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8424704>.

174. Kepka L, DeLaney TF, Suit HD, Goldberg SI. Results of radiation therapy for unresected soft-tissue sarcomas. *Int J Radiat Oncol Biol Phys* 2005;63:852-859. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16199316>.

175. Grunhagen DJ, de Wilt JHW, Graveland WJ, et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. *Cancer* 2006;106:1776-1784. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16541435>.

176. Wray CJ, Benjamin RS, Hunt KK, et al. Isolated limb perfusion for unresectable extremity sarcoma: Results of 2 single-institution phase 2 trials. *Cancer* 2011;117:3235-3241. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21246524>.

177. Deroose JP, Eggermont AMM, van Geel AN, et al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. *J Clin Oncol* 2011;29:4036-4044. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21931039>.

178. Hegazy MAF, Kotb SZ, Sakr H, et al. Preoperative isolated limb infusion of doxorubicin and external irradiation for limb-threatening soft tissue sarcomas. *Ann Surg Oncol* 2007;14:568-576. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17094027>.

179. Moncrieff MD, Kroon HM, Kam PC, et al. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. *Ann Surg Oncol* 2008;15:2749-2756. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18648882>.

180. Brady MS, Brown K, Patel A, et al. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. *Melanoma Res* 2009;19:106-111. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19282789>.

181. Turaga KK, Beasley GM, Kane JM, et al. Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms. *Arch Surg* 2011;146:870-875. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21768436>.

182. Kane JM, Finley JW, Driscoll D, et al. The treatment and outcome of patients with soft tissue sarcomas and synchronous metastases. *Sarcoma* 2002;6:69-73. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18521331>.

183. Ferguson PC, Deheshi BM, Chung P, et al. Soft tissue sarcoma presenting with metastatic disease: outcome with primary surgical resection. *Cancer* 2011;117:372-379. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20830769>.

184. Whooley BP, Mooney MM, Gibbs JF, Kraybill WG. Effective follow-up strategies in soft tissue sarcoma. *Semin Surg Oncol* 1999;17:83-87. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10402642>.

185. Whooley BP, Gibbs JF, Mooney MM, et al. Primary extremity sarcoma: what is the appropriate follow-up? *Ann Surg Oncol* 2000;7:9-14. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10674442>.

186. Kane JM, 3rd. Surveillance strategies for patients following surgical resection of soft tissue sarcomas. *Curr Opin Oncol* 2004;16:328-332. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15187887>.

187. Lewis JJ, Leung D, Casper ES, et al. Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. *Arch Surg* 1999;134:190-194. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10025462>.



188. Fleming JB, Cantor SB, Varma DG, et al. Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. *Cancer* 2001;92:863-868. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11550159>.

189. Choi H, Varma DG, Fornage BD, et al. Soft-tissue sarcoma: MR imaging vs sonography for detection of local recurrence after surgery. *AJR Am J Roentgenol* 1991;157:353-358. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/1853821>.

190. Arya S, Nagarkatti DG, Dudhat SB, et al. Soft tissue sarcomas: ultrasonographic evaluation of local recurrences. *Clin Radiol* 2000;55:193-197. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10708612>.

191. Briccoli A, Galletti S, Salone M, et al. Ultrasonography is superior to computed tomography and magnetic resonance imaging in determining superficial resection margins of malignant chest wall tumors. *J Ultrasound Med* 2007;26:157-162. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17255176>.

192. Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. *Ann Surg* 1999;229:602-610. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10235518>.

193. Zagars GK, Ballo MT, Pisters PWT, et al. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. *Int J Radiat Oncol Biol Phys* 2003;57:739-747. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14529779>.

194. Kim S, Ott HC, Wright CD, et al. Pulmonary resection of metastatic sarcoma: prognostic factors associated with improved outcomes. *Ann Thorac Surg* 2011;92:1780-1786. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22051274>.

195. Singer S, Antman K, Corson JM, Eberlein TJ. Long-term salvageability for patients with locally recurrent soft-tissue sarcomas. *Arch Surg* 1992;127:548-553. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/1575625>.

196. Catton C, Davis A, Bell R, et al. Soft tissue sarcoma of the extremity. Limb salvage after failure of combined conservative therapy. *Radiother Oncol* 1996;41:209-214. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9027935>.

197. Torres MA, Ballo MT, Butler CE, et al. Management of locally recurrent soft-tissue sarcoma after prior surgery and radiation therapy. *Int J Radiat Oncol Biol Phys* 2007;67:1124-1129. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17208389>.

198. Canter RJ, Qin LX, Downey RJ, et al. Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity: a retrospective analysis. *Cancer* 2007;110:2050-2060. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17828771>.

199. Anaya DA, Lev DC, Pollock RE. The role of surgical margin status in retroperitoneal sarcoma. *J Surg Oncol* 2008;98:607-610. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19072853>.

200. Bevilacqua RG, Rogatko A, Hajdu SI, Brennan MF. Prognostic factors in primary retroperitoneal soft-tissue sarcomas. *Arch Surg* 1991;126:328-334. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/1998475>.

201. Heslin MJ, Lewis JJ, Nadler E, et al. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. *J Clin Oncol* 1997;15:2832-2839. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9256126>.

202. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a

single institution. *Ann Surg* 1998;228:355-365. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/9742918>.

203. Bonvalot S, Rivoire M, Castaing M, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. *J Clin Oncol* 2009;27:31-37. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19047280>.

204. Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. *J Clin Oncol* 2009;27:24-30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19047283>.

205. Musat E, Kantor G, Caron J, et al. Comparison of intensity-modulated postoperative radiotherapy with conventional postoperative conformal radiotherapy for retroperitoneal sarcoma. *Cancer Radiother* 2004;8:255-261. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/15450519>.

206. Yoon SS, Chen YL, Kirsch DG, et al. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas. *Ann Surg Oncol* 2010;17:1515-1529. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20151216>.

207. Swanson EL, Indelicato DJ, Louis D, et al. Comparison of three-dimensional (3D) conformal proton radiotherapy (RT), 3D conformal photon RT, and intensity-modulated RT for retroperitoneal and intra-abdominal sarcomas. *Int J Radiat Oncol Biol Phys* 2012;83:1549-1557. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22270176>.

208. Zlotecki RA, Katz TS, Morris CG, et al. Adjuvant radiation therapy for resectable retroperitoneal soft tissue sarcoma: the University of Florida experience. *Am J Clin Oncol* 2005;28:310-316. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/15923806>.

209. Pawlik TM, Pisters PWT, Mikula L, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for

localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. *Ann Surg Oncol* 2006;13:508-517. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/16491338>.

210. Tzeng CW, Fiveash JB, Popple RA, et al. Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma. *Cancer* 2006;107:371-379. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/16752414>.

211. Catton CN, O'Sullivan B, Kotwall C, et al. Outcome and prognosis in retroperitoneal soft tissue sarcoma. *Int J Radiat Oncol Biol Phys* 1994;29:1005-1010. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/8083069>.

212. Jones JJ, Catton CN, O'Sullivan B, et al. Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma. *Ann Surg Oncol* 2002;9:346-354. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/11986186>.

213. Le Péchoux C, Musat E, Baey C, et al. Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma? *Annals of Oncology* 2013;24:832-837. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/23123508>.

214. Sindelar WF, Kinsella TJ, Chen PW, et al. Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. *Arch Surg* 1993;128:402-410. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/8457152>.

215. Alektiar KM, Hu K, Anderson L, et al. High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. *Int J Radiat Oncol Biol Phys* 2000;47:157-163. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/10758318>.

216. Gieschen HL, Spiro IJ, Suit HD, et al. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent

retroperitoneal soft tissue sarcoma. *Int J Radiat Oncol Biol Phys* 2001;50:127-131. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/11316555>.

217. Petersen IA, Haddock MG, Donohue JH, et al. Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. *Int J Radiat Oncol Biol Phys* 2002;52:469-475. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/11872294>.

218. Bobin JY, Al-Lawati T, Granero LE, et al. Surgical management of retroperitoneal sarcomas associated with external and intraoperative electron beam radiotherapy. *Eur J Surg Oncol* 2003;29:676-681. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14511617>.

219. Pisters PWT, Ballo MT, Fenstermacher MJ, et al. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. *J Clin Oncol* 2003;21:3092-3097. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/12915599>.

220. Krempien R, Roeder F, Oertel S, et al. Intraoperative electron-beam therapy for primary and recurrent retroperitoneal soft-tissue sarcoma. *Int J Radiat Oncol Biol Phys* 2006;65:773-779. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/16682152>.

221. Ballo MT, Zagars GK, Pollock RE, et al. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. *Int J Radiat Oncol Biol Phys* 2007;67:158-163. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/17084545>.

222. Gronchi A, Casali PG, Fiore M, et al. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. *Cancer* 2004;100:2448-2455. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/15160351>.

223. Stoeckle E, Coindre JM, Bonvalot S, et al. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. *Cancer* 2001;92:359-368. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/11466691>.

224. Raut CP, Pisters PWT. Retroperitoneal sarcomas: combined-modality treatment approaches. *J Surg Oncol* 2006;94:81-87. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16788949>.

225. Thomas DM, O'Sullivan B, Gronchi A. Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. *Expert Rev Anticancer Ther* 2009;9:1145-1157. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19671034>.

226. Mendenhall WM, Zlotecki RA, Hochwald SN, et al. Retroperitoneal soft tissue sarcoma. *Cancer* 2005;104:669-675. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/16003776>.

227. Windham TC, Pisters PWT. Retroperitoneal sarcomas. *Cancer Control* 2005;12:36-43. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/15668651>.

228. Singer S, Corson JM, Demetri GD, et al. Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. *Ann Surg* 1995;221:185-195. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/7857146>.

229. Mullinax JE, Zager JS, Gonzalez RJ. Current diagnosis and management of retroperitoneal sarcoma. *Cancer Control* 2011;18:177-187. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21666580>.

230. Yoon SS, Chen Y-L, Kambadakone A, et al. Surgical placement of biologic mesh spacers prior to external beam radiation for retroperitoneal and pelvic tumors. *Practical Radiation Oncology* 2013;3:199-208. Available at:  
<http://linkinghub.elsevier.com/retrieve/pii/S187985001200118X?showall=true>.



231. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science* 1998;279:577-580. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9438854>.

232. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. *Semin Diagn Pathol* 2006;23:70-83. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17193820>.

233. Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. *J Natl Compr Canc Netw* 2010;8 Suppl 2:S1-41. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20457867>.

234. Sepe PS, Moparty B, Pitman MB, et al. EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield. *Gastrointest Endosc* 2009;70:254-261. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19482280>.

235. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. *Science* 2003;299:708-710. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12522257>.

236. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. *Gastroenterology* 2003;125:660-667. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12949711>.

237. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. *Arch Pathol Lab Med* 2006;130:1466-1478. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17090188>.

238. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. *Histopathology* 2008;53:245-266. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18312355>.

239. Lasota J, Corless CL, Heinrich MC, et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. *Mod Pathol* 2008;21:476-484. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18246046>.

240. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. *J Clin Oncol* 2005;23:5357-5364. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15928335>.

241. Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. *Proc Natl Acad Sci U S A* 2011;108:314-318. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21173220>.

242. Italiano A, Chen CL, Sung YS, et al. SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors. *BMC Cancer* 2012;12:408. Available at:

243. Oudijk L, Gaal J, Korpershoek E, et al. SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. *Mod Pathol* 2013;26:456-463. Available at:

244. Pantaleo MA, Astolfi A, Urbini M, et al. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST. *Eur J Hum Genet* 2014;22:32-39. Available at:

245. Doyle LA, Nelson D, Heinrich MC, et al. Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study. *Histopathology* 2012;61:801-809. Available at:

246. Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal



stromal tumors. *Genes Chromosomes Cancer* 2008;47:853-859. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18615679>.

247. Agaimy A, Terracciano LM, Dirnhofer S, et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRα wild-type gastrointestinal stromal tumours. *J Clin Pathol* 2009;62:613-616. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19561230>.

248. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. *Am J Surg Pathol* 2009;33:1401-1408. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19606013>.

249. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. *Am J Surg Pathol* 2005;29:52-68. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15613856>.

250. Miettinen M, Makhlof H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. *Am J Surg Pathol* 2006;30:477-489. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16625094>.

251. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med* 2002;347:472-480. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12181401>.

252. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. *Lancet* 2004;364:1127-1134. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15451219>.

253. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily

imatinib dose of 800 mg after progression on 400 mg. *Eur J Cancer* 2005;41:1751-1757. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16098458>.

254. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. *J Clin Oncol* 2008;26:620-625. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18235121>.

255. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. *J Clin Oncol* 2008;26:626-632. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18235122>.

256. von Mehren M, Heinrich MC, Joensuu H, et al. Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST) [abstract]. *J Clin Oncol* 2011;29(15\_Suppl):Abstract 10016. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/29/15\\_suppl/10016](http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/10016).

257. Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. *J Surg Oncol* 2009;99:42-47. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18942073>.

258. McAuliffe JC, Hunt KK, Lazar AJF, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. *Ann Surg Oncol* 2009;16:910-919. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18953611>.



259. Fiore M, Palassini E, Fumagalli E, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). *Eur J Surg Oncol* 2009;35:739-745. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19110398>.

260. Blesius A, Cassier PA, Bertucci F, et al. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. *BMC Cancer* 2011;11:72. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21324142>.

261. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. *Ann Surg Oncol* 2004;11:465-475. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15123459>.

262. Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. *Ann Surg* 2006;244:176-184. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16858179>.

263. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. *Ann Surg* 2000;231:51-58. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10636102>.

264. Dematteo RP, Antonescu CR, Chadaram V, et al. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000 [abstract]. *J Clin Oncol* 2005;23 (16\_Suppl):Abstract 9009. Available at: [http://meeting.jco.org/cqi/content/abstract/23/16\\_suppl/9009](http://meeting.jco.org/cqi/content/abstract/23/16_suppl/9009).

265. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. *Lancet* 2009;373:1097-1104. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19303137>.

266. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. *JAMA* 2012;307:1265-1272. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22453568>.

267. Guilhot F. Indications for imatinib mesylate therapy and clinical management. *Oncologist* 2004;9:271-281. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15169982>.

268. Trent JC, Patel SS, Zhang J, et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. *Cancer* 2010;116:184-192. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19885836>.

269. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet* 2006;368:1329-1338. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17046465>.

270. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. *Eur J Cancer* 2009;45:1959-1968. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19282169>.

271. Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. *Clin Genitourin Cancer* 2009;7:11-19. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19213662>.

272. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. *Acta Oncol* 2009;48:9-17. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18752081>.

273. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. *Lancet* 2007;370:2011-2019. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18083403>.

274. Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. *Nat Rev Clin Oncol* 2009;6:219-228. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19333228>.

275. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *J Clin Oncol* 2003;21:4342-4349. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14645423>.

276. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRα mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer* 2004;40:689-695. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15010069>.

277. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. *Eur J Cancer* 2006;42:1093-1103. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16624552>.

278. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. *J Clin Oncol* 2008;26:5360-5367. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18955451>.

279. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. *J Clin Oncol* 2010;28:1247-1253. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20124181>.

280. Cassier PA, Fumagalli E, Rutkowski P, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. *Clin Cancer Res* 2012;18:4458-4464. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22718859>.

281. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. *J Clin Oncol* 2008;26:5352-5359. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18955458>.

282. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. *Clin Cancer Res* 2005;11:4182-4190. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15930355>.

283. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. *J Clin Oncol* 2006;24:4764-4774. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16954519>.

284. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. *Clin Cancer Res* 2006;12:1743-1749. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16551858>.

285. Desai J, Shankar S, Heinrich MC, et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. *Clin Cancer Res* 2007;13:5398-5405. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17875769>.

286. Gajiwala KS, Wu JC, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. *Proc Natl Acad Sci U S A* 2009;106:1542-1547. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19164557>.



287. Guo T, Hajdu M, Agaram NP, et al. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. *Clin Cancer Res* 2009;15:6862-6870. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19861442>.

288. Nishida T, Takahashi T, Nishitani A, et al. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. *Int J Clin Oncol* 2009;14:143-149. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19390946>.

289. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013;381:295-302. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23177515>.

290. Kindler HL, Campbell NP, Wroblewski K, et al. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial [abstract]. *J Clin Oncol* 2011;29(15\_Suppl):Abstract 10009. Available at: [http://meeting.ascopubs.org/cgi/content/abstract/29/15\\_suppl/10009](http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/10009).

291. Park SH, Ryu MH, Ryoo BY, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. *Invest New Drugs* 2012;30:2377-2383. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22270258>.

292. Montemurro M, Gelderblom H, Bitz U, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. *Eur J Cancer* 2013;49:1027-1031. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23140824>.

293. Kefeli U, Benekli M, Sevinc A, et al. Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line

treatment: A retrospective multicenter experience. *Oncol Lett* 2013;6:605-611. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24137379>.

294. Demetri GD, Casali PG, Blay JY, et al. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. *Clin Cancer Res* 2009;15:5910-5916. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19723647>.

295. Montemurro M, Schoffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. *Eur J Cancer* 2009;45:2293-2297. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19467857>.

296. Sawaki A, Nishida T, Doi T, et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. *Cancer* 2011;117:4633-4641. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21456006>.

297. Reichardt P, Blay JY, Gelderblom H, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. *Ann Oncol* 2012;23:1680-1687. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22357255>.

298. Cauchi C, Somaiah N, Engstrom PF, et al. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. *Cancer Chemother Pharmacol* 2012;69:977-982. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22119758>.

299. Dewaele B, Wasag B, Cools J, et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. *Clin Cancer Res* 2008;14:5749-5758. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18794084>.

300. Trent JC, Wathen K, von Mehren M, et al. A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST) [abstract]. J Clin Oncol 2011;29(15\_Suppl):Abstract 10006. Available at:

[http://meeting.ascopubs.org/cgi/content/abstract/29/15\\_suppl/10006](http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/10006).

301. Ganjoo KN, Villalobos VM, Kamaya A, et al. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol 2014;25:236-240. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24356634>.

302. Van den Abbeele AD. The lessons of GIST--PET and PET/CT: a new paradigm for imaging. Oncologist 2008;13 Suppl 2:8-13. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18434632>.

303. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-1759. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17470865>.

304. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 1999;35:1773-1782. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10673991>.

305. Prior JO, Montemurro M, Orcurto MV, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 2009;27:439-445. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19064982>.

306. DeMatteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary

gastrointestinal stromal tumor (GIST). Cancer 2008;112:608-615.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18076015>.

307. Gold JS, Gonen M, Gutierrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009;10:1045-1052. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19793678>.

308. Wang D, Zhang Q, Blanke CD, et al. Phase II Trial of Neoadjuvant/Adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 2011. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22203182>.

309. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24:2325-2331. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16710031>.

310. Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006;93:304-311. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16496358>.

311. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007;14:14-24. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17072676>.

312. DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007;245:347-352. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17435539>.

313. Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. *Ann Surg* 2007;245:341-346. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17435538>.

314. Sym SJ, Ryu M-H, Lee J-L, et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). *J Surg Oncol* 2008;98:27-33. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18452195>.

315. Mussi C, Ronellenfitch U, Jakob J, et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? *Ann Oncol* 2010;21:403-408. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19628568>.

316. Yeh C-N, Chen T-W, Tseng J-H, et al. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. *J Surg Oncol* 2010;102:599-603. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20976730>.

317. Van Den Abbeele AD, Badawi RD, Manola J, et al. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning [abstract]. *J Clin Oncol* 2004;22(14\_Suppl):Abstract 3012. Available at: [http://meeting.jco.org/cqi/content/abstract/22/14\\_suppl/3012](http://meeting.jco.org/cqi/content/abstract/22/14_suppl/3012).

318. Raut CP, Wang Q, Manola J, et al. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. *Ann Surg Oncol* 2010;17:407-415. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19898902>.

319. Fumagalli E, Coco P, Morosi C, et al. Rechallenge with Imatinib in GIST patients resistant to second or third line therapy [abstract]. *Connective Tissue Oncology Society (CTOS) 15th Annual Meeting*; 2009:Abstract 39404. Available at: <http://www.ctos.org/meeting/2009/program.asp>.

320. Kang YK, Ryu MH, Yoo C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* 2013;14:1175-1182. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24140183>.

321. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. *J Clin Oncol* 2007;25:1107-1113. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17369574>.

322. Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. *Lancet Oncol* 2010;11:942-949. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20864406>.

323. Patrikidou A, Chabaud S, Ray-Coquard I, et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. *Annals of Oncology* 2013;24:1087-1093. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23175622>.

324. Friedl W, Caspari R, Sengteller M, et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. *Gut* 2001;48:515-521. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11247896>.

325. Durno C, Monga N, Bapat B, et al. Does early colectomy increase desmoid risk in familial adenomatous polyposis? *Clin Gastroenterol Hepatol* 2007;5:1190-1194. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17916546>.

326. Nugent KP, Spigelman AD, Phillips RK. Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous

polyposis. *Dis Colon Rectum* 1993;36:1059-1062. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8223060>.

327. Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. *Am J Pathol* 2008;173:1518-1527. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18832571>.

328. Domont J, Salas S, Lacroix L, et al. High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. *Br J Cancer* 2010;102:1032-1036. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20197769>.

329. Le Guellec S, Soubeyran I, Rochaix P, et al. CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. *Mod Pathol* 2012;25:1551-1558. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22766794>.

330. Colombo C, Miceli R, Lazar AJ, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: An independent, multicenter validation study. *Cancer* 2013;119:3696-3702. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23913621>.

331. Mullen JT, DeLaney TF, Rosenberg AE, et al. beta-Catenin mutation status and outcomes in sporadic desmoid tumors. *Oncologist* 2013;18:1043-1049. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23960186>.

332. Godwin Y, McCulloch TA, Sully L. Extra-abdominal desmoid tumour of the breast: review of the primary management and the implications for breast reconstruction. *Br J Plast Surg* 2001;54:268-271. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11254428>.

333. Yamaguchi H, Sakakibara T, Hino M, et al. A case of fibromatosis of the breast. *Breast Cancer* 2002;9:175-178. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12016399>.

334. Kouriefs C, Leris ACA, Mokbel K, et al. Infiltrating fibromatosis of the breast: a potential pitfall. *Int J Clin Pract* 2002;56:401-402. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12137452>.

335. Neuman HB, Brogi E, Ebrahim A, et al. Desmoid tumors (fibromatoses) of the breast: a 25-year experience. *Ann Surg Oncol* 2008;15:274-280. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17896146>.

336. Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. *J Clin Oncol* 2007;25:1785-1791. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17470870>.

337. Pritchard DJ, Nascimento AG, Petersen IA. Local control of extra-abdominal desmoid tumors. *J Bone Joint Surg Am* 1996;78:848-854. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8666602>.

338. Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. *J Clin Oncol* 1999;17:158-167. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10458229>.

339. Stojadinovic A, Hoos A, Karpoff HM, et al. Soft tissue tumors of the abdominal wall: analysis of disease patterns and treatment. *Arch Surg* 2001;136:70-79. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11146782>.

340. Gronchi A, Casali PG, Mariani L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. *J Clin Oncol* 2003;21:1390-1397. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12663732>.

341. Peng PD, Hyder O, Mavros MN, et al. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. *Ann Surg Oncol* 2012;19:4036-4042. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22972507>.



342. Melis M, Zager JS, Sondak VK. Multimodality management of desmoid tumors: how important is a negative surgical margin? *J Surg Oncol* 2008;98:594-602. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19072851>.

343. Huang K, Fu H, Shi YQ, et al. Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution. *J Surg Oncol* 2009;100:563-569. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19722232>.

344. Stoeckle E, Coindre JM, Longy M, et al. A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases. *Eur J Surg Oncol* 2009;35:129-134. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18760561>.

345. Mullen JT, Delaney TF, Kobayashi WK, et al. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. *Ann Surg Oncol* 2012;19:4028-4035. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22965569>.

346. Gluck I, Griffith KA, Biermann JS, et al. Role of radiotherapy in the management of desmoid tumors. *Int J Radiat Oncol Biol Phys* 2011;80:787-792. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20615622>.

347. Crago AM, Denton B, Salas S, et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. *Ann Surg* 2013;258:347-353. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23532110>.

348. Goy BW, Lee SP, Eilber F, et al. The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors. *Int J Radiat Oncol Biol Phys* 1997;39:659-665. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9336146>.

349. Jelinek JA, Stelzer KJ, Conrad E, et al. The efficacy of radiotherapy as postoperative treatment for desmoid tumors. *Int J*

*Radiat Oncol Biol Phys* 2001;50:121-125. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11316554>.

350. Fontanesi J, Mott MP, Kraut MJ, et al. The role of postoperative irradiation in the treatment of locally recurrent incompletely resected extra-abdominal desmoid tumors. *Sarcoma* 2004;8:83-86. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18521399>.

351. Baumert BG, Spahr MO, Von Hochstetter A, et al. The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network. *Radiat Oncol* 2007;2:12-12. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17343751>.

352. Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. *Int J Radiat Oncol Biol Phys* 2008;71:441-447. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18068311>.

353. Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. *Eur J Surg Oncol* 2008;34:462-468. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17709227>.

354. Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. *Ann Surg Oncol* 2009;16:2587-2593. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19568815>.

355. Lewis JJ, Boland PJ, Leung DH, et al. The enigma of desmoid tumors. *Ann Surg* 1999;229:866-872. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10363901>.

356. Kiel KD, Suit HD. Radiation therapy in the treatment of aggressive fibromatoses (desmoid tumors). *Cancer* 1984;54:2051-2055. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/6488135>.

357. Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. *Int J Radiat Oncol Biol Phys* 1998;42:1007-1014. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9869223>.

358. Schulz-Ertner D, Zierhut D, Mende U, et al. The role of radiation therapy in the management of desmoid tumors. *Strahlenther Onkol* 2002;178:78-83. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11942041>.

359. Keus RB, Nout RA, Blay JY, et al. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998). *Ann Oncol* 2013;24:2672-2676. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23868907>.

360. Janinis J, Patriki M, Vini L, et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. *Ann Oncol* 2003;14:181-190. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12562642>.

361. de Camargo VP, Keohan ML, D'Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). *Cancer* 2010;116:2258-2265. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20187095>.

362. Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. *Cancer* 2004;100:612-620. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/14745880>.

363. Leithner A, Schnack B, Katterschafka T, et al. Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin. *J Surg Oncol* 2000;73:21-25. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10649274>.

364. Benson JR, Mokbel K, Baum M. Management of desmoid tumours including a case report of toremifene. *Ann Oncol* 1994;5:173-177.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8186162>.

365. Bus PJ, Verspaget HW, van Krieken JH, et al. Treatment of mesenteric desmoid tumours with the anti-oestrogenic agent toremifene: case histories and an overview of the literature. *Eur J Gastroenterol Hepatol* 1999;11:1179-1183. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10524651>.

366. Heidemann J, Ogawa H, Otterson MF, et al. Antiangiogenic treatment of mesenteric desmoid tumors with toremifene and interferon alfa-2b: report of two cases. *Dis Colon Rectum* 2004;47:118-122.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14719159>.

367. Maseelall P, Robins JC, Williams DB, Thomas MA. Stabilization and regression of a recurrent desmoid tumor with the antiestrogen toremifene. *Fertil Steril* 2005;84:509. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16086575>.

368. Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. *Cancer* 1993;72:3244-3247. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8242548>.

369. Poritz LS, Blackstein M, Berk T, et al. Extended follow-up of patients treated with cytotoxic chemotherapy for intra-abdominal desmoid tumors. *Dis Colon Rectum* 2001;44:1268-1273. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11584198>.

370. Garbay D, Le Cesne A, Penel N, et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). *Ann Oncol* 2012;23:182-186. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21444357>.

371. Constantinidou A, Jones RL, Scurr M, et al. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. *Eur J Cancer* 2009;45:2930-2934. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19767198>.

372. Weiss AJ, Horowitz S, Lackman RD. Therapy of desmoid tumors and fibromatosis using vinorelbine. *Am J Clin Oncol* 1999;22:193-195.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10199460>.

373. Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. *Cancer* 2001;92:1259-1264. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11571741>.

374. Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). *J Clin Oncol* 2006;24:1195-1203. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16505440>.

375. Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. *Clin Cancer Res* 2010;16:4884-4891. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20724445>.

376. Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. *Ann Oncol* 2011;22:452-457. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20622000>.

377. Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of Sorafenib against desmoid tumor/deep fibromatosis. *Clin Cancer Res* 2011;17:4082-4090. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21447727>.

378. Ferrari A, Dileo P, Casanova M, et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. *Cancer* 2003;98:571-580. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12879475>.

379. Newton WA, Jr., Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification--an Intergroup Rhabdomyosarcoma Study. *Cancer* 1995;76:1073-1085. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8625211>.

380. Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: an update. *Arch Pathol Lab Med* 2006;130:1454-1465. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17090187>.

381. Hawkins WG, Hoos A, Antonescu CR, et al. Clinicopathologic analysis of patients with adult rhabdomyosarcoma. *Cancer* 2001;91:794-803. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11241248>.

382. Little DJ, Ballo MT, Zagars GK, et al. Adult rhabdomyosarcoma: outcome following multimodality treatment. *Cancer* 2002;95:377-388. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12124838>.

383. Nascimento AF, Fletcher CDM. Spindle cell rhabdomyosarcoma in adults. *Am J Surg Pathol* 2005;29:1106-1113. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16006807>.

384. Sultan I, Qaddoumi I, Yaser S, et al. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. *J Clin Oncol* 2009;27:3391-3397. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19398574>.

385. Yasuda T, Perry KD, Nelson M, et al. Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature. *Hum Pathol* 2009;40:341-348. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18973919>.

386. Simon JH, Paulino AC, Ritchie JM, et al. Presentation, prognostic factors and patterns of failure in adult rhabdomyosarcoma. *Sarcoma* 2003;7:1-7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18521362>.

387. Gaffney EF, Dervan PA, Fletcher CD. Pleomorphic rhabdomyosarcoma in adulthood. Analysis of 11 cases with definition of diagnostic criteria. *Am J Surg Pathol* 1993;17:601-609. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8333559>.

388. Furlong MA, Mentzel T, Fanburg-Smith JC. Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers. *Mod Pathol* 2001;14:595-603. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11406662>.

389. Stock N, Chibon F, Binh MBN, et al. Adult-type rhabdomyosarcoma: analysis of 57 cases with clinicopathologic description, identification of 3 morphologic patterns and prognosis. *Am J Surg Pathol* 2009;33:1850-1859. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19898221>.

390. Esnaola NF, Rubin BP, Baldini EH, et al. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. *Ann Surg* 2001;234:215-223. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11505068>.

391. Sultan I, Ferrari A. Selecting multimodal therapy for rhabdomyosarcoma. *Expert Rev Anticancer Ther* 2010;10:1285-1301. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20735314>.

392. Arndt CAS, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. *J Clin Oncol* 2009;27:5182-5188. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19770373>.

393. Raney RB, Walterhouse DO, Meza JL, et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. *J Clin Oncol* 2011;29:1312-1318. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21357783>.

394. Arndt CAS, Hawkins DS, Meyer WH, et al. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide

and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group. *Pediatr Blood Cancer* 2008;50:33-36. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17091486>.

395. Klingebiel T, Pertl U, Hess CF, et al. Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial. *Med Pediatr Oncol* 1998;30:269-275. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9544222>.

396. Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. *J Clin Oncol* 2007;25:362-369. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17264331>.

397. Vassal G, Couanet D, Stockdale E, et al. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. *J Clin Oncol* 2007;25:356-361. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17264330>.

398. Mascarenhas L, Lyden ER, Breitfeld PP, et al. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group. *J Clin Oncol* 2010;28:4658-4663. Erratum in *J Clin Oncol*. 2011;4629(4610):1394. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20837952>.

399. McNall-Knapp RY, Williams CN, Reeves EN, et al. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors. *Pediatr Blood Cancer* 2010;54:909-915. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20405511>.

400. Pappo AS, Lyden E, Breneman J, et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma



study. J Clin Oncol 2001;19:213-219. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/11134215>.

Hematol Oncol 1997;19:438-442. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/9329466>.

401. Saylor RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-3469. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11481351>.

402. Walterhouse DO, Lyden ER, Breitfeld PP, et al. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. J Clin Oncol 2004;22:1398-1403. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15007087>.

403. Casanova M, Ferrari A, Bisogno G, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 2004;101:1664-1671. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/15378498>.

404. Casanova M, Ferrari A, Spreafico F, et al. Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 2002;94:3263-3268. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/12115359>.

405. Ogilvie CM, Crawford EA, Slotcavage RL, et al. Treatment of adult rhabdomyosarcoma. Am J Clin Oncol 2010;33:128-131. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19770626>.

406. Tateishi U, Hosono A, Makimoto A, et al. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med 2009;23:155-161. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/19225939>.

407. Pappo AS, Bowman LC, Furman WL, et al. A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma. J Pediatr